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SUMMARY
1. The pharmacological actions of adenosine, adenine nucleotides and uracil 
nucleotides on purinoceptors are reviewed and the ontogeny of these receptors 
were studied.
2.1. In the rat vas deferens the presence of pre-junctional A% receptors mediating 
inhibition of transmitter release and post-junctional Ai and A2 receptors 
mediating enhancement and inhibition of contractions respectively were 
confirmed and the distribution of adenosine receptors in the prostatic and 
epididymal portions of the bisected rat vas deferens was investigated.
2.2. Cyclopentyladenosine (CPA) inhibited nerve-mediated contractions in the 
epididymal and prostatic regions and responses were antagonised by a 
nanomolar concentration of l,3-dipropyl-8-cyclopentylxanthine (DPCPX), 
suggesting that pre-junctional Ai receptors are present on both portions of the 
bisected tissue. Also, CPA (< 1 pM) enhanced contractions induced by KCl in 
both regions of the tissue, suggesting that post-junctional excitatory Ai 
receptors are also present in both portions of the tissue. However, post­
junctional A2 receptors appear to be present only in the prostatic region as 5'- 
N-ethylcarboxyamidoadenosine (NECA) potently inhibited contractions 
induced by KCl in the prostatic region but not in the epididymal region, and 
the inhibition of nerve-mediated contractions by NECA was antagonised by a 
nanomolar concentration of DPCPX in the epididymal region, whereas in the 
epididymal region a micromolar concentration was required. 2-p- 
((carboxyethyl)phenylethylamino)-5'-N-ethylcarboxyamidoadenosine (CGS 
21680) was 1000 fold less potent than NECA in inhibiting nerve-mediated 
contractions in the prostatic region, suggesting that A2 receptors here are of 
the A2b subtype. Therefore these results suggest that adenosine receptors are
differentially distributed along the length of the rat vas deferens with pre- and 
post-junctional Ai receptors being present in both regions whereas post­
junctional A2 receptors, of the A2b subtype, are present only in the prostatic 
region of the tissue.
3.1. In the whole rat vas deferens the ability of CPA to enhance contractions 
induced by a variety of contractile agents in the rat vas deferens was 
investigated. CPA (< 1 pM) enhanced contractions induced by exogenous 
adenosine triphosphate (ATP) (10 pM), 5-hydroxytryptamine (5-HT) (3 pM), 
tyramine (10 pM), 2-methyl-5-hydroxytryptamine (2-Me-5-HT) (10 pM) and 
KCl (35 mM) and this enhancement was blocked by an A 1-selective 
concentration (3 nM) of l,3-dipropyl-8-cyclopentylxanthine (DPCPX). CPA 
failed to enhance contractions induced by exogenous noradrenaline (NA) (10 
pM), bradykinin (0.1 pM), phenylephrine (3 pM) or carbachol (10 pM).
3.2. The contractions induced by ATP (10 pM), 5-HT (3 pM), 2-Me-5-HT (10 pM) 
and KCl (35 mM) were unaffected by tetrodotoxin (1 pM), suggesting that 
they were not due to the stimulation of excitatory nerves, as well as by 
desensitisation of the P2x-purinoceptors with the ATP analogue adenosine 5'- 
(a, p-methylene)triphosphonate (AMPCPP), suggesting that they were not due 
to the release of ATP. The contractions induced by tyramine (10 pM) and 2- 
Me-5-HT(10 pM) were blocked by prazosin (100 nM), or by imipramine (1 
pM), suggesting that they were due to the release of NA. Ketanserin (10 nM) 
antagonised the response to 5-HT giving a dose-ratio of 12.9 corresponding to 
an apparent pA2 of 9.1, suggesting a direct action on 5 -HT2 receptors.
3.3. In the rat vas deferens, the Ai-mediated effect was clearly selective for certain 
contractile agents and not due to a non-specific increase in contractility of the 
tissue. CPA enhanced contractions induced by both ATP and indirect
sympathomimetics which release endogenous NA, and this enhancement of 
the two sympathetic co-transmitters may have a functional significance, and 
demonstrates the complexity of the neuromodulatory effects of adenosine in 
the rat vas deferens.
4. The ontogeny of adenosine receptors in the rat vas deferens was investigated. 
The pre-junctional A% receptor in the rat vas deferens was present from day 15 
onwards, day 15 being the earliest age at which nerve-mediated contractions 
could be detected. The potency of CPA in activating this receptor was 
constant across the ages studied, suggesting that the receptor is similar to the 
adult throughout the ages. The post-junctional A% receptors were also present 
as early as they could be detected, from day 10 onwards (day 10 being the 
earliest age at which responses to KCl could be observed). The potency of 
NECA and CPA in activating this receptor also remained constant with an 
increase in age. However the post-junctional Ai receptor displayed a different 
developmental profile to that of the pre-junctional Ai and post-junctional A2 
receptors. At 10 and 15 days, no enhancement by CPA of contractions 
induced by KCl was detected, whereas from day 20 to day 40, this 
enhancement increased with an increase in age, and the level of enhancement 
achieved statistical significance from day 30. These results show a differential 
development of the adenosine receptors in the rat vas deferens with post­
junctional Ai receptors demonstrating delayed development, while pre­
junctional Ai and post-junctional A2 receptors were present from the earliest 
ages studied.
5.1. The location of adenosine receptors in the separated layers of the rat 
duodenum, the longitudinal muscle and the muscularis mucosae, was 
investigated.
5.2. In the adult rat duodenum longitudinal muscle adenosine analogues caused 
relaxation with a potency order of CPA = NECA > adenosine, and a 
nanomolar concentration of DPCPX antagonised the response to CPA and 
NECA, suggesting the activation of Ai receptors here. At a higher 
concentration of DPCPX (1 pM), the responses to CPA were abolished, 
whereas the responses to NECA were antagonised, suggesting that CPA 
activates Ai receptors, whereas NECA activates possibly a mixture of both Ai 
and A2 receptors on this tissue as shown for the whole tissue. This was also 
shown by Schild analysis for CPA versus DPCPX which gave a slope that did 
not differ from unity, suggesting that CPA was acting on one receptor type 
(Ai receptors), whereas the Schild analysis for DPCPX versus NECA gave a 
slope that was much lower than unity, suggesting that NECA was acting on a 
mixed population of receptors, presumably Ai and A2 receptors. The A2 
receptor was shown to be of the A2b subtype due to the low activity of CGS 
21680 compared to NECA.
5.3. In the adult rat duodenum muscularis mucosae adenosine analogues caused 
contraction with a potency order of CPA = NECA > adenosine, and DPCPX 
in the micromolar range antagonised the response to CPA and NECA, 
suggesting the activation of A2 receptors in this tissue. Contractions here were 
not blocked by indomethacin, indicating that they were not due to the release 
of prostaglandins. CGS 21680 (10 |xM) was inactive in this tissue suggesting 
that the receptor is of the A2b subtype.
6. The ontogeny of adenosine receptors in the separated layers of the rat 
duodenum was investigated. In the longitudinal muscle CPA caused 
relaxations from day 20 onwards, acting via Ai receptors as the effects were 
antagonised by a nanomolar concentration of DPCPX, whereas no relaxations
were observed to CPA at day 15 (the earliest age it could be tested due to the 
fragility of the tissue). NECA also caused relaxations in this tissue, but 
relaxations here were apparent from day 15 onwards. NECA was activating 
A2 receptors at day 15 as responses were antagonised by a micromolar 
concentration of DPCPX, and as CGS 21680 was less potent than NECA the 
A2 receptors were of the A2b subtype. However from day 20 onwards, NECA 
activated a mixture of Ai and A2b receptors, as shown for the adult tissue 
where responses were antagonised by a micromolar concentration of DPCPX. 
In the muscularis mucosae, contractions to CPA were detected from day 10 
onwards (the earliest it could be tested due to the fragility of the tissue). 
Contractile responses in the neonatal muscularis mucosae were antagonised by 
a micromolar concentration of DPCPX suggesting the activation of A2 
receptors in this tissue. The A2 receptors were of the A2b subtype as CGS 
21680 was 100 fold less potent than NECA. Overall, these results show that 
in the rat duodenum A2b receptors are present early in the postnatal period, 
whereas the development of the A% receptor takes place after day 20.
7.1. The ontogeny of P2 -purinoceptors in the longitudinal muscle and the 
muscularis mucosae of the rat duodenum was investigated. The degradation 
of P2"purinoceptor agonists by the rat duodenum muscularis mucosae was also 
studied.
7.2. In the rat duodenum longitudinal muscle 2-methylthioadenosine-5'- 
triphosphate (2-Me-S-ATP) and AMPCPP both caused a relaxation with a 
potency order of 2-Me-S-ATP > AMPCPP from day 20 onwards. This 
suggests the activation of P2Y receptors as previously reported for the adult 
tissue. Weak relaxations were observed to both the agonists at day 15 (the 
earliest age it could be studied), but only at high concentrations, and the
agonists appeared to be equipotent. The potency of 2-Me-S-ATP and 
AMPCPP in causing relaxations was least in the neonates below day 20, and 
reached values not significantly different from adult by day 25.
7.3. In the rat duodenum muscularis mucosae AMPCPP, ATP, uridine triphosphate 
(UTP) and 2-Me-S-ATP all caused a contraction throughout the ages studied, 
day 10 being the earliest age it could be tested. The potency order of agonists 
above day 25 were AMPCPP > ATP = UTP > 2-Me-S-ATP and is similar 
to the potency order previously reported for the adult tissue. However in the 
neonates below day 25, the potency of 2-Me-S-ATP was considerably 
increased and at days 10 and 15 it was the most potent agonist with a potency 
order of 2-Me-S-ATP > AMPCPP > ATP = UTP.
7.4. In the rat duodenum muscularis mucosae from greater than 25 day old tissues, 
as in adult tissues, AMPCPP and 2-Me-S-ATP activated P%x receptors to 
cause contraction, as AMPCPP was more potent than 2-Me-S-ATP and as 
responses to AMPCPP were desensitised at day 30 with cross-desensitization 
observed between AMPCPP and 2-Me-S-ATP. However in the neonates at 
days 10 and 15, AMPCPP and 2-Me-S-ATP activated P2Y receptors to cause 
contraction as 2-Me-S-ATP > AMPCPP and as no desensitization of the 
response to AMPCPP or no cross-desensitization between AMPCPP and 2- 
Me-S-ATP was observed. On the other hand ATP and UTP were equipotent 
in causing contractions in the muscularis mucosae throughout the neonatal 
ages and as no cross-desensitization was observed between AMPCPP and 
ATP or UTP it is likely that they activated P2U receptors in this tissue, as in 
adult tissues.
7.5. The potency of all the agonists in causing contraction in the rat duodenum 
muscularis mucosae decreased with age. The potency of AMPCPP and 2-Me-
S-ATP in causing contractions in this tissue was highest in the neonates below 
day 25, and reached values not significantly different from adult by day 30, 
with a drop in potency of > 3 log units for 2-Me-S-ATP and 1 log unit for 
AMPCPP. The potency of ATP and UTP in causing contractions in this tissue 
was also highest in the neonates at days 10 and 15, and reached values not 
significantly different from adult by day 20, with drops in potency of one log 
unit for both the agonists. These decreases in potency could simply reflect 
differences in receptor number or they could be explained in terms of 
increasing degradation of agonists with age.
7.6. Degradation of ATP, UTP, 2-Me-S-ATP by the rat duodenum muscularis 
mucosae was investigated using tissues from 15 and 30 day old rats. At days 
15 and 30, ATP was degraded to adenosine 5'-diphosphate (ADP), adenosine 
5'-monophosphate (AMP) and inosine with no adenosine being detected, 2- 
Me-S-ATP was degraded to 2-methylthioadenosine 5'-diphosphate (2-Me-S- 
ADP), 2-methylthioadenosine 5'-monophosphate (2-Me-S-AMP) and 2- 
methylthioadenosine (2-Me-S-adenosine), and uridine 5'-triphosphate (UTP) 
was degraded to uridine 5'-diphosphate (UDP), uridine 5'-monophosphate 
(UMP) and uridine. AMPCPP was also degraded with AMPCP being 
detected, however the rate of degradation of AMPCPP was much slower than 
for ATP, UTP or 2-Me-S-ATP at day 30. The rates of degradation of ATP, 
UTP, 2-Me-S-ATP were similar to each other at both ages, but the rates were 
faster at day 30 than at day 15. The rate of degradation of AMPCPP observed 
at day 15 was not significantly different from the rate observed at day 30. 
Therefore the decrease in potency of agonists with age in this tissue may well 
be due to the increased activity of ectonucleotidases, while the larger drop in 
potency of 2-Me-S-ATP may indeed confirm the suggestion that contractions
are mediated by a P2Y receptor in the neonates but a P2X receptor in the 
adults.
7.7. Overall, these results suggests that in the neonatal rat duodenum longitudinal
muscle there are P2 Y receptors mediating relaxation and the receptor 
population is fully developed by day 25. In the neonatal rat duodenum 
muscularis mucosae there are P2Y receptors below day 2 0  mediating 
contraction, and after day 25 a P2X receptor mediates this effect. In this tissue 
a P2U receptor was also shown to mediate contraction throughout the ages. 
The results also indicate that the ectonucleotidase activity in the rat duodenum 
muscularis mucosae increases with age and the drop in potency of the agonists 
in this tissue may partly be due to this.
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1.1. GENERAL BACKGROUND
Purine nucleosides, such as adenosine, and purine nucleotides, such as 
adenosine triphosphate (ATP), produce a wide range of pharmacological effects other 
than their well known role in energy metabolism. In 1929, Drury and Szent-Gyorgyi 
showed that adenosine when injected into anaesthetised animals produced a large 
number of biological effects, including bradycardia, reduction in the contractility of 
the atria, dilation of the coronary vessels and lowering of the arterial pressure (Drury 
& Szent-Gyorgyi, 1929).
Further to this initial finding little interest was shown until 1963 when Berne 
proposed that adenosine was involved in metabolic regulation of coronary blood flow. 
During hypoxia, adenosine is released and it was suggested that this reduced 
metabolic demand and/or increased oxygen availability by reducing the heart rate and 
inducing arteriolar dilation thereby increasing coronary blood flow (Berne, 1963). 
This feedback effect of adenosine gave an understanding of adenosine as a metabolic 
modulator. In 1970, Sattin and Rail showed that adenosine increased cAMP 
accumulation in brain slices and that this effect was inhibited by methylxanthines 
(Sattin & Rail, 1970). Therefore the evidence of adenosine acting on specific 
receptors began to emerge.
Not only is adenosine recognised as having an important role in the 
cardiovascular system, it has also been shown to have an important role in the central 
nervous system. It has been implicated as a neuromodulator acting via pre-junctional 
receptors to cause inhibition of neurotransmitter release (Phillis and Wu, 1981).
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ATP has been shown to exert excitatory effects in the nervous system. ATP is 
released as a co-transmitter with noradrenaline from sympathetic nerves innervating 
vascular smooth muscle, and with acetylcholine from parasympathetic nerves 
controlling tissues such as the urinary bladder (Bumstock, 1990; 1993). For example, 
in smooth muscle preparations such as the guinea-pig taenia caeci, nerve stimulation 
produced a relaxation which was resistant to blockade by the cholinoceptor antagonist 
atropine (Bumstock et al., 1963), or the adrenergic neurone blocker guanethidine 
(Bumstock et al., 1964). This led to the realisation that nerve stimulation of many 
smooth muscle preparations gave responses that were resistant to both adrenergic and 
cholinergic antagonists, and these nerves were termed "non-adrenergic non- 
cholinergic" (NANC) nerves (Bumstock, 1972). It has since also been shown that 
ATP can activate specific receptors in sensory neurones indicating a connection 
between ATP and pain (Kennedy and Leff, 1995a).
As well as these findings, adenosine and ATP have now been shown to 
influence many biological processes (for review see White, 1988), and their effects 
have been shown to be mediated via receptors known as purinoceptors (Bumstock, 
1978).
1.2. PRODUCTION AND METABOLISM OF ADENOSINE
Intracellular adenosine is produced by two main pathways. Adenosine is 
formed by the dephosphorylation of AMP to adenosine by cytosolic 5'-nucleotidases. 
AMP is formed as a result of energy metabolism where ATP is dephosphorylated by 
adenosine triphosphatase to ADP, which then can be converted to AMP by adenylate 
kinase. Alternatively, adenosine can be formed by the catabolism of S-
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adenosylhomocysteine which is derived from S-adenosylhomomethionine. S- 
adenosylhomocysteine undergoes enzymatic hydrolysis by adenosylhomocysteine 
hydrolase to yield adenosine (Henderson, 1985). Adenosine can also be synthesised 
via a number of other minor pathways including the reaction of adenine and ribose-1- 
phosphate and from adenosine end groups of ribonucleic acid (Phillis and Wu, 1981; 
Henderson, 1985; White, 1988).
Extracellular adenosine can result from more than one source. It can result 
from the transport of intracellular adenosine via a bi-directional nucleoside transport 
system when the intracellular adenosine concentration exceeds extracellular levels. 
This process can be reversed when extracellular concentration of adenosine exceeds 
intracellular levels (Patterson et al., 1985). The adenosine transport system can be 
controlled by adenosine uptake inhibitors such as dipyridamole and 
nitrobenzylthioinosine (NBTI) (Pearson and Gordon, 1985). Alternately adenosine 
can be formed by the metabolism of extracellular adenine nucleotides to AMP (see 
section 1.3.) via ecto-5’-nucleotidase located on the outer face of the plasma 
membrane which converts this extracellular AMP to adenosine (Meghji, 1993).
Intracellular or extracellular adenosine can be metabolised into inosine, 
hypoxanthine and uric acid by adenosine deaminase, xanthine oxidase and xanthine 
dehydrogenase respectively. Inosine is pharmacologically inactive and the rate of 
breakdown of adenosine has been shown to vary from tissue to tissue. The rate of 
breakdown of adenosine is much slower in the guinea-pig taenia caeci and vas 
deferens than it is in the rat duodenum (Welford et al., 1986; 1987; Nicholls et al, 
1992). This breakdown of adenosine can be prevented by the use of adenosine 
deaminase inhibitors such as erythro-9-(2-hydroxy-3-nonyl)adenine (BHNA) and 
deoxycoformycin (Henderson et al., 1977; Agrawal, 1982).
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1.3. PRODUCTION AND METABOLISM OF ATP
ATP is synthesised by glycolysis and by oxidative phosphorylation. ATP has 
been generally considered not to cross cell membranes, presumably to conserve the 
high energy molecule within the cell. However ATP is stored with acetylcholine in 
cholinergic synaptic vesicles (Dowdall et al., 1974), with noradrenaline within 
sympathetic vesicles (Lagercrantz and Stjarne, 1974) and in adrenal chromafin 
granules (Winkler and Carmichael, 1982). During exocytosis, ATP is released from 
the cell when the vesicle contents are secreted. Once released, ATP can act on its 
receptors before undergoing rapid dephosphorylation to adenosine via cell surface 
ectonucleotidases (Pearson, 1985). The dephosphorylation of ATP occurs via a series 
of steps and different enzymes have been associated with this process (Pearson, 
1985). ATP is dephosphorylated to ADP by ecto ATPase, ADP to AMP by ecto 
ADPase, and AMP to adenosine by ecto 5’-nucleotidase. Although this is the major 
route of degradation of extracellular ATP, the involvement of extracellular ATP- 
diphosphorylase has also been shown in some tissue preparations such as in the 
mouse liver and in the dog kidney (Knowles et al., 1983).
Nucleotidase activity is highly dependent on divalent cations such as Mg^+ or 
Ca^+. These enzymes are widespread, and have been shown on most cells including 
vascular endothelial and smooth muscle cells, synaptosomes, various blood cells and 
in visceral smooth muscle cells (Pearson, 1985; Ziganshin et al., 1994). 
Ectonucleotidases have been shown to be stereoselective. L-ATP and L-ADP appear 
to be poor substrates compared to the D-enantiomers for ecto ATPase and ecto 
ADPase found on endothelial cells respectively. Also the ecto 5'-nucleotidase shows 
stereoselectivity as L AMP is inactive compared to AMP itself (Cusack et al., 1983; 
Pearson and Cusack, 1985; Pearson 1986). The substituted analogues of ATP such as
28
2-methylthioadenosine-5'-triphosphate (2-Me-S-ATP) are dephosphorylated at a similar 
rate to ATP via ectonucleotidases on visceral smooth muscle preparations such as in 
the guinea-pig taenia caeci and in the urinary bladder, where stereo selectivity for the 
D- enantiomer compared to the L-enantiomer was also noted (Welford et al., 1986; 
1987). The phosphorothioates such as adenosine-5'-0-(3-thiotriphosphate) (ATP-y-S) 
are resistant to dephosphorylation but adenosine-5'-0-( 1 -thiotriphosphate) (ATP-a-S) 
has been shown to be dephosphorylated in the pig aorta smooth muscle cells and in 
the guinea-pig urinary bladder (Welford et al., 1987) but not in the guinea-pig taenia 
caeci (Welford et al., 1986). There are differences between ectonucleotidases located 
on different types of cells. For example on vascular smooth muscle cells, the 
dephosphorylation of ATP to adenosine is immediate and rapid, whereas on 
endothelial cells, ATP is metabolised to AMP before any significant conversion to 
adenosine occurs (Gordon et al., 1986; 1989). These differences in kinetics have been 
suggested to be due to the preferential delivery of intermediates between 
ectonucleotidases at the surface of vascular smooth muscle cells (Gordon et al., 1989; 
Slakey et al., 1990). In addition vascular smooth muscle cells lack the high affinity 
adenosine transport system found on endothelial cells whereby extracellular adenosine 
can be removed (Pearson et al., 1978).
The rapid degradation of ATP to adenosine makes pharmacological analysis of 
the effects of ATP difficult to interpret. Thus ectonucleotidase inhibitors would be 
useful in the study of the pharmacological activity of ATP. There are a number of 
compounds known to inhibit nucleotidase activity. The ATP analogues such as ATP- 
y-S and adenosine 5'-(p,y-methylene)triphosphonate (AMPPCP) have been shown to 
inhibit the breakdown of ADP, however they themselves have a direct action on P2- 
purinoceptors (Pearson, 1986). Suramin has also been shown to behave as an 
inhibitor of ecto ATPase (Hourani and Chown, 1989), however it is a P2-purinoceptor
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antagonist, therefore its use is also limited. Recent studies have identified a novel 
analogue of ATP, 6 -N,N-diethyl-p,y-dibromomethylene D-ATP (ARL 67156 or 
formally known as FPL 67156), as an inhibitor for ecto ATPase in the rabbit ear 
artery (Crack et al., 1995), but this compound also acts as a weak antagonist at P2 - 
purinoceptors. However this compound is not yet conmiercially available. Overall, 
the major problem of current ectonucleotidase inhibitors is the fact that they 
themselves act as agonists or as antagonists at P2-purinoceptors, therefore the use of 
such compounds in a purinoceptor study can complicate the interpretation of results.
1.4. PURINOCEPTORS
Adenosine and adenine nucleotides exert their effect via receptors known as 
purinoceptors. Bumstock in 1978 classified these receptors into two subclasses based 
on the relative potencies of adenosine and ATP and the susceptibility to blockade by 
methylxanthines (Bumstock, 1978). Pi-purinoceptors (adenosine receptors) show an 
agonist potency order of adenosine > AMP > ADP > ATP and their effects can be 
antagonised by methylxanthines, whereas at P2-purinoceptors the agonist order is 
ATP > ADP > AMP > adenosine and the effects are not blocked by 
methylxanthines.
1.5. Pi-PURINOCEPTORS
Pi-purinoceptors were further subdivided on the basis of whether they inhibit or 
stimulate adenylate cyclase. Those receptors mediating inhibition of adenylate 
cyclase were termed Ai and those mediating stimulation of adenylate cyclase were
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^  Rank order of agonist potency cannot be solely relied upon to characterize 
receptors. For example more than one receptor type at which the agonists act may 
indeed give a distorted order of potency. In addition potency is not directly related to 
affinity and also is affected by efficacy and the number of receptors present, therefore 
the use of selective competitive antagonists is more reliable.
termed A% (Van Calker et al., 1979). These same receptors were termed Ri and Rg 
receptors respectively (Londos et al., 1980), but the former has become the accepted 
nomenclature. However it is now known that adenosine can bind to many effector 
systems other than adenylate cyclase such as potassium channels, calcium channels, 
phospholipase C, phospholipase A2 and guanylate cyclase (for review see Fredholm 
et al., 1994), and therefore the A1/A2 nomenclature does not imply modulation of a 
specific effector system. The A2 receptor has been further subdivided into A2a and 
A2b receptors (Daly et al., 1983; Bruns et al., 1986; 1987a). There has been a third 
addition to the Pi-purinoceptor classification. In 1992, Zhou and co-workers 
proposed the A3 receptor on the basis of cloning and functional characterisation of a 
receptor from the rat striatum (Zhou et al., 1992). The cloning of Ai, A2a and A2b 
receptors has also been carried out, thus confirming the existence of separate Pi- 
purinoceptor subtypes, and they all form a class of G-protein coupled receptors (for 
reviews see Collis and Hourani, 1993, Fredholm et al., 1994; Olah and Stiles, 1995). 
The classification of Pi-purinoceptors is shown in Figure 1.1.
Adenosine has been modified in a number of ways to produce a range of 
analogues (Jacobson, 1990) and these analogues have been used in functional studies 
to classify Pi-purinoceptor^ C2-substitution of the adenine moiety gives analogues 
such as 2-chloroadenosine (2CAD0), 2-phenylaminoadenosine (CV1808) and 2-p- 
((carboxyethyl)phenylethylamino)-5'-N-ethylcarboxyamidoadenosine (CGS 21680).
-substitution of the adenine moiety gives analogues such as N^- 
(phenylisopropyl)adenosine (PIA), N^-cyclohexyladenosine (CHA) and N^- 
cyclopentyladenosine (CPA) which are potent agonists at Ai receptors. Alterations at 
the ribose moiety is rarely tolerated by P 1 -purinoceptors, however 5'-N- 
ethylcarboxyamidoadenosine (NECA) has been used as a non selective Pi- 
purinoceptor agonist (Bruns et al., 1986). The potency of adenosine can be influenced
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by uptake and deamination, therefore the interpretation of potency orders can be 
complicated by these processes. However adenosine analogues such as NECA or 
CPA are not affected by uptake or deamination. For example, uptake blockers do not 
enhance the effect of NECA in the guinea-pig trachea (Brown and Collis, 1982) or in 
the taenia caeci (Prentice et al., 1995), and NECA is not deaminated (Raberger et al., 
1977). CPA is also not deaminated and the effects of N^-substituted analogues are 
also not enhanced by blockade of uptake (Brown and Collis, 1982). Some of the P%- 
purinoceptor agonists are shown in Figure 1.2.
1.5.1. A i receptor
The adenosine A% receptor is a G-protein coupled receptor (Munshi et al., 
1991), and is known to be present mainly pre-synaptically playing an important role 
in the central and peripheral nervous system. It has been shown to inhibit the release 
of a variety of neurotransmitters, including acetylcholine, dopamine, noradrenaline, 
GABA and 5-HT (Stone, 1981; Harms et al., 1978; Williams, 1984). The Ai receptor 
has also been shown post-junctionally on smooth muscle preparations including the 
rat colon, guinea-pig aorta and guinea-pig trachea mediating contractions of the tissue 
(Bailey et al., 1992; Stoggall and Shaw, 1990; Farmer et al., 1988). A% receptors are 
also present in the heart, for example in guinea-pig atria Ai receptors have been 
shown to mediate cardiac depression (Collis, 1983). The second messenger system 
linked to A% receptors was originally considered to be only the inhibition of adenylate 
cyclase activity (Van Calker et al., 1979; Londos et al., 1980). However this receptor 
has now been shown to be linked to many other effector systems including the 
inhibition of phospholipase A2 , stimulation of guanylate cyclase, stimulation of 
phospholipase C, activation of potassium channels and inhibition of calcium channels
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(for review see Fredholm., 1994). The functional classification of the Ai receptor has 
been largely based on the potency orders of adenosine agonists and antagonists.
1.5.11. Ai receptor agonists
Many Ai selective agonists have been derived by N^-substitution of 
adenosine, which markedly increase A% potency. These include CHA, PI A and CPA 
(Bruns et al., 1986). PIA can exist as two isomers, R-PIA and S-PIA, and the Ai 
receptor has been considered to show stereoselectivity as R-PIA is about 100 fold 
more potent in activating the Ai receptor compared to S-PIA (Collis, 1983). For 
example R-PIA has an affinity of 1.2 nM whereas S-PIA has an affinity of 0.53 pM at 
Ai receptors. CPA is used as a potent agonist at A% receptors with an affinity of 0.6 
nM. CPA is about 700 fold selective for the Ai receptor over the A2 receptor and is 
also about 400 fold selective for the Ai over the A3 receptor (Bruns et al., 1986; Van 
Galen et al., 1994). NECA has an affinity of 6.3 nM at Ai receptors and binds to both 
Ai or A2a receptors, however it is about 400 fold selective for Ai over A2b receptors, 
but only 10 fold for Ai over A3 receptors (Bruns et al., 1986; Van Galen et al., 1994), 
Therefore NECA has been widely used as a non selective P%-purinoceptor agonist in 
many tissue preparations.
15.1.2. Ai receptor antagonists
Naturally occurring xanthines such as caffeine and theophylline were first 
proposed as adenosine receptor antagonists by Sattin and Rail (1970). Caffeine and 
theophylline are both non selective, weak, competitive antagonists and caffeine has
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affinities at the Ai, A2a and A2b receptor of 44, 45 and 30 pM respectively, while 
theophylline has affinities of 14, 22 and 32 pM at the same subtypes respectively 
(Bruns et al., 1986; Van Galen et al., 1994). Since then, more selective Ai xanthine 
antagonists have been developed using the theophylline structure. Replacement of the 
methyl groups in the theophylline structure with bulky propyl groups has led to the 
development of the Ai selective antagonist, l,3-dipropyl-8-cyclopentylxanthine (CPX 
or more conunonly known as DPCPX) (Bruns, 1990). DPCPX has an affinity of 0.9 
nM at Ai receptors and is greater than 500 fold selective for Ai receptors over A2 
receptors (DPCPX has micromolar affinity at A2 receptors) (for review see Collis and 
Hourani, 1993). Further modification to the DPCPX structure has led to the 
development of several other Ai antagonists, however the most widely and 
successfully used compound to date is DPCPX (Coates et al., 1994).
The 8 -phenyl analogues such as 8 -phenyltheophylline (8 -PT) have also been 
used as A% receptor antagonists. 8 -PT is a non selective antagonist with affinities in 
the micromolar range for both Ai and A2 receptors, and also displays low water 
solubility (Bruns and Fergus, 1989). The addition of a sulphur group to the 8 -PT 
structure has produced 8 -(sulphophenyl)theophylline (8 -SPT) which is highly water 
soluble. However 8 -SPT still remains a non selective antagonist at Pi-purinoceptors 
with an affinity of 4.5 pM at both A% and A2 receptors. There are also a number of 
nonxanthine antagonists at Ai receptors, however low water solubility limits the 
usefulness of many such compounds (for review see Daly and Jacobson, 1995). The 
structures of some of the A% receptor antagonists are shown in Figure 1.3 and the 
potency order of antagonists is shown in Table 1.2.
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1.51.3. Cloning of Ai receptors
Molecular biology studies have further confirmed the existence of Ai 
receptors in many tissues. Libert and co-workers (1989) cloned two orphan receptors, 
RDC7 and RDC8  from a canine cDNA library. They identified the RDC7 as the A% 
receptor and showed that it was expressed in the canine thyroid gland, brain, kidney, 
heart and testis (Libert et al., 1991; 1992). The canine receptor when expressed in 
Chinese hamster ovary (CHO) cells confers CPA-mediated inhibition of forskolin- 
stimulated adenylate cyclase activity. The A% receptor has now been cloned from 
other species of animal including rat and bovine tissues (Repert et al., 1991; Mahan et 
al., 1991; Tucker et al., 1992; Olah et al., 1992). The rat Ai receptor shows 91% 
sequence homology to the canine A% receptor. The bovine Ai receptor also has a 
greater than 90% sequence homology with the canine and rat Ai receptor, but shows a 
different agonist potency order. In the canine and the rat, the agonist potency order is 
R-PIA > NECA > S-PIA, which is similar to the classical agonist order at A% 
receptors, whereas in the bovine, the order is R-PIA > S-PIA > NECA (Tucker et 
al., 1992, Olah et al., 1992). The human A% receptor has also been cloned and shows 
a 94% sequence homology to the canine, rat and bovine Ai receptors and it also 
displays the classical Ai potency order of agonists (Salvatore et al., 1992).
1.5.2. À2a and Â2b receptors
A2 receptors are also G-protein coupled and are thought to be mainly present 
post-junctionally mediating relaxation of smooth muscle preparations such as in the 
guinea-pig taenia coli (Bumstock et al., 1984b), guinea-pig trachea (Brown and 
Collis, 1982), guinea-pig aorta (Collis and Brown, 1983) and rat aorta (Lewis et al..
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1994; Prentice and Hourani, 1996). However the presence of A% receptors pre- 
synaptically in the central nervous system mediating excitatory actions has also been 
suggested (Fredholm, 1995; Correiadesa and Ribeiro, 1994). For example A2 a 
receptors are present on cholinergic striatal nerve terminals stimulating acetylcholine 
release (Kirk and Richardson, 1994).
The A2 receptor exists as two subtypes (Daly et al., 1983), the high affinity 
A2a receptor and the low affinity A2b receptor, which are both linked to adenylate 
cyclase activation. The A2a receptor has a higher affinity for adenosine agonists 
compared to the A2b receptor.
An adenosine receptor termed A4  has also been characterised in rat brain using 
the radioligand [^HjCV 1808 (Cornfield et al., 1992). This receptor, like the rat A3 
receptor, is insensitive to xanthine antagonists, and is thought to be linked to the 
stimulation of potassium channels. However, subsequent binding studies by Luthin 
and Linden (1995) has indicated that the A4 receptor may be a temperature-sensitive 
form of the A2a receptor, and therefore it is not included as a separate Pi-purinoceptor 
subclass.
I.5.2.I. A2a and A%b receptor agonists
Most A2a selective agonists are based on the C2-substitution of the adenine 
moiety which increases A2a potency. CGS 21680 has an affinity of 15 nM for the A2a 
receptor whereas it is almost inactive at the A2b subtype (up to 100 |iM), and has 
micromolar affinity at both Ai and A3 receptors. Therefore, CGS 21680 is 
considered to be the standard A2a selective agonist used to distinguish between
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subtypes (170 and 39 fold selective for A2a receptor versus A% and A3 receptors 
respectively) (Bruns et al., 1986; Hutchinson et al., 1989, Van Galen et al., 1994). 
CV 1808 is also used as a potent agonist at A2a receptors, showing nanomolar affinity 
at A2a receptors compared to micromolar affinity at A2b receptors (it can also active 
Ai receptors with only 2 fold selectivity for A2a compared to A% receptors) (Bruns et 
al., 1986). There are no selective A2b receptor agonists to date and the identification 
of such a compound would prove useful in the pharmacological analysis of A2 
receptors.
The non selective ligand, NECA, is also used as an A2 receptor agonist (Bruns 
et al., 1986; Van Galen et al., 1994), with an affinity of 10 nM at the A2 a receptor 
subtype compared to an affinity of 1.9 |XM at the A2b subtype (Bruns et al., 1986). In 
contrast with Ai receptors, the N^-substituted analogues such as R-PIA, S-PIA and 
CPA have low potency at A2 receptors. The affinities of R-PIA, S-PIA and CPA at 
the A2a subclass are 0.12, 0.22 and 0.46 pM respectively (Bruns et al., 1986). Also, 
unlike the A% receptor, A2a and A2b receptors do not show stereoselectivity with R- 
and S- isomers of PIA having similar affinities (for reviews see Collis and Hourani, 
1993; Fredholm et al., 1994). The structures of some of the A2 receptor agonists are 
shown in Figure 1.2 and the potency orders are shown in Table 1.1.
I.5.2.2. À2a and À2b receptor antagonists
The commonly used xanthine antagonists at A2 receptors have evolved from 
caffeine which is a weak non selective antagonist. CSC (8-(3-chlorostyryl)caffeine) is 
such a ligand which has an affinity of 54 nM at the A2a subtype but only 8.2 pM at 
the A2b subtype, displaying more than 1 0 0  fold selectivity for A2a receptors compared
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to A2b receptors (Jacobson et al., 1993). CSC is also a weak Ai receptor antagonist 
with an affinity of around 28 pM at the Ai receptor displaying more than 500 fold 
selectivity for A2a over Ai receptors (Jacobson et al., 1993). The xanthine analogue, 
N-[2-(dimethyl-amino)ethyl]-N-methyl-4-(2,3,6,7-tetra-hydro-2,6-dioxo-l,3-dipropyl- 
lH-purin-8 -yl) benzene-sulphonamide (PD 115,199), is also used as an antagonist to 
distinguish between A2a and A2b receptor subtypes (Bruns et al., 1987a). PD 115,199 
has an affinity of 15.5 nM at A2a receptors, whereas the affinity is reduced at the A2b 
subtype to 0.16 pM, so it has only 10 fold selectivity for A2a receptor compared to 
A2b receptors. However, PD 115,199 does not distinguish between Ai and A2 a 
receptors, as it also has nanomolar affinity at A% receptors (13.9 nM). DPCPX has 
been used widely to distinguish between Ai and A2 receptors where the receptor 
affinity order is Ai > A2 b > A2a (the affinities of DPCPX at Ai, A2b and A2a 
receptors are 0.9 nM, 0.36 pM and 0.47 pM respectively) (Bruns et al., 1987b; Collis 
et al., 1989; for reviews see Collis and Hourani, 1993; Coates et al., 1994; Fredholm 
et al., 1994).
There are several non xanthine A2 receptor antagonists, and the most selective 
ligand has been shown to be ZM 241385 (4-(2-[7-amino-2-(2-furyl)-[l,2,4]- 
triazolo[2,3-a]-[ 1,3,5]-triazin-5-yl)amino]ethyl)phenol) (Poucher et al., 1995). This 
compound has nanomolar affinity at A2a receptors with a pA2 of 8.57 and is 400-1000 
fold selective for A2a versus A% receptors, 30-80 fold selective for A2a versus A2 b 
receptors and 6700 fold selective for A2a versus A3 receptors (Poucher et al., 1995). 
The structure of some of the A2 receptor antagonists are shown in Figure 1.3 and tlje 
potency orders are shown in Table 1.2.
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1.5.2.3, Cloning of A2a and A2b receptors
The RDC8  receptor was cloned from the canine thyroid gland which led to the 
identification of the A%a receptor (Schiffman et al., 1990). The clone expressed in 
African green monkey kidney (COS) cells exhibited characteristics of the high affinity 
A2a receptor with a IQ of 26 nM for CGS 21680 and an agonist potency order of 
NECA > 2CAD0 > adenosine > CPA (Maenhaut et al., 1990). A rat A2a receptor 
has also been cloned from brain cDNA libraries (Chem et al., 1992; Fink et al., 1992). 
The rat A2a receptor shows 82% sequence homology with the canine A2a receptor and 
CGS 21680 has a IQ of 37 nM, and the agonist potency order is NECA > R-PIA > 
CPA > S-PIA, which is the general order of potency of agonists at A2a receptors. A 
human A2a receptor has also been cloned from the heart, ventricle and striatal cDNA 
libraries (Salvatore et al., 1992), and has 93% sequence homology with the canine A2a 
receptor but only 82% sequence homology with the rat subtype. This receptor when 
expressed in COS cells also exhibits the general A2 a potency order of agonists 
observed in the rat, and CGS 21680 also has a IQ in the nanomolar range (17 nM).
In contrast to the A2 a receptors, which are localised in the striatum, A2 b 
receptors are widely distributed in the brain (Daly et al., 1983; Bruns et al., 1986). A 
rat A2b receptor, designated as RFL9, was cloned from a rat brain cDNA library and 
when expressed in COS cells, no binding of the A2a selective ligand CGS 21680 was 
observed and only binding of NECA was seen (Stehle et al., 1992). A human A2b 
receptor has also been cloned and shows 8 6 % sequence homology with the rat A2b 
subtype (Salvatore et al., 1992).
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1.5.3. A3 receptor
The existence of a pre-junctional adenosine receptor, named the A3 receptor, 
was originally proposed by Riberio and Sebastiao (1986), in the frog neuromuscular 
junction, due to the fact that the potency order of agonists did not quite follow the 
general A1/A2 classification. They found an agonist order of CPA = CHA = R-PIA 
= NECA > 2CAD0 in atrial tissues and suggested the presence of a novel receptor 
in these tissues which they called A3 . However this receptor has not gained wide 
acceptance and later studies by Kennedy and co-workers (1992) have shown that this 
receptor is in fact an Ai receptor, as the presence of both Ai and A2 receptors in a 
single tissue may account for discrepancies in potency orders. For example, in the rat 
vas deferens the potency order of agonists mediating inhibition of nerve-mediated 
contractions is NECA = CPA > adenosine, and as there are both inhibitory pre­
junctional Ai and post-junctional A2 receptors in this tissue, the observed potency 
order can be explained by the fact that CPA can activate the Ai receptor whereas 
NECA and adenosine can activate A2 receptors (Hourani et al., 1993b).
A new A3 receptor has now been identified. Unlike Ai or A2 receptors, the 
existence of this receptor has been shown by cloning studies. This A3 receptor was 
first proposed in the rat by Zhou and co-workers (1992).
1.5.3.x. A3 receptor agonists and antagonists
Selective agonists at the A3 receptor are formed by the N-benzyl substitution 
of NECA, giving compounds such as N6-(iodobenzyl)-5'-(N-methyl-carbaxo- 
amido)adenosine (EB-MECA). This compound has nanomolar affinity (0.33 nM) at
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A3 receptors and is used as a selective A3 agonist (Gallo-Rodriguez et al., 1994). IB- 
MECA is also active on A% and A2 a receptors with affinities of 54 and 56 nM 
respectively, showing 50 fold selectivity for A3 receptors compared to A% or A2 a 
receptors (Kim et al., 1994a; Van Galen at al., 1994). The N^-substituted ligand 
APNEA (N^-2-(4-amino-3-phenyl)-ethyladenosine) is also used as an A3 agonist, but 
it is a non selective ligand as it has nanomolar affinity at both A% and A3 receptors 
(Van Galen et al., 1994). APNEA has been shown to induce hypotension in the 
pithed rats, and this has been suggested to be due to the activation of A3 receptors 
present on mast cells (Fozard & Hannon, 1994).
1.5 3.2. A3 receptor antagonists
As the A3 receptor is not highly conserved, species differences can complicate 
the definition of A3 selective antagonist ligands. Other receptors such as tachykinin 
receptors also show species differences where changing a single amino acid in the 
sequence can alter the pharmacological actions of some antagonists, however there 
are other receptors, such as muscarinic receptors, where such differences are rare (for 
review see Hall et al., 1993). In the case of adenosine A3 receptors, some antagonists 
appear to be active at the sheep and human A3 receptors whereas they appear to be 
inactive at the rat subtype. Even though this may suggest A3 receptor subtypes, 
species variation of the receptor seems more likely. The antagonists at A3 receptors 
include acidic substituted 8 -phenylxanthines such as 3-(3-iodo-4-aminobenzyl)-8-(4- 
oxyacetate) -1 -propylxanthine (BW-A522, I-ABOPX), where BW-A522 has 
nanomolar affinity at human and sheep A3 receptors (18 and 3 nM respectively) 
(Salvatore et al., 1993; Linden et al., 1993). BW-A522 has been shown to block the 
hypotensive responses of APNEA in the pithed rat, although the potency of BW-A522
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was lower (in the micromolar range) than at the sheep or the human A3 receptors, 
where it has nanomolar affinity (Fozard & Hannon, 1994). Kim and co-workers 
(1994b) have also recently shown that, at rat A3 receptors BW-A522 and DPCPX 
have affinities in the micromolar range, 1.7 jxM and 5.3 pM respectively. However, 
no potent xanthine or nonxanthine antagonists are available at rat A3 receptors.
1.5.3 3. Cloning of A3 receptors
A new adenosine receptor demonstrating 58% sequence homology with Ai 
and A2 receptors was cloned from a rat brain cDNA library, and the clone designated 
as the A3 receptor (Zhou et al., 1992). Expression in COS and CHO cells showed that 
the transfected rat A3 receptor was able to bind ligands such as R-PIA, S-PIA and 
APNEA, all of which are also Ai agonists. NECA was also active at this receptor 
with a potency order of R-PIA = NECA > S-PIA > adenosine. In contrast with Ai 
receptors, the rat A3 receptor has been shown to be insensitive to xanthine 
antagonists, such as DPCPX and 8 -SPT (Zhou et al., 1992).
The highest expression of rat A3 receptors was in the testis, with low levels in 
the lung, kidney, heart, cortex, striatum and olfactory bulb (Zhou et al., 1992). 
However, the tissue distribution of A3 receptors appears to be different among 
species. In the sheep, high levels are expressed in the lung, spleen, pars tuberalis and 
pineal gland, and moderate levels in the testis, kidney and brain (Linden et al., 1993). 
In contrast, in the human high levels of A3 receptors are expressed in the lung and 
liver, moderate levels in the aorta and brain, and low levels in the testis and heart 
(Linden et al., 1993; Salvatore et al., 1993). The sheep A3 receptor is 72% 
homologous to the rat A3 receptor whereas the human A3 receptor is also 72%
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homologous to the rat, but is 85% homologous to the sheep. The agonist potency 
order for the sheep and the human A3 receptor remains the same as that observed for 
the rat, R-PIA = NECA > S-PIA. However the human and sheep A3 receptor, 
unlike rat A3 receptors, can bind xanthine antagonists such as DPCPX, 8 -PT and BW- 
A522 (Linden et al., 1993; Salvatore et al., 1993), and this has been suggested to be 
due to species variation (Linden, 1994). Recent studies in the rat have shown that A3 
receptor mRNA is present in the central nervous system and many peripheral tissues, 
similar to that observed for this receptor in the human and sheep (Linden, 1994), 
suggesting that the rat A3 receptor has also a wide tissue distribution (Dixon et al., 
1996). The second messenger system linked to the rat, human and sheep A3 receptors 
is inhibition of forskolin stimulated cAMP production, whereas in cultured rat mast 
cells A3 receptors are positively coupled to phospholipase C thereby producing 
inositol trisphosphate (IP3) leading to an increase in intracellular calcium (Ramkumar 
et al., 1993).
1.5.4. P site
In vitro, high concentrations (mM) of adenosine, inhibit the adenylate cyclase 
activity via the "P site" (Londos & Wolff, 1977). This site is within the adenylate 
cyclase catalytic subunit and binds adenosine but not 2CAD0 to inactivate the 
enzyme (Londos & Wolff, 1977). It is not sensitive to other Pi-purinoceptor agonists 
such as NECA, R-PIA and CHA, and their effects are not antagonised by P%- 
purinoceptor antagonists such as 8 -SPT (Daly, 1982; Collis and Brown, 1983). Since 
it requires a high concentration of adenosine to cause inhibition of the adenylate 
cyclase, and since intracellular adenosine is regulated by adenosine deaminase, the P 
site is unlikely to play an important role physiologically.
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Figure 1.2. Structures of some P^-puriuoceptor agonists.
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Figure 1.3. Structures of some Pi-purinoceptor
antagonists.
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1.5.5. ATP as a Pi-purinoceptor agonist
Generally, ATP is thought to act on Pi-purinoceptors after breakdown of ATP to 
adenosine. In the guinea-pig atrium and in the ileum, responses to ATP and the ATP 
analogue, adenosine 5’-(|3,Y-methylene)triphosphonate (p,y-MeATP or AMPPCP), 
have been shown to be blocked by the Pi-purinoceptor antagonist 8-SPT (Moody et 
al., 1984; Collis and Pettinger, 1982). In these tissues contractions to both ATP and 
AMPPCP were not reduced in the presence of adenosine deaminase, which converts 
the metabolically active compound adenosine to the inactive compound inosine, 
suggesting a direct action by ATP and AMPPCP on Pi-purinoceptors. Similarly a 
direct action by AMPPCP on P i -purinoceptors in the rat colon and in the rat 
duodenum has also been suggested as AMPPCP is considered to be relatively stable 
in these tissues and responses were antagonised by Pi-purinoceptor antagonists (such 
as 8-SPT), but not by P2 -purinoceptor antagonists (such as suramin) (Bailey and 
Hourani, 1990; Hourani et al., 1991). However, in tissues such as in the rat 
duodenum and the rat colon, other ATP analogues including adenosine-5'-((x,p- 
methylene)triphosphonate (a,p-McATP or AMPCPP, also metabolically stable) or 2- 
methylthioadenosine-5'-triphosphate (2-Me-S-ATP) activate P2-purinoceptors (Bailey 
and Hourani, 1990; Hourani et al., 1991).
1.6. P2-PURINOCEPTORS
Like P1 -purinoceptors, P2-purinoceptors do not form a homogeneous group. 
They were initially subdivided into P2x and P2Y receptors by Bumstock and Kennedy 
(1985) on the basis of rank order of potencies of various analogues of ATP. They 
showed that on P2X receptors AMPCPP is the most potent ATP analogue, with a
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agonist potency order of AMPCPP > AMPPCP > ATP > 2-Me-S-ATP, whereas on 
P2Y receptors the potent ATP analogue was 2-Me-S-ATP with a agonist potency 
order of 2-Me-S-ATP »  ATP > AMPCPP = AMPPCP.
Following this original sub classification of the P2-purinoceptor into P2X and 
P2Y, P2T and P2Z were also described (Gordon, 1986), the former being an ADP 
sensitive receptor and the latter a non selective ion pore sensitive to ATP^‘. 
Subsequently, P21J receptors, responsive to ATP as well as the pyrimidine nucleotide 
uridine 5'-triphosphate (UTP), have also been proposed (O'Connor et al., 1991), as has 
the P2D receptor, which is sensitive to diadenosine polyphosphates (Hoyle, 1990; 
Pintor and Miras-Portugal, 1993). Diadenosine polyphosphates are a class of 
compounds in which two adenosine molecules are linked via three or more 
phosphates (ApxA). These compounds such as Ap4A, Ap^A and Ap^A have been 
suggested to mediate their effects via receptors named as P2D receptors (Hoyle, 1990; 
Pintor and Miras-Portugal, 1993). However, diadenosine polyphosphates have also 
been shown to activate other purinoceptors such as P2X receptors in the guinea-pig 
vas deferens and the human bladder (MacKenzie et al., 1988; Hoyle et al., 1989; 
Westfall et al., 1996b). Also Ap^A is susceptible to breakdown by ecto ATPase in 
the guinea-pig bladder and in the vas deferens (Westfall et al., 1996b). Therefore this 
subclass has yet to gain wide acceptance.
The classification of P2-purinoceptors has been difficult due the fact that many 
ATP analogues used as agonists undergo metabolism via ectonucleotidases to 
differing degrees. Thus the different rank order of potencies of agonists used to 
define a particular receptor subtype in an isolated tissue may also reflect the structure 
activity relationship and activity of the ectonucleotidases present (Welford et al., 
1986; 1987).
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With the recent cloning of members in the P2-purinoceptor family, a revision of 
the existing nomenclature has been suggested by the lUPHAR Committee on 
Receptor Nomenclature. Abbracchio and Bumstock (1994) have suggested that the 
receptors mediating actions of adenine nucleotides should be classified into two broad 
superfamilies; the P2X receptor family, a receptor class mediating the fast actions of 
ATP and related nucleotides through ligand-gated ion channels, and the P2Y receptor 
family, a class of receptors acting via G-protein coupled receptors. The new receptor 
subtypes have been designated as the P 2 X 1 , 2 , 3 . . .  and P 2 Y 1 , 2 , 3 . . .  For example the 'old' 
P2Y receptor is now described as the P2YI subclass, the P21J receptor is referred to as 
the P2Y2 receptor and the P2Z receptor is the P2X7 receptor (Bumstock and King, 
1996). However, with the uncertainty of P2-purinoceptor nomenclature due to the 
cloning of an increasing number of members in this family, in writing this present 
study, the current widely recognised nomenclature (Fredholm et al., 1994) will be 
used.
1.6.1. P2X receptor
P2X receptors are generally considered to contract smooth muscle preparations 
such as the guinea-pig urinary bladder and the vas deferens (Bumstock and Kennedy 
1985). P2X receptors are ion channels permeable to Na+, K+ and Ca^+, and are 
referred to as ATP-gated ion channels, where activation of these receptors results in 
an overall increase in intracellular Ca^+ levels (Bean and Friel, 1990; Kennedy, 1990; 
Dubyak and El-Moatassim, 1993). ATP analogues with modifications at the C2- 
position of the adenine base such as 2-Me-S-ATP and 2-chloroadenosine-5'- 
triphosphate (2-Cl-ATP) are weak agonists at P2X receptors being less potent than
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ATP (Cusack, 1993). However modification of the oxygen link in the phosphate 
chain of ATP gives analogues such as AMPCPP and AMPPCP which are more potent 
than ATP at P%x receptors (Bumstock et al., 1994). Replacement of the oxygen atom 
by a sulphur group gives analogues such as adenosine-5'-0-(l-thiotriphosphate) 
(ATP-a-S), adenosine-5'-0-(2-thiotriphosphate) (ATP-P-S) and adenosine-5'-0-(3- 
thiotriphosphate) (ATP-y-S), which are also agonists at P2X receptors with an order of 
ATP-y-S = ATP-p-S > ATP = ATP-a-S (Brown et al., 1979; Kasakov and 
Bumstock, 1983). UTP is virtually inactive on P2X receptors, and the designated 
pharmacological agonist potency order at the P2X receptor is AMPCPP > AMPPCP 
> ATP > ADP > 2-Me-S-ATP »  UTP (for review see Fredholm et al., 1994). 
P2X receptors exhibit only weak stereoselectivity as L-ATP in the guinea-pig urinary 
bladder is equipotent with ATP. Indeed Cusack and Hourani have shown that in the 
guinea-pig urinary bladder, L-AMPPCP is a potent and a specific agonist at P2 X 
receptors, but this is due to its enhanced stability (Cusack and Hourani, 1984).
1.61.1. Cloning of ?2x  receptors
A cDNA encoding the P2X receptor has been cloned from the rat vas deferens 
and has been expressed in xenopus oocytes and mammalian cells (Valera et al., 1994). 
Here ATP activates a cation channel with relatively high Ca^+ permeability. The 
stmcture consists of only two transmembrane domains plus a pore forming motif 
which resembles that of potassium channels (Valera et al., 1994). P2X receptors have 
also been cloned from several other tissues including the rat pheochromocytoma 
PC12 cells (Brake et al., 1994), rat dorsal root ganglia (Chen et al., 1995) and the 
human bladder (Valera et al., 1995). The smooth muscle P2X receptor from the rat 
vas deferens and the human bladder have approximately 50% sequence homology to
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the ?2x receptor cloned from PC 12 cells (Evans et al., 1995). A P2X receptor cloned 
from rat neuronal tissues has also been shown to posses 47% sequence homology to 
the rat smooth muscle receptor and only 37% sequence homology to the P2X receptor 
cloned from PC12 cells (Seguela et al., 1996). Since these cloned receptors only 
show less than 50% sequence homology between each other, it appears that there may 
be different subtypes of P2X receptors.
The existence of several P2X receptor subtypes is further supported by the fact 
that the cloned receptors when expressed in isolated cells show differences in agonist 
potency orders. For example, at the cloned receptor from the rat vas deferens and the 
human bladder the potency order is 2-Me-S-ATP > ATP > AMPCPP (Valera et al., 
1994; 1995), whereas at the P2X receptor cloned from PC 12 cells the agonist order is 
2-Me-S-ATP > ATP, with AMPCPP being inactive. The P2X receptor from the rat 
dorsal root ganglia also has an order of 2-Me-S-ATP > ATP > AMPCPP (Chen et 
al., 1995). Therefore, the P2X receptor forms a heterogeneous group, where the 
cloned receptors from the rat vas deferens and the human bladder are designated as 
the P2XI subtype, and the cloned receptors from the rat PC 12 cells and rat dorsal root 
ganglia are termed P2X2 and P2X3 receptors respectively. Other members of the P2X 
family including P2X4, P2X5 and P2X6 receptors have also been cloned recently from 
rat tissues, ATP being the most potent agonist at these receptors (for review see 
Bumstock and King, 1996).
The difference in potency order of agonists at the cloned receptors when 
compared to the whole tissue preparations have been attributed to the presence of 
ectonucleotidases in the whole tissue which rapidly dephosphorylate less stable 
analogues of ATP (Welford et al., 1986; 1987). Therefore the potency of ATP and 2- 
Me-S-ATP is greatly reduced in these tissues, whereas the potency of AMPCPP,
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which is less susceptible to degradation, is not so greatly affected (Kennedy and Leff, 
1995b). Even though potency orders obtained from classical smooth muscle 
preparations have indeed been greatly distorted, the fact remains that they are 
consistent and therefore can be used to identify P2-purinoceptor subtypes, as long as 
care is taken in the interpretation of the results. Unfortunately there are no 
conmiercially available selective ecto ATPase inhibitors to date.
1.6.2. P2Y receptor
P2 Y receptors are generally considered to mediate relaxations of smooth 
muscle preparations such as the guinea-pig taenia coli and the rabbit portal vein 
longitudinal muscle (endothelium dependent), with a potency order of 2-Me-S-ATP 
»  ATP > AMPCPP = AMPPCP (Bumstock and Kennedy, 1985). The 
phosphothioate analogues are also active at P2y receptors with a potency order of 
ATP-a-S > ATP-p-S = ATP-y-S = ATP (Bumstock et al., 1984a). Unlike P2X 
receptors, P2Y receptors exhibit stereoselectivity as the D-enantiomers of 2-Cl-ATP 
and 2-Me-S-ATP are more potent than the L-enantiomers, whereas L-AMPPCP is 
inactive at this subtype (Bumstock et al., 1983; Hourani et al., 1985; 1986).
P2 Y receptors are G-protein coupled receptors. They are linked to the 
activation of phospholipase C which results in the formation of diacylglycerol and 
inositol trisphosphate (IP3), leading to a subsequent rise in intracellular Ca^+. The 
increase in intracellular Ca^+ in some cases opens Ca^+ dependent potassium channels 
thereby causing hyperpolorization thus mediating relaxations of smooth muscle 
preparations including the guinea-pig taenia caeci (Den Hertog et al., 1989). P2 Y 
receptors have also been linked to other second messenger systems, including the
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inhibition of adenylate cyclase activity thereby reducing cAMP levels in rat C6  
glioma cells (Boyer et al., 1993). The receptor is also linked to the activation of 
phospholipase A2 which is a secondary effect due to the activation of inositol lipid 
signalling pathway (Ferrero and Frischknecht, 1983) and to stimulation of 
phosphatidylcholine breakdown by activating phospholipase D (Dubyak, 1991; 
Dubyak and El-Moatassium, 1993; Harden et al., 1995), supporting the existence of 
multiple P2Y receptor types.
I.6.2.I. Cloning of ?2Y receptors
P2Y receptors were originally cloned from cDNA libraries of the chick whole 
brain (Webb et al., 1993). A cDNA has also been isolated from turkey whole brain 
which has 98% sequence homology to the P2Y receptors cloned from chick brain 
(Filtz et al., 1994). When expressed, the cloned P2Y receptors displays a potency 
order of 2-Me-S-ATP > ATP > ADP »  AMPCPP = AMPPCP = UTP which is 
similar to the characteristic order at P2Y receptors in smooth muscle preparations. 
P2Y receptors have also been cloned recently from other tissues. For instance, P2 Y 
receptors have been cloned from bovine aortic endothelial cells (Henderson et al., 
1995) where the agonist potency order is 2-Me-S-ATP > ATP »  UTP, and from 
rat insulinoma cells where the order is 2-Me-S-ATP > 2-Cl-ATP > ATP, with 
AMPCPP being inactive (Tokuyama et al., 1995). These cloned P2Y receptors from 
bovine aortic endothelial cells and the rat insulinoma cells show greater than 85% 
sequence homology to the P2 Y receptors cloned from the chick whole brain. 
Therefore, these cloned P2 Y receptors all fall into a homogenous group and are 
designated as the P2YI subclass. However P2YI receptors are markedly different from 
other members of G-protein coupled P2-purinoceptor family, for example from P2Y2
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receptors (see section 1.6.3.1). On P2Y3 receptors adenosine diphosphate (ADP) is 
the most potent agonist with an agonist order of ADP > UTP ATP = UDP (Webb 
et al., 1996).
1.6.3. P2U receptor
In the late 1980s, it became apparent that the activation of phospholipase C by 
ATP in many tissues occurs through a receptor pharmacologically distinct from the 
P2Y subclass. This receptor has been termed the P2u (or "nucleotide") receptor on the 
basis of the pyrimidine nucleotide UTP being equipotent with ATP (O'Connor et al., 
1991). The characteristic agonist potency order at the P2U receptor is UTP = ATP = 
ATP-y-S »  2-Me-S-ATP = AMPCPP (Dubyak, 1991; O'Connor et al., 1991). The 
presence of this receptor has been recognised in many different types of cells. For 
example, P2u receptors are present on bovine aortic endothelial and smooth muscle 
cells (Demolle et al., 1988; Purkis et al., 1994) causing vasodilatation (however the 
presence of P2Y receptors also on endothelial cells mediating the same effect must not 
be neglected), and on human airway epithelial cells causing inflammatory responses 
and stimulation of transepithelial Cl" secretion (Mason et al., 1991). Recently P2U 
receptors have been identified in the rat duodenum mediating contractions of the 
smooth muscle (Johnson and Hourani, 1994; Johnson et al., 1996).
The P2U receptor is a G-protein coupled receptor where the overall signalling 
response is that of phospholipase C activation (similar to P2Y receptors) leading to 
mobilization of Ca^+ and the activation of protein kinase C (Dubyak, 1991; Dubyak 
and El-Moatassium, 1993; Harden et al., 1995). The activation of phospholipase A2 , 
which apparently occurs secondarily to activation of inositol lipid signalling pathway.
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is also a prominent effect. As with P2Y receptors, stimulation of phosphatidylcholine 
breakdown due to activation of phospholipase D also occurs in response to P21J 
activation (Harden et al., 1995), but unlike P2 Y receptors, which are coupled to 
pertussis toxin insensitive G-proteins, here P21J receptors are coupled to pertussis 
toxin sensitive G-proteins (Purkiss et al., 1994).
1.6.31. Cloning of P21J receptors
A cDNA encoding the P2 U receptor was originally cloned from mouse 
neuroblastoma-glioma hybrid (NG108-15) cells. It displays an agonist potency order 
of ATP = UTP »  2-Me-S-ATP while AMPCPP and AMPPCP showed little or no 
activity (Lustig et al., 1993). P21J receptors have also been cloned from several other 
tissues. For instance, a P21J receptor has been cloned from rat lung tissues (Rice et al., 
1995), human airway epithelial (CF/T43) cells (Parr et al., 1994) and pituitary cells 
(Chen et al., 1995). All these cloned P2U receptors show a high degree of sequence 
homology (80-90%) to each other, but not to the P2Y receptor (which is also a G- 
protein coupled receptor). Therefore, these receptors form a homogenous group of 
receptors, and have been named P2Y2 receptors.
I.6.3.2. Actions of UTP other than on P2U receptors
UTP has actions other than on P2U receptors. For example, UTP has been 
shown to activate P2X receptors and pre-junctional Pi-purinoceptors in the mouse vas 
deferens (Von Kugelgen et al., 1989; 1990). However, some workers have proposed a 
new class of receptors at which UTP act, termed the pyrimidinoceptor, due to the fact
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that uracil nucleotides are potent while adenine nucleotides are inactive (Seifert and 
Schultz, 1989) . For example, Seifert and co-workers (1989) have shown that, in 
HL60 cells responses to ATP are mediated via P2-purinoceptors, whereas responses to 
UTP are via pyrimidinoceptors. Also in the smooth muscle of the rat tail and femoral 
arteries and in the dog saphenous vein, ATP induces contractions via P2x  receptors, 
whereas contractions by UTP are suggested to be via pyrimidinoceptors (Von 
Kugelgen and Starke, 1990). The existence of these receptors has been further 
supported by recent cloning studies. A pyrimidinoceptor has been cloned from the 
human placenta showing little sequence homology to the P2u receptor (Communi et 
al., 1996b), and this receptor is currently classified as the P2Y4 subclass, with an 
agonist order of UTP = uridine diphosphate (UDP) > ATP = adenosine 
diphosphate (ADP). A P2Y6 receptor has also been cloned at which UDP is more 
potent than UTP with a potency order of UDP > UTP > ADP »  ATP (Communi 
et al., 1996a).
1.6.4. P2Z receptor
ATP can exist as the tetrabasic anion, ATP^- as well as the form complexed to 
magnesium or calcium. This is present as a minor equilibrium component when ATP 
is added to physiological solutions containing Mg^+ or Ca^+ (Cockcroft and 
Gomperts, 1979). ATP4- can activate receptors on mast cells, macrophages and 
lymphocytes which have been named P2Z receptors. The P2Z receptor is a non 
selective pore permeable to Na+, K+ or Ca^+ ions (Dubyak and El-Moatassim, 1993), 
and the activation of this receptor causes a permeabilization of the cell. The C2- 
substituted analogues of ATP^- are more potent than ATP^- itself here, and the 
receptor appears to show stereoselectivity as the L-enantiomer of ATP^- is inactive
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(Tatham et al., 1988). A receptor having 35-40% sequence homology to ?2X 
receptors, and thought to be the P2Z receptor, has been cloned from the rat brain, and 
high levels of the receptor mRNA were also found to be expressed in macrophages, 
lung, spleen, brain and spinal chord (Suprenant et al., 1996). This receptor has been 
included as a P2X receptor subclass and called the P2X7 receptor. P2X7 receptors can 
operate as bifunctional molecules, acting as ion channels permeable to small cations 
and also inducing lysis. Therefore the receptors may be involved in both fast 
transmission and in the ATP-mediated lysis of cells (Suprenant et al., 1996).
1.6.5. ?2T receptor
P2T receptors are present on platelets. Here ADP is the naturally occurring 
agonist causing platelet aggregation while ATP acts as a competitive antagonist 
(Gordon, 1986). Analogues such as 2-methylthioadenosine-5'diphosphate and 2- 
chloroadenosine-5'-diphosphate are more potent than ADP (Cusack and Hourani,
1982). P2T receptors are thought to be G-protein coupled, however the second 
messenger system is somewhat unclear, and it maybe linked to both phospholipase C 
and inhibition of adenylate cyclase activity. However the presence of both a ligand 
gated ion channel and a G-protein coupled receptor (i.e. a P2 X- and a P2Y-Hke 
receptor) on platelets has been suggested (Hourani and Hall, 1994). Therefore the 
nature of this receptor remains uncertain as it is not yet cloned.
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1.6.7. P2-purinoceptor antagonists
P2 "purinoceptor research has been difficult due to the lack of selective 
antagonists. ANAPP3 (arylazido aminopropionyl ATP) has been claimed to be a 
selective P2x recptor antagonist on the guinea-pig vas deferens (Hogaboom et al., 
1980) and the guinea-pig bladder (Westfall et al., 1983). However it has also been 
shown to antagonise responses to adenosine via Pi-purinoceptors and responses to 
ATP via P2y receptors on the guinea-pig taenia coli (Westfall et al., 1982). Also this 
compound is not commercially available and therefore is not used as a selective P2x 
receptor antagonist.
The anthraquinone-sulphonic acid derivative compound, reactive blue 2, has 
since then been used as a P2-purinoceptor antagonist specific for P2Y receptors. It has 
been shown to antagonise responses mediated via P2Y receptors in the rat duodenum 
(Manzini et al., 1986a) and in the rabbit mesenteric artery (Bumstock & Warland, 
1987). However it has also been shown to antagonise responses to ATP, acting via 
f*2X receptors, in the guinea-pig urinary bladder (Choo, 1981) and in the rabbit portal 
vein (Reilly et al., 1987). Therefore, it is also a non selective antagonist at P2- 
puiinoceptors.
Suramin has been widely used as an antagonist inhibiting responses to ATP in a 
number of tissue preparations including the guinea-pig urinary bladder (Hoyle et al., 
1990), guinea-pig taenia caeci (Den Hertog et al., 1989) mouse vas deferens (Dunn & 
Blakeley, 1988), rabbit ear artery (Leff et al., 1990). However it does not appear to be 
selective for either P2X or P2 Y receptors as it has an apparent pA2 of 5.0 at both 
receptor subtypes. Suramin can also act as an antagonist at P2 T receptors, as it 
inhibited the response to ADP in human platelets with an apparent pA2 of 4.6
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(Hourani et al., 1992). P2U receptors also appear to show some sensitivity to suramin, 
as in the rat PC 12 cells suramin is a competitive antagonist at P2U receptors (Murrin 
and Boarder, 1991). However in the bovine aortic endothelial cells, which contains 
P2Y and P21J receptors, it is a P2Y receptor antagonist but does not inhibit responses to 
UTP (Wilkinson et al., 1993), and has been used to distinguish between the P2Y and 
the P21J subclasses. Suramin can also behave as a non competitive antagonist, as in 
the presence of the antagonist a reduction in the maximum response has been shown 
(Hoyle et al., 1990). It can also display time dependency, as low concentrations of the 
antagonist require a longer incubation (greater than 3 hours), whereas a 1 mM 
concentration of suramin only requires a short incubation of about 10 minutes (Leff et 
al., 1990). Further complicating the antagonism of suramin is the behaviour of this 
compound as an ectonucleotidase inhibitor (Hourani & Chown, 1989; Crack et al., 
1994). Therefore the concentration-response curves to ATP may not be right-shifted 
by suramin to the same extent as those for AMPCPP (which is relatively stable and 
does not undergo rapid dephosphorylation via ectonucleotidases like ATP), as 
suramin acts as an ectonucleotidase inhibitor with ATP, but as an antagonist with 
AMPPCP (Crack et al., 1994). ARL (formally FPL) 66301 (2-methylthio-L- 
adenosine 5'-(P,y-dibromomethylene)triphosphonate), is also a P2 X receptor 
antagonist, but like suramin, it is also an ectonucleotidase inhibitor (Crack et al., 
1994).
Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) is a P2- 
purinoceptor antagonist. It has been claimed to be a P2X selective receptor antagonist 
(at concentrations of less than 30 |iM) in the rabbit vas deferens (Lambrecht et al., 
1992) and in the rabbit urinary bladder (Ziganshin et al., 1993). However, recent 
studies have shown that at high concentrations (greater than 30 |iM), PPADS also
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antagonises responses mediated via P2Y receptors in the guinea-pig taenia coli and in 
the rat duodenum (Ziyal et al., 1994).
At P2T receptors, ATP acts as the naturally occurring competitive antagonist 
with a pA2 of 4.6 (for review see Hourani and Hall, 1996). Recently a selective P2T 
receptor antagonist has been developed which is 2-propylthio-D-p ,y- 
diflouromethylene ATP (ARL 66096) having a pKg of 8.7 (Humphries et al., 1993).
Due to the limited selectivity of the P2-purinoceptor antagonists, 
desensitization of P2 -purinoceptors has been used as a basis to characterise P2- 
purinoceptors. Repeated administration of the ATP analogue, AMPCPP, can 
desensitize responses mediated via the P2X receptor in a number of smooth muscle 
preparations. For example in the guinea-pig vas deferens (Meldrum & Bumstock,
1983), or in the guinea-pig urinary bladder (Kasakov & Bumstock, 1983), 
desensitization of the contractile response to AMPCPP is seen. However, in the 
rabbit ileum and the colon, P2Y receptor mediated relaxant responses are susceptible 
to desensitization by AMPCPP (Crema et al., 1982), also in the rat colon muscularis 
mucosae desensitization is observed with 2-Me-S-ATP acting at P2 Y receptors 
(Hourani et al., 1993a). P21J receptors are also generally regarded to be resistant to 
desensitization and this method is therefore used to distinguish between P2 - 
purinoceptor mediated responses in smooth muscle (Johnson et al., 1996). However 
in the bovine aortic endothelial cells, responses to UTP acting via P21J receptors have 
been shown to be desensitized (Wilkinson et al., 1994)
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Figure 1.4. Structures of some P2-purinoceptor agonists.
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1.7. PHARMACOLOGICAL ACTIONS OF ADENOSINE, ATP 
AND UTP
Extracellular nucleosides and nucleotides have actions on almost every cell 
type. For example the control of smooth muscle function by nucleotides is a very 
important physiological role. In the case of blood vessels they influence important 
factors such as blood flow and in the case of visceral smooth muscle such as in the 
gut, bladder and the vas deferens, they play an important role in the normal 
functioning of the tissue.
In this section the role of adenosine, ATP and UTP on a variety of biological 
systems including the cardiovascular system, gastrointestinal system, bladder and the 
vas deferens will be discussed.
1.7.1. Cardiovascular system
Adenosine can regulate coronary blood flow and has negative dromotropic, 
chronotropic and inotropic effects on the heart contractility (Fredholm and Sollevi,
1986). These effects of adenosine can be mediated directly through interactions with 
Pi-purinoceptors. Adenosine acts via A% receptors in the atrioventricular node to 
cause bradycardia and the observed agonist potency order is CPA > R-PIA > 
NECA > 2CAD0 (for review see Olsson and Pearson, 1990). A% receptors have 
also been shown on atria producing negative inotropic effects causing a decrease in 
the force of contraction (Collis, 1983), where a decrease in the action potential and an 
increase in the potassium conductance is observed (Jahnel and Nawrath, 1989). 
Adenosine has little or no direct effect on the ventricular myocardium, however the
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inhibition of the positive ionotropic effects of catecholamines by adenosine has been 
shown (Belardinelli and Isenberg, 1983).
Adenosine mediates vasodilation in a variety of blood vessels in the 
cardiovascular system. The order of potency of adenosine analogues at relaxing the 
coronary vessels is NECA > R-PIA > 2CADO and the antagonist DPCPX has 
micromolar affinity, suggesting that adenosine mediates vasodilation via A2 receptors 
(Ramogopal et al., 1988). In the guinea-pig coronary artery the presence of A2 a 
receptors and in the rat coronary artery the presence of A2 a, A2 b and a further 
undefined xanthine resistant site has been shown (Otley et al., 1996). In the rat aorta, 
adenosine relaxes the tissue via A2a receptors due to the high potency of CGS 21680 
compared with NECA (Lewis et al., 1994). However in this tissue, relaxant responses 
other than via A2a receptors are also shown. An A2b receptor present on the smooth 
muscle of the rat aorta, activated by R-PIA and CPA, and also an additional site has 
been shown (Prentice and Hourani, 1996). This undefined site was insensitive to PD 
115,199 and 8 -SPT, but it is unlikely to be an A3 receptor as IB MECA was not 
potent in this tissue (Prentice and Hourani, 1996).
The location of the A2 receptors in blood vessels was suggested originally to 
be on the vascular smooth muscle (Collis and Brown 1983). However when the 
endothelium has been removed, a reduction in the relaxant response is seen in the 
guinea-pig aorta (Rose'Meyer and Hope, 1990). Therefore it was suggested that an 
endothelium independent mechanism may also be involved in this process. In the rat 
aorta responses to adenosine are abolished by endothelium removal and by the nitric 
oxide synthase inhibitor, L-NAME, showing an endothelium dependent mechanism 
via the nitric oxide pathway (Lewis et al., 1994). The presence of A% receptors was 
also shown in the guinea-pig aorta, where they mediate vasoconstriction. However
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this response may only be apparent when the A2 receptor mediated response has been 
blocked (Stoggall and Shaw, 1990).
By contrast to adenosine, ATP is not thought to have an important action on 
the heart. ATP has been shown to induce negative ionotropism directly by an action 
on Al receptors and positive ionotropism by an action on P2X receptors (Froldi et al., 
1994). On the other hand, ATP plays an important role in a number of blood vessels 
causing vasodilation acting via P2Y receptors. For example in the rat pulmonary 
vessels (Liu et al., 1989), in the dog coronary artery (Houston et al., 1987) and in the 
rat mesenteric arterial bed (Ralevie and Bumstock, 1988), ATP relaxes the vessels by 
activating P2Y receptors. Like the A2 receptor mediated endothelium dependent 
vasodilation, the activation of P2Y receptors on coronary vessels also results in the 
release of nitric oxide (Murad, 1986) which activates guanylate cyclase. However in 
some tissues, such as in the rabbit mesenteric artery, P2Y receptors (also mediating 
vasodilation) have been shown to be located in the smooth muscle of the tissue 
(Kennedy and Bumstock, 1985). P2U receptors have also been shown on endothelial 
cells. For example in the bovine aortic endothelial cells the co-existence of both P2U 
and P2Y receptors has been shown (Wilkinnson et al., 1993).
When the endothelium has been removed, ATP can cause contractions acting 
via P2X receptors which are located on the smooth muscle of the tissue (Bumstock 
and Kennedy, 1985). Similarly, P21J receptors have also been linked to contractions 
of some blood vessels. For example P2X receptors were shown on the rabbit ear 
artery (Leff et al., 1990), rabbit and rat mesenteric artery (Bumstock and Warland, 
1987; Ralevic and Bumstock, 1988) and on the dog coronary artery (Houston et al.,
1987), and P21J receptors were shown on the rat mesenteric artery (Ralevic and
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Bumstock, 1991), rabbit and bovine aorta (Chinellato et al., 1992; Demolle et al.,
1988), where both receptors mediate vasoconstriction.
1.7.2. Gastrointestinal tract
The gastrointestinal tract includes a number of tissues; stomach, duodenum, 
ileum, taenia caeci and the colon. Pharmacological actions of ATP, UTP and 
adenosine on these tissues will be discussed in this section.
1.7.2.x. Stomach
In the rat gastric fundus longitudinal muscle relaxations were observed to ATP 
and its analogues with a potency order of 2-Me-S-ATP > AMPCPP > ATP 
(Matham and Hollingsworth, 1992). Contractions were also observed to ATP after 
the initial relaxation and these responses were reduced by indomethacin, suggesting 
that they are due to prostaglandin synthesis (Lefebvre and Bumstock, 1990). 
However, work by Matharu and Hollingsworth (1992) has shown that after 
desensitization to AMPCPP the relaxant response to ATP was completely suppressed 
whereas the response to 2-Me-S-ATP was only slightly blocked. The rebound 
contractions to both the agonists were considerably increased on the other hand by 
desensitization and were antagonised by reactive blue 2. Therefore the presence of 
both a contractile and a relaxant P2 -purinoceptor is suggested here. Relaxant 
responses to ATP and AMPCPP are said to be mediated via P2x  receptors, but 2-Me- 
S-ATP is suggested to activate P2x  receptors as well as an additional site to mediate
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this effect. Contractions were suggested to be mediated via P2Y receptors as the 
agonist potency order was 2-Me-S-ATP »  ATP
Adenosine can also cause relaxation of the stomach muscle, where responses 
were antagonised by 8 -SPT and potentiated by the adenosine uptake inhibitor, NBTI. 
Therefore the presence of a Pi-purinoceptor also mediating relaxations in this tissue is 
apparent (Matharu and Hollingsworth, 1992).
I.7.2.2. Duodenum
ATP may be the non-adrenergic, non-cholinergic inhibitory neurotransmitter in 
the rat duodenum (Manzini et al., 1985; 1986b). ATP is much more potent than 
adenosine in relaxing the tissue and the responses to both ATP and nerve stimulation 
are not blocked by 8 -PT, indicating that Pi-purinoceptors are not involved. Following 
relaxations to ATP, a rebound contraction was observed and was shown to be due to 
prostaglandin synthesis (Manzini et al., 1985, 1986b). The relaxation caused by ATP 
is due to the activation of P2Y receptors where the agonist order is 2-Me-S-ATP »  
ATP > AMPCPP (Nicholls et al., 1990; Hourani et al., 1991). Contractions to UTP 
and ATP-y-S have also been shown on the rat duodenum, where the activation of a 
P2U receptor has been suggested (Johnson and Hourani, 1994).
Adenosine causes a relaxation in the rat duodenum with an agonist order of 
NECA > CPA > adenosine > CGS 21680, where responses to CPA are 
antagonised by DPCPX in the nanomolar range, and responses to NECA are 
antagonised by a micromolar concentration of DPCPX (Nicholls et al., 1992). 
Therefore the activation of a mixed population of Pi-purinoceptors, A% and A2b
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receptors, in this tissue has been suggested (Nicholls et al., 1992). The relatively 
stable ATP analogue, AMPPCP, is also inhibitory in this tissue, but responses are due 
to a direct action on Pi-purinoceptors rather than on P2Y receptors as responses were 
antagonised by 8 -SPT (Hourani et al., 1991). Binding studies using [^HJDPCPX in 
the whole rat duodenum have identified a high affinity single site with a for 
DPCPX in the nanomolar range confirming the presence of Ai receptors in this tissue 
(Peachey et al., 1994).
Recent studies have shown the presence of P2-purinoceptors in the separated 
layers of the rat duodenum, the longitudinal muscle and the muscularis mucosae 
(Johnson et al., 1996). However the location of Pi-purinoceptors in the separated 
layers of the rat duodenum remains to be established. Relaxations via P2Y receptors 
are shown on the longitudinal muscle with an agonist order of 2-Me-S-ATP > ATP 
= ATP-y-S > AMPCPP (Johnson et al., 1996). Contractions in the muscularis 
mucosae via P21J and P2X receptors were also shown with an agonist order of ATP-y- 
S > AMPCPP = ATP = UTP »  2-Me-S-ATP (Johnson et al., 1996). In this 
tissue, AMPCPP activates P2X receptors with a potency order of AMPCPP > 2-Me- 
S-ATP and responses were antagonised by suramin, whereas ATP and UTP were 
equipotent in this tissue and were insensitive to suramin, suggesting the activation of 
P21J receptors by ATP and UTP (Johnson et al., 1996). ATP-y-S has been suggested 
to activate both P2X and P2U receptors in this tissue (Johnson et al., 1996).
1.7.2 3. Ileum
In the ileum, unlike in the duodenum it appears that ATP may not be the non- 
adrenergic, non-cholinergic transmitter (Bauer and Kuriyama, 1982). ATP and 
adenosine act on the guinea-pig ileum to inhibit the nerve-mediated release of
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acetylcholine. The site of action of adenosine and ATP is via pre-junctional A% 
receptors in this tissue and the action of ATP is due to its breakdown to adenosine 
(Moody and Bumstock, 1982; Wiklund et al., 1985).
By contrast to adenosine, ATP can also have excitatory effects on this tissue. 
In the guinea-pig ileum longitudinal muscle contractions were observed to ATP 
(Kennedy and Humphrey, 1994). In this tissue AMPCPP has been shown to activate 
pre-junctional P%x receptors, as contractions to AMPCPP were blocked by atropine 
and tetrodotoxin (Kennedy and Humphrey, 1994). There is also a post-junctional site 
of action of ATP with 2-Me-S-ATP being more potent than ATP in contracting the 
tissue, suggesting the presence of a P2Y receptor in the guinea-pig tissue (Kennedy 
and Humphrey, 1994). However in an earlier study by Wiklund and Gustafsson 
(1988) a novel purinoceptor subtype, a P2S receptor, had been suggested as the 
agonist potency order was 2-Me-S-ATP > ATP but responses were insensitive to 
desensitization with AMPCPP or reactive blue 2. This is not widely accepted as 
results could be explained in terms of activation of pre-junctional P2X receptors by 
ATP and P2 Y receptors on the smooth muscle by 2-Me-S-ATP (Kennedy and 
Humphrey, 1994). UTP is inactive in the guinea-pig ileum longitudinal muscle 
suggesting the absence of P21J receptors in this tissue (Kennedy and Humphrey, 
1994).
I.7.2.4. Colon
The rat colon is another tissue in which the two layers respond differently. In 
the rat colon longitudinal muscle, relaxations were observed with an agonist potency 
order of NECA > CPA > adenosine, where DPCPX displayed micromolar affinity.
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suggesting the activation of A% receptors in this tissue, and the A2 receptor has been 
identified as the A2 b subtype (Bailey and Hourani, 1992). Also, the relaxant 
responses to ATP and AMPPCP in this tissue were entirely due to the activation of 
A2b receptors (due to degradation of compounds), as responses were antagonised by a 
micromolar concentration of DPCPX and not by suramin. AMPCPP is also active in 
the rat colon, and its effects were antagonised by suramin but not by DPCPX, 
suggesting the presence of P2 -purinoceptors (Bailey and Hourani, 1992). The 
differential effects of the ATP analogues in the rat colon longitudinal muscle can be 
explained by the fact that AMPPCP and ATP are degraded to adenosine which is 
active on Pi-purinoceptors, whereas AMPCPP is only broken down to AMPCP which 
is inactive at Pi-purinoceptors but can activate P2-purinoceptors, thus AMPCPP can 
retain a P2-purinoceptor mediated effect in spite of its breakdown. With high levels 
of degradation of compounds observed in this tissue it is difficult to characterise the 
P2-purinoceptors here, but Bailey and Hourani (1992) have suggested it to be of the 
P2Y class which is consistent with a receptor mediating a relaxant response.
In the muscularis mucosae of the rat colon, contractions were observed to 
purines with a potency order of CPA > NECA > adenosine, with DPCPX having 
nanomolar affinity, suggesting the presence of an Ai receptor (Bailey and Hourani, 
1990). ATP also contracted the muscularis mucosae and the potency order for 
analogues was 2-Me-S-ATP > ATP > AMPCPP, suggesting the activation of P2Y 
receptors in this tissue (Bailey and Hourani, 1990). AMPPCP has also been shown to 
have a direct action on Pi-purinoceptors in this tissue (i.e. it activates Ai receptors to 
mediate contractions in the rat colon muscularis mucosae) (Bailey and Hourani, 
1990). Binding studies using pHjDPCPX in the whole rat colon have also identified 
a high affinity single site with a Kj for DPCPX in the nanomolar range confirming the 
presence of Ai receptors in this tissue (Peachey et al., 1994).
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UTP is also active in the rat colon muscularis mucosae, where it causes 
contraction of the tissue (Hourani et al., 1993a). However UTP has been shown to be 
less potent than ATP in mediating contractions, and cross-desensitization was 
observed between ATP and UTP in this tissue suggesting that UTP activates the P2Y 
receptor rather than a pyrimidinoceptor in this tissue (Hourani et al., 1993a).
1.7.2 5. Taenia Caeci
ATP is released from the non-adrenergic, non-cholinergic nerves in the 
guinea-pig taenia coli to cause relaxation of the tissue (Bumstock et al., 1970, 
Satchell, 1981). These responses in the guinea-pig taenia caeci led to the initial 
characterization of the P2Y subclass (Bumstock and Kennedy, 1985). The potency 
order of agonists in this tissue was 2-Me-S-ATP > ATP > AMPCPP > AMPPCP 
(Satchell and Maguire, 1975; Bumstock and Kennedy, 1985). ATP is thought to relax 
the taenia by mobilization of calcium which activates apamin-sensitive potassium 
channels, resulting in hyperpolarisation, a mechanism which would be consistent with 
a phospholipase C coupled receptor (Den Hertog, 1982). AMPCPP activates apamin- 
sensitive potassium channels directly as well as via mobilization of intracellular 
calcium (Den Hertog et al., 1985), suggesting that in addition to a relaxation- 
mediating P2Y receptor, there is an additional relaxation-mediating P2-purinoceptor. 
This is not a P2 X receptor as L-AMPPCP, a potent P2X agonist, is inactive in this 
tissue (Hourani et al., 1985). Also responses to AMPCPP were more sensitive to 
PPADS than to those of ATP or 2-Me-S-ATP, suggesting PPADS sensitive and 
insensitive P2-purinoceptors in this tissue (Windscheif et al., 1995). However this 
could be explained by the fact that PPADS acts as an ectonucleotidase inhibitor in this
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tissue (Windschief et al., 1995). UTP is also active in the guinea-pig taenia caeci but 
there is no evidence for the presence of P%u receptors as UTP is much less potent than 
ATP in this tissue (Piper and Hollingsworth, 1995).
Adenosine also is inhibitory in the guinea-pig taenia caeci with a potency 
order of NECA > 2CAD0 > R-PIA > CHA > S-PIA, and a micromolar 
concentration of DPCPX was required to antagonise responses, which suggests the 
activation of A2 receptors (Bumstock et al., 1984b; Prentice et al., 1995). Part of the 
relaxant response observed by AMPPCP has also been suggested to be due to the 
activation of A2 receptors present in this tissue (Hourani et al., 1991). NECA also 
activates a site other than A2 receptors as Schild analysis for NECA versus DPCPX 
gave a slope that was significantly different from unity and curves to NECA were 
biphasic (Prentice et al., 1995).
1.7.3. Bladder
Contractions of the bladder to neuronal stimulation are only partially 
antagonised by the muscarinic antagonist atropine. This atropine resistant contraction 
is proposed to be due to the release of ATP as a neurotransmitter (Bumstock et al., 
1972). The original classification of P2-purinoceptors by Bumstock and Kennedy 
(1985) defined the responses to ATP in the guinea-pig and the rat urinary bladder as 
being due to the activation of P2X receptors with an agonist potency order of 
AMPCPP > AMPPCP > ATP = 2-Me-S-ATP (Bumstock et al., 1983), and 
marked desensitization was readily observed following the administration of 
AMPPCP or AMPCPP (Hourani, 1984; Hoyle and Bumstock, 1985; Moss and 
Bumstock, 1985).
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ATP is a weak agonist compared to AMPCPP or AMPPCP in the guinea-pig 
bladder, and this is due to its degradation by ectonucleotidases (Welford et al., 1987). 
Also the potency order obtained at P2x  receptors cloned from the human urinary 
bladder smooth muscle cells (2-Me-S-ATP > ATP > AMPCPP »  ADP) is 
markedly different from that obtained in pharmacological studies in the rat and 
guinea-pig tissues (Valera et al., 1995). These differences in potency orders have 
been suggested to be due to the absence of ectonucleotidases on the cells in which the 
cloned receptor has been expressed (Kennedy and Leff, 1995b). In the guinea-pig 
bladder, ARL 67156 significantly enhanced the purinergic component of the 
neurogenic contraction (and to exogenous ATP, but not AMPCPP), showing the role 
of ecto ATPase in the purinergic neurotransmission (Westfall et al., 1996c).
Adenosine causes relaxation of the rat bladder with a potency order of NECA 
»  adenosine > CPA = CGS 21680, with DPCPX having micromolar affinity, 
suggesting the activation of A2b receptors in this tissue (Bumstock et al., 1972; 
Brown et al., 1979; Nicholls et al., 1992). The lack of A% receptors in the rat bladder 
is shown by binding studies where no specific [H^]DPCPX binding was detected 
(Peachey et al., 1994). Relaxant responses other than via A2b receptors have also 
been shown. In the mouse and rat bladder, relaxation was observed with an agonist 
potency order of 2-Me-S-ATP > ATP > AMPPCP suggesting the presence of P2Y 
receptors in this tissue as responses were not blocked by 8 -SPT (Boland et al., 1993; 
Bolego et al., 1995).
UTP has also been shown to be active in the guinea-pig bladder. However it 
appears to be a weak agonist and causes a contraction in this tissue. Responses to 
UTP were abolished in the presence of suramin, suggesting that UTP may also
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activate ? 2x  receptors on this tissue (Bailey and Hourani, 1994). However following 
desensitization to AMPCPP, responses to UTP were unaffected which indicates the 
presence of a site at which UTP may act upon other than the P2X receptor (Bolego et 
al., 1995).
1.7.4. Vas deferens
The smooth muscle of the vas deferens is innervated by sympathetic nerve 
fibres of the hypogastric nerve. Stimulation of these sympathetic nerves produces a 
biphasic contraction where the initial twitch like contraction is due to the release of 
ATP, referred to as the purinergic component, and the second slow contraction is due 
to the release of noradrenaline (Fedan et al., 1986; Meldrum and Bumstock, 1983; 
Bumstock, 1990; Von Kugelgen & Starke, 1991). ATP has a co-transmitter role with 
noradrenaline in this tissue (Sneddon and Bumstock, 1984; White, 1988). Released 
ATP causes a contraction of the smooth muscle via P2x-purinoceptors which are 
ligand gated cation channels, and the agonist order is AMPCPP = AMPPCP > ATP 
= 2-Me-S-ATP, which is characteristic of this subtype (Bumstock and Kennedy, 
1985). However, this agonist order is not reflected at the cloned P2X receptor from 
the rat vas deferens (Valera et al., 1994) and this discrepancy is thought to be due to 
breakdown of some agonists by the ectonucleotidases present in this tissue (Kennedy 
and Leff, 1995b). In experiments in the guinea-pig vas deferens where the divalent 
cation concentration was altered, the active form of ATP was suggested to be the 
anionic form, ATP4“, as the presence of Mg^+ in the buffer solution increases the 
concentration of ATP required to stimulate contraction (Fedan et al., 1990). 
However, this could also be explained in terms of ectonucleotidase activity as these 
enzymes are also dependent on divalent cations and if the cation concentrations are
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altered in the buffer solutions it could also influence the activity of the enzymes 
thereby increasing or decreasing the rate of breakdown of ATP, thus influencing the 
amount of ATP available to activate P2x  receptors. In the guinea-pig vas deferens, 
ARL 67156 significantly enhanced the purinergic component of the neurogenic 
contraction to a greater extent than in the guinea-pig bladder, thus showing that ecto 
ATPase may have a greater role in modulating neurotransmission in this tissue 
(Bailey and Hourani, 1994; Westfall et al., 1996c).
Even though the vas deferens was used as a tissue which was instrumental in 
the classification of P2x  receptors, recent studies have shown that there may be more 
than one type of P2-purinoceptor mediating contraction here. For example in the 
guinea-pig vas deferens, the contraction induced by high concentrations of ATP is 
biphasic, where the first phase of contraction is mediated via a P2X receptor and the 
second phase of contraction is associated with the transfer of a phosphate from the 
ATP to the tissue, following cleavage of the phosphate chain by an ecto-kinase (Fedan 
and Lamport, 1990; Lamport-Vrana et al., 1991). It was also shown in this tissue that 
suramin at low concentrations had little effect, whereas at high concentrations (> 1 0 0  
|iM) potentiated the effects of ATP (Bailey and Hourani, 1994). Although this may 
be explained by the fact that suramin acts as an ectonucleotidase inhibitor, 
desensitization of the P2X receptor by AMPCPP abolishes the response to ATP in the 
absence of suramin, whereas the response to ATP in the presence of suramin is 
unaffected. Therefore it was suggested that there is a contractile receptor other than a 
P2X receptor in the guinea-pig vas deferens at which ATP acts (Bailey and Hourani, 
1994). Similarly it was suggested that in the mouse vas deferens there is also more 
than one site of action for ATP. Suramin was found to antagonise the responses to 
AMPCPP, whereas only low concentrations of ATP-induced responses were 
antagonised by suramin (Von Kugelgen et al., 1990). Also in the rat vas deferens a
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contraction-mediating receptor of the ? 2x  class which is sensitive to suramin and 
reactive blue 2 , and a non ? 2x  receptor, which is insensitive to suramin and reactive 
blue 2 was suggested (Bultmann and Starke, 1994). This differential antagonism of 
the effects of ATP or AMPCPP can well be explained in terms of the ectonucleotidase 
activity in the tissue and therefore may suggest the activation of a single class of 
receptor. However recent studies on the guinea-pig vas deferens in the presence of an 
ecto ATPase inhibitor (ARL 67156) has also shown differential effects of suramin, 
and therefore these data suggests that the differential antagonism by suramin cannot 
simply be due to the inhibition of ectonucleotidases (Westfall et al., 1996a).
A biphasic response was observed to ATP in the mouse vas deferens where a 
contraction was preceded by a marked relaxation. The relaxation has been shown to 
be mediated via a P2Y receptor as the agonist potency order was 2-Me-S-ATP > ATP 
> AMPCPP and responses were antagonised by reactive blue 2, but not by the Pi- 
purinoceptor antagonist, 8 -SPT (Boland et al., 1992).
UTP is also active on the guinea-pig and mouse vas deferens, where it is less 
potent than ATP in eliciting contractions. However like ATP, responses to UTP are 
antagonised by suramin and were cross-desensitised by ATP, suggesting the 
activation of P2X receptors in these tissues (Von Kugelgen et al., 1990; Bailey and 
Hourani, 1994). In contrast to this, at the cloned P2X receptor, UTP appears to be 
inactive (Valera et al., 1994).
In the DDT 1 MF-2 cell line derived from the Syrian hamster vas deferens, it 
was shown that ATP increases IP3 levels and intracellular calcium acting via a G- 
protein coupled receptor rather than a P2X receptor (which is an ion channel) (Hoiting 
et al., 1990; Gerwins and Fredholm, 1992). Since UTP is also active in this cell line.
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the receptor is suggested to be of the ? 2 u class (Van der Zee et al., 1992). The 
presence of adenosine Ai receptors in the DDTi MF-2 cells which are negatively 
coupled to adenylate cyclase has also been shown (Dickenson and Hill, 1993a). In 
addition, an Ai receptor-mediated inositol phospholipid hydrolysis and the 
mobilization of Ca^+ in these cells are also established and is due to G-protein 
coupling to phospholipase C (Gerwins and Fredholm, 1992; Dickenson and Hill, 
1993b).
The presence of Pi-purinoceptors has also been shown in the rat vas deferens. 
Adenosine is inhibitory in the vas deferens and the presence of Ai receptors on the 
sympathetic nerves mediating inhibition of neurotransmitter release (noradrenaline 
and ATP) has been shown (Paton, 1981). Neuronally released ATP can also activate 
pre-junctional Ai receptors as an indirect result of breakdown, but a direct action by 
ATP on pre-junctional Pi-purinoceptors in the rat vas deferens has also been 
suggested, however an indirect role of ATP in this tissue seems more reasonable 
(Forsyth et al., 1991; Kurz et al., 1993). Noradrenaline, which is the other co- 
transmitter in the vas deferens, has also been shown to have a feedback mechanism 
acting via pre-junctional a 2 -adrenoceptors to cause the inhibition of transmitter 
release, whereas the post-junctional contractile effect of noradrenaline is mediated via 
ai-adrenoceptors (Mallard et al., 1992; Bultmann & Starke 1993). The potency order 
of adenosine agonists in causing inhibition of nerve mediated contraction has been 
shown to be NECA = CPA > adenosine (Hourani et al., 1993b). Even though this 
potency order of agonists does not fall into either Ai or A2 classes, the antagonist 
DPCPX has been shown to inhibit the effects of CPA in the nanomolar range whereas 
the effects of NECA and adenosine have been shown to be inhibited in the 
micromolar range. This suggests the presence of both inhibitory Ai and A2 receptors 
here (Hourani et al., 1993b). Indeed, a post-junctional inhibitory effect of adenosine
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causing inhibition of the smooth muscle contraction has been shown. The agonist 
order in causing inhibition of ATP or noradrenaline induced contractions was NECA 
»  adenosine, with CPA being inactive, suggesting the activation of A2 receptors in 
this tissue (Hourani et al., 1993b). Also, CV 1808, which is an A2a selective ligand, is 
inactive in this tissue (Major et al., 1989), suggesting that the A2 receptor is of the 
A2b subtype. Recently, excitatory post-junctional effects by CPA and R-PIA, but not 
by NECA, causing enhancement of ATP induced contractions has also been shown in 
the rat vas deferens with DPCPX having nanomolar affinity, suggesting the presence 
of a post-junctional Ai receptor in this tissue (Hourani and Jones, 1994). Binding 
studies using [^HJDPCPX in the rat vas deferens have also identified a high affinity 
single site with a Ka for DPCPX in the nanomolar range confirming the presence of 
Ai receptors in this tissue (Peachey et al., 1994).
1.8. ONTOGENY OF PURINOCEPTORS
There has been little information on the development of purinoceptors. 
Binding studies (pHjCHA) have provided some information on the development of 
adenosine receptors in the central nervous system. In the guinea-pig forebrain A% 
binding sites appear as early as embryonic day 36, and the receptor number is stable 
throughout the ages except just before birth where a small increase in the receptor 
number is seen. However in the cerebellum A% binding sites are low during the 
embryonic ages when compared with the forebrain, and after birth a steady increase in 
the number of binding sites occurs up to adulthood (Morgan et al., 1990). A similar 
Ai binding pattern has also been shown in the rat brain, where the Ai binding sites 
increase gradually in the forebrain reaching adult levels after one month, whereas in 
the cerebellum they increase earlier on and reach adult values by day 24 (Marangos et
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al., 1982). This is also consistent with the studies by Geiger and co-workers (1984) in 
the rat brain, where in the cortex a steady increase in the Ai receptor number begins 
from day 1 and stops at the adult level by day 2 1 , whereas in the cerebellum, 
maximum receptor proliferation occurs at about day 14 and continues to adulthood.
Development of purinoceptors in some peripheral tissues has also been 
studied. In the chick embryo retina, adenosine A% receptors have been shown to be 
present at all ages of development (Paes de Carvalho, 1990). In other tissues such as 
in the rat aorta for instance, a decrease in the adenosine-induced vasodilation has been 
observed with age, and has been suggested to be due to a decrease in number of A2 
receptors on the endothelium (Moritoki et al., 1990). Also, the inunature coronary 
vascular bed of the guinea-pig is significantly more sensitive to adenosine than the 
mature bed (Matheme et al., 1990), suggesting that there may be a higher population 
of adenosine receptors in the neonatal tissues. In the chick heart, Ai receptors are 
present as early as day 5, but their functional coupling is inoperative at that age and 
develops after day 10 (Blaie et al., 1989). Recent studies have identified Ai receptor 
mRNA in the rat heart atria of pre-natal animals as early as gestation day 14 showing 
that the Ai receptor gene is one of the earliest expressed G protein-coupled receptor 
genes in the heart (Rivkees, 1995).
The development of purinoceptors in the gastrointestinal tract has also been 
studied. In the rat duodenum excitatory actions to ATP, acting via P2-purinoceptors, 
and inhibitory actions to adenosine, via Pi-purinoceptors, were shown. Here P2- 
purionoceptors are present as early as day 1 whereas Pi-purinoceptors develop much 
later on, after day 14 (Furukawa and Nomoto, 1989). A study by Nicholls and co­
workers (1990), also investigated the ontogeny of purinoceptors in the rat duodenum. 
They also showed that adenosine was inhibitory on this tissue, but responses were
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seen from as early as day 2. However, the potency of adenosine in mediating 
relaxations in the rat duodenum is least in the neonatal tissues at days 2 , 5 and 10 and 
reaches adult values after day 15 (Nicholls et al., 1990). Low concentrations of ATP 
(< 1 jiM) were shown to be inhibitory in the rat duodenum and the potency increased 
with age and reached adult values by day 20. However in the neonates high 
concentrations of ATP (> 1 |iM) were excitatory, but only until day 15 (Nicholls et 
al., 1990). In the rat colon muscularis mucosae, ATP and adenosine both caused 
contractions, with responses being present throughout the ages, appearing as early as 
day 2, and the potency of ATP and adenosine increased with age (Hourani et al., 
1993c). In the guinea-pig taenia caeci responses to purines were also present on the 
smooth muscle as early as day 1 , but in this tissue there was no change in the 
sensitivity to ATP with age (Zagorodnyuk et al., 1993).
In the bladder of the new bom guinea-pig ATP is more potent than in the adult 
bladder, showing that there may be changes in the non-adrenergic, non-cholinergic 
innervation of the bladder with age, indicating that purinergic responses may be more 
important in the neonates than in the adults (Zderic et al., 1990; Sneddon and 
Machaly, 1992). Also in the rat bladder the potency of ATP in causing contractions 
increased with age but then declined, being highest in the neonates between days 1 0  
and 25 (Nicholls et al., 1990). Adenosine is inhibitory in the rat bladder and the 
potency of adenosine in mediating relaxations decreased with age being highest in the 
neonates below day 25 (Nicholls et al., 1990).
In the rat vas deferens, ATP plays an important role as a co-transmitter with 
noradrenaline. The ontogeny of responses in the rat vas deferens to nerve-stimulation 
and exogenous ATP have been shown to mirror each other, with no contractions being 
observed to nerve stimulation or ATP at day 10 and the effects increasing up to day
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25 (Hourani et al., 1993b). However the responses to noradrenaline showed a 
different pattern in this tissue, with the responses decreasing with age (Hourani et al., 
1993b). Therefore it was suggested that ATP is more important as a transmitter than 
noradrenaline in the neonatal tissues. This is also in agreement with the results 
observed by MacDonald and McGrath (1984), who showed that the vasa deferentia 
from sexually immature rats (3-4 weeks old) were more sensitive to noradrenaline 
than were vasa deferentia from adult rats, but appeared to lack functional adrenergic 
transmission. In the guinea-pig seminal vesicles responses to ATP and the purinergic 
component of the nerve-mediated response were significantly higher in the neonatal 
animals compared to adult adult animals, whereas contractions to noradrenaline and 
the adrenergic component of the nerve-mediated response were significantly greater 
in the adult animals compared to neonatal animals (Pinna et al., 1996). These 
differences have been suggested to be related to the reproductive function which is not 
present in young animals (Pinna et al., 1996).
1.9. AIM OF THE THESIS
The aim of the present study was to investigate the ontogeny of purinoceptors in 
the rat duodenum and the rat vas deferens to assess the importance of the purinergic 
responses in neonatal tissues and to demonstrate differences between neonatal and 
adult preparations.
In the rat vas deferens, adenosine, formed by the breakdown of ATP, has been 
shown to have a neuromodulatory role causing inhibition of neurotransmitter release 
by activating pre-junctional A% receptors (Paton, 1981). In this tissue, the presence of 
a post-junctional adenosine A% receptor causing enhancement of ATP induced
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contractions as well as a post-junctional A% receptor causing inhibition of contractions 
has also been reported (Hourani et ah, 1993b; Hourani & Jones, 1994). The 
enhancement by an Ai selective agonist, CPA, of agents inducing contractions, as 
well as of ATP, was investigated in this study to determine whether the effect was 
specific for certain contractile agents over others and to find an agent to use in the 
ontogenetic study. In this tissue it is known that the adrenergic component of the 
nerve-mediated response predominates in the epididymal region whereas the 
purinergic component predominates in the prostatic region (Sneddon & Machaly, 
1992). Therefore the distribution of adenosine receptors in the prostatic and 
adrenergic regions of the bisected rat vas deferens was investigated to see whether 
these receptors are also differentially localised. Also, the potency of adenosine in 
inhibiting nerve-mediated contractions decreased with age reaching adult values after 
day 30 (Hourani et al., 1993b). However the receptor involved here was not 
investigated and as there are both pre- and post-junctional inhibitory receptors (A% 
and A2 respectively) in this tissue (Hourani et al., 1993b), this potency profile does 
not give a clear picture of the development of Pi-purinoceptors in the rat vas deferens. 
Therefore in this study the ontogeny of pre-junctional A% receptors and post 
junctional Ai and A2 receptors are investigated using the A% selective agonist, CPA, 
the non selective agonist, NECA, and the selective antagonist, DPCPX (which has 
nanomolar affinity at Ai and micromolar affinity at A2 receptors).
In the rat duodenum the presence of A% and A2b receptors, both mediating 
relaxation has been reported (Nicholls et al., 1992). Therefore the localization of 
these receptors in the longitudinal muscle and in the muscularis mucosae of the rat 
duodenum was investigated in the present study. The potency of adenosine in causing 
relaxations in the whole rat duodenum increased with age reaching adult values by 
day 15 (Nicholls et al., 1990). Therefore the ontogeny of Pi-purinoceptors in the 
separated layers of the rat duodenum was investigated using the CPA, NECA and
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DPCPX. The location of P2 -purinoceptors in the separated layers of the rat 
duodenum has been shown recently with relaxant P2Y receptors being present in the 
longitudinal muscle and contractile P2X and P2u receptors in the muscularis mucosae 
(Johnson et al., 1996). The ontogenetic study of P2-purinoceptors in the whole tissue 
showed a contractile P2Y receptor in the neonates (below day 15), and the response 
changes with age, with a relaxant response mediated via P2Y receptors being observed 
in the adult (Nicholls et al., 1990). Therefore the ontogeny of P2-purinoceptors was 
also followed in the separated layers of the rat duodenum using a series of ATP 
analogues and UTP to investigate any differences between adult and neonatal tissue 
preparations.
Ectonucleotidase activity has been shown on the adult rat duodenum 
muscularis mucosae (Johnson et al., 1996). The degradation of compounds by 
neonatal tissues was also investigated to show the development of ecto enzymes on 
the muscularis mucosae and to see if there is any correlation between the ontogeny of 
pharmacological response and the metabolism of agonists.
Ontogenetic studies were carried out in parallel to binding studies to make a 
direct comparison of binding and functional studies. Developmental studies may also 
identify an age when only one receptor may be present or functional allowing a better 
characterization of adenosine receptors in these tissues. Also these studies may give 
hints as to the function of adenosine receptors in the vas deferens and the duodenum 
and may have implications in drug development and the use of drugs acting via 
adenosine receptors at various ages.
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CHAPTER 2
METHODS
88
2.1. ANIMALS
Male Wistar albino rats were obtained from the University of Surrey 
Experimental Biology Unit, Surrey, U.K., or from Bantin and Kingman, Hull, U.K. 
Animals used in this study were aged 10, 15, 20, 25, 30, 35,40 and > 60 days (adult), 
and were killed by cervical dislocation. Litters of neonatal rats were culled to 8  to 10 
rats per mother to maintain a standard litter size. The day of birth was designated as 
day 1 and neonatal rats were weaned at day 20. The weight of rats used in this study 
increased with age as shown in Figure 2.1.
2.2. TISSUES
2.2.1. Rat vas deferens
The whole vasa deferentia were dissected out by cutting below the epididymus 
and above the urethra and 3 cm lengths were used. The tissues were cleared of any 
connective tissues and trimmed at both ends. For bisected rat vasa deferentia, equal 
portions (1.5 cm) of both the prostatic and epididymal ends were used.
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Figure 2.1. Variation in weight of rats with age. Each 
point is the mean of 4-8 determinations, s.e.mean 
contained within symbol size.
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2.2.2. Rat duodenum
The duodenum was dissected out by cutting at the base of the pyloris and 
lengths of 1.5 cm (adult) or 0.75 cm (neonates) were used, cleared of any connective 
tissue and placed over a glass rod. The longitudinal muscle was separated by making 
a longitudinal cut and gently rubbing the layer with moist cotton wool. The 
remaining thick walled tube contained the muscularis mucosae.
2.3. PHARMACOLOGICAL STUDIES
2.3.1. Rat vas deferens
The whole vas deferens or equal portions of the bisected tissue were mounted 
in 4 ml organ baths containing Mg^+ free Krebs of the following composition; 118 
mM NaCl, 25 mM NaCOs, 1.2 mM KH2 PO4 , 4.8 mM KCl, 2.5 mM CaCl2 , 11 mM 
glucose, gassed with 95% O2  : 5% CO2 , and maintained at 37°C. A resting tension 
of 0.5 g was used for adult and neonatal tissues from rats at day 20 or above, while a 
resting tension of 0.2 g was used for neonatal tissues from rats at day 15 or below. 
The tissues were equilibrated for 90 minutes, during which Krebs buffer was replaced 
every 20 minutes. Responses were recorded isometrically with a Grass FT03 
transducer linked to a Grass model 79D polygraph.
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2.3.I.I. Concentration-response curves
Concentration-response curves to various contractile agonists were constructed 
non-cumulatively, with a 10 minute dose cycle for ATP, noradrenaline (NA), 
phenylephrine, tyramine, 5-hydroxytryptamine (5-HT), 2-methyl-5- 
hydroxytryptamine (2-Me-5-HT) and a 20 minute dose cycle for bradykinin and 
carbachol on the adult rat vas deferens. For each agonist a concentration was selected 
which gave a consistent sub-maximal contractile response, and this concentration ( 1 0  
pM ATP, 10 pM NA, 3 pM phenylephrine, 10 pM carbachol, 3 pM 5-HT, 10 pM 2- 
Me-5-HT, 10 pM tyramine and 0.1 pM bradykinin) was used in further experiments. 
35 mM KCl was also used, and the contraction induced by this concentration was sub- 
maximal, as it was lower than that induced by 70 mM KCl, although no 
concentration-response curve was constructed to KCl.
2.3.I.2. Inhibition of contractions
In this study, tissues were contracted with a sub-maximal concentration of 
ATP (10 pM), NA (10 pM) or by field stimulation (Grass S48 stimulator, twin pulses 
of 1 ms duration, 75 ms apart, 70 V, via parallel platinum electrodes at a frequency of 
0.1 Hz resulting in regular contractions 10 s apart). Nerve-mediated contractions 
were abolished after incubating the tissue with tetrodotoxin (1 pM) for 30 minutes. 
To measure the inhibitory effects of purines on ATP or NA-induced contractions, the 
tissues were pre-incubated with the purines for 1 minute before the addition of the 
contractile agonist. The inhibition was expressed as percent reduction of control 
contractions in the absence of the purines, calculated as the mean of several stable 
control contractions obtained in each tissue over the course of the experiment. The
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potency of NECA and CPA causing inhibition of the ATP or NA-induced 
contractions was expressed as the negative logarithm of the molar concentration of the 
agonist producing 5 0 % inhibition of the ATP-induced response (pECso) or 30% 
inhibition of the NA-induced response (pECgo). To measure the inhibitory effects of 
purines on the nerve mediated contractions, the tissues were field stimulated at a 
frequency of 0.1 Hz, the purines were added when the response to the nerve 
stimulation had stabilised and left in contact with the tissue until maximal inhibition
z'
of the contractions were observed. The inhibition was expressed as percent reduction 
of the nerve mediated response. To investigate the effect of DPCPX (10 nM or 100 
nM) on the inhibition by CPA of nerve mediated contractions, concentration-response 
curves to CPA were obtained in the same tissue before and after incubation for 30 
minutes with the antagonist. pECgo values were calculated as the negative logarithm 
of the molar concentration of the agonist producing 50% inhibition of the nerve- 
mediated response and dose ratios were calculated using these values. An apparent 
pA2 value was calculated as the negative logarithm of the molar concentration of the 
antagonist divided by the dose ratio - 1 .
2.3.I.3. Enhancement of contractions
To measure the enhancement by CPA (1 nM - 3 pM) of contractions induced 
by the contractile agents (10 pM ATP, 10 pM NA, 3 pM phenylephrine, 10 pM 
carbachol, 3 pM 5-HT, 10 pM 2-Me-5-HT, 35 mM KCl, 10 pM tyramine and 0.1 pM 
bradykinin), the tissues were pre-incubated for 1 minute with various concentrations 
of CPA, before addition of the contractile agent. The response in the presence of CPA 
was expressed as % of the response in the absence of CPA, calculated as the mean of 
several control contractions obtained in each tissue over the course of the experiment.
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To further investigate the enhancement by CPA, concentration-response curves to 
ATP, NA and tyramine were carried out in parallel either in the presence or absence 
of 0.3 pM CPA pre-incubated with the tissue for 1 minute as above. In the case of 
DPCPX (3 nM) and tetrodotoxin (TTX) (1 pM), enhancement of contractions by CPA 
(0.3 pM) was obtained in the same tissue before and after incubation for 30 minutes 
with DPCPX or TTX. Student's t test was used to compare results, and differences 
were considered significant if p < 0.05.
2.3.I.4. Effect of prazosin, imlpramlne, atropine, ketanserin, MDL 72222 and 
desensitization of ? 2x  receptors
In experiments to investigate the effect of prazosin (100 nM), imipramine (1 
pM) and atropine (1 pM), these were incubated with the tissue for one hour before 
challenge with the contractile agents. In experiments to investigate the effect of 
desensitizing the P2x-purinoceptor in this tissue, contractions to the ATP analogue 
AMPCPP (100 pM), were induced repeatedly until no response to ATP (10 pM) was 
observed. Responses to the contractile agents were obtained in the same tissue before 
and after treatment with imipramine, prazosin, atropine or AMPCPP. Student's t test 
was used to compare results in the presence and absence of antagonists or 
desensitization, and differences were considered significant if p < 0.05.
For 5-HT and 2-Me-5-HT, the effects of ketanserin (10 nM) and 3-tropanyl- 
3,5-dichlorobenzoate (MDL 72222) (1 pM) were investigated on agonist 
concentration-response curves and the negative logarithm of the concentration 
producing 0.75 g response was used to calculate dosae ratios. A pA2 value for
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ketanserin was calculated as the negative logarithm of the molar concentration of the 
antagonist divided by the dose ratio - 1 .
2.3.15. Bisected rat vas deferens
In experiments to investigate the adenosine receptor distribution along the adult 
rat vas deferens, the tissue was divided into equal portions of the prostatic and 
epididymal ends and mounted separately in organ baths. The inhibition by CPA and 
NECA of nerve-stimulated contractions was investigated and the effect of DPCPX 
(10 nM or 1 pM) was studied as discussed in section 2.3.1.2. The inhibitory effect of 
NECA and the enhancement by CPA (< 1 pM) of contractions induced by KCl (35 
mM) was also investigated, where tissues were pre-incubated with the purines for 1 
min before the addition of KCl. Responses were expressed as percent reduction (% 
inhibition) or increase (% enhancement) of control response in the absence of the 
purines, calculated as the mean of several control contractions obtained in each tissue 
over the course of the experiment. For inhibition of nerve-mediated responses, pEC^o 
(negative logio of the molar concentration of the agonist producing 50% inhibition) 
values were calculated and dose ratios were obtained using these values. For 
inhibition of KCl-induced contractions, a pEC20 value was calculated as the negative 
log 10 of the molar concentration of the agonist producing 2 0 % inhibition.
Concentration-response curves to NA and ATP were also constructed in the 
epididymal and prostatic portions of the rat vas deferens. The potency of NA was 
expressed as the negative logio of the molar concentration of the agonist producing 
50% of the response induced by KCl (pECgq), and the potency of ATP was expressed 
as the negative logio of the molar concentration of the agonist producing 2 0 % of the
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response induced by KCl (pEC2o)- These potency values were used as they represent 
near midpoint locations of the concentration-response curves obtained. Contractions 
induced by 5-HT (3 pM), 2-Me-5-HT (10 pM) and tyramine (10 pM) were also 
investigated in the bisected tissue. Student's t test was used to compare results, and 
differences were considered significant if p < 0.05.
2.3.I.6. Neonatal rat vas deferens
The inhibitory effects of CPA and NECA on KCl-induced (35 mM) 
contractions were investigated from day 1 0  onwards, and the potency was expressed 
as the negative logarithm of the molar concentration of the agonist producing 25% 
inhibition of the KCl-induced response (pEC2s). The inhibitory effect of CPA and 
NECA on nerve-mediated contractions was also investigated as before from day 15 
onwards, and the potency was calculated as pECso values. The potency values of 
pEC25 or pECso were used in each case as these represent midpoint responses of the 
curves obtained and were appropriate to use to compare the effects of the agonists 
with age. The effect of DPCPX (10 nM) on the inhibition of nerve-mediated 
contractions by CPA was also investigated at days 15 and 25, however at day 15 
tissue fragility prevented two concentration response curves from being constructed 
on one tissue preparation, therefore experiments in the absence and presence of 
DPCPX were performed on separate tissues. The enhancement by CPA of 
contractions induced by KCl (35 mM) was also investigated, and responses were 
expressed as the % enhancement by CPA of the KCl-induced contraction in the 
absence of CPA. Here the potency across the ages was expressed as % enhancement 
at 0.3 |xM CPA (the concentration giving maximal enhancement). Statistical analysis
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across the ages was carried out using one-way ANOVA followed by Duncan’s New 
Multiple Range post-hoc test and differences were considered significant if p < 0.05.
2.3.2. Rat duodenum
The muscularis mucosae and the longitudinal muscle of the adult and neonatal 
rat duodenum were mounted in 4 ml organ baths containing Krebs of the following 
composition; 1.2 mM MgSO^, 118 mM NaCl, 25 mM NaCOg, 1.2 mM KH2 PO4 , 4.8 
mM KCl, 2.5 mM CaCl2 , 11 mM glucose, gassed with 95% O2  : 5% CO2 , and 
maintained at 35-36°C. A resting tension of 1 g was used for tissues from adult 
animals, 0.5 g for neonatal tissues from rats at day 20-40 and 0.3 g was used for 
neonatal tissues from rats at day 10-15. Tissues were equilibrated for 45 minutes, 
during which Krebs buffer was replaced every 20 minutes. Responses were recorded 
isometrically with a Grass FT03 transducer linked to a Grass model 79D polygraph. 
Concentration-response curves were obtained non-cumulatively, and a 10 minute dose 
cycle was used.
2.3.21. Adult rat duodenum longitudinal muscle
A concentration-response curve to carbachol was obtained in the rat duodenum 
longitudinal muscle and a sub-maximal concentration was used in this study (0.3 gM) 
to pre-contract the tissue. The inhibitory effects of CPA, NECA, 2-Me-S-ATP and 
AMPCPP were investigated in this tissue. The tissue was pre-contracted with 
carbachol (0.3 pM), and after the contraction had stabilised the agonists were added. 
Responses were expressed as % reduction of the carbachol-induced contraction. 
Contractions to carbachol were measured from the top of the spontaneous activity to
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the highest point of the carbachol contraction and relaxations were measured as a 
reduction in the height of the rhythmic contraction induced by carbachol. The effect 
of DPCPX (10 nM and 1 |xM) was investigated on the inhibition by CPA and NEC A 
with concentration-response curves being obtained for CPA and NBCA in the same 
tissue before and after incubation with the antagonist for 30 minutes. The potency of 
CPA and NBCA causing inhibition was expressed as the negative logarithm of the 
molar concentration of the agonist producing 35% reduction of carbachol contraction 
(PBC35). Dose ratios were calculated using these values and apparent pA2 values for 
DPCPX were estimated as the negative logarithm of the molar concentration of the 
antagonist divided by the dose ratio - 1. The potency of 2-Me-S-ATP and AMPCPP 
in causing inhibition was expressed as the negative logarithm of the molar 
concentration of the agonist producing 30% reduction of carbachol contraction 
(pBCso).
2.B.2.2. Adult rat duodenum muscularis mucosae
The contractile effects of CPA, NBCA, 2-Me-S-ATP, AMPCPP, ATP and UTP 
were investigated in this tissue. Agonists were added directly to the organ baths and 
expressed as % contraction induced by KCl (35 mM). The effect of DPCPX (1 p,M) 
on the contractions by CPA and NBCA was investigated with concentration-response 
curves being obtained for CPA and NBCA in the same tissue before and after 
incubation with the antagonist for 30 minutes. The effect of indomethacin (25 |xM) 
was also investigated, a concentration-response curve to CPA being obtained in the 
same tissue before and after incubation with indomethacin for 30 minutes. The 
potency of CPA and NBCA in causing contractions was expressed as the negative 
logarithm of the molar concentration of the agonist producing 40% of the KCl-
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induced contraction (pEC4o), and dose ratios were calculated using these values. An 
apparent pA2 value for DPCPX was also calculated as in section 2.3.2.1. The potency 
of 2-Me-S-ATP, AMPCPP, ATP and UTP causing contractions was expressed as the 
negative logarithm of the molar concentration of the agonist producing 60% of the 
KCl-induced contraction (pECôo)* For 2-Me-S-ATP which did not achieve 60% 
contraction in this tissue, pEC^o values were calculated by extrapolation of the 
individual log concentration-response curves.
2.B.2.3. Neonatal rat duodenum longitudinal muscle
A concentration-response curve to carbachol was obtained in the neonatal rat 
duodenum longitudinal muscle (day 2 0 ) and a sub-maximal concentration was used in 
this study (0.3 pM) to pre-contract the tissue. CPA, NECA, 2-Me-S-ATP and 
AMPCPP were added to the carbachol-contracted tissue taken from rats aged from 
day 15 onwards. The inhibitory effect of CGS 21680 on the contractions to carbachol 
was also investigated in this tissue at day 15. The effect of DPCPX (1 pM or 10 nM) 
on the inhibition by NECA or CPA was also studied here. A potency value of PEC35 
for NECA, CPA, and CGS 21680 was determined as it represented the near mid point 
locations of the curves and was appropriate to use for the comparison of potency at 
different ages. For 2-Me-S-ATP and AMPCPP, a potency value of PEC30  was 
determined, as it too was appropriate for the comparison of effects with age.
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2.3.2.4. Neonatal rat duodenum muscularis mucosae
In the neonatal rat duodenum muscularis mucosae contractions were obtained to 
CPA, NECA, 2-Me-S-ATP, AMPCPP, ATP and UTP in tissues from rats aged day 10 
onwards. Contractile effects of CGS 21680 were also investigated in this tissue at day 
20. The effect of DPCPX (1 pM) was also investigated and an apparent pA2 value for 
DPCPX was calculated. The potency of CPA and NECA in causing contractions in 
this tissue was expressed as pEC^o values and these values were used to compare the 
effects across the ages. A potency value of pECgo was also determined for 2 -Me-S- 
ATP, AMPCPP, ATP and UTP to study the effects of the agonists with age. 
Statistical analysis was carried out using one-way ANOVA followed by Duncan's 
New Multiple Range post-hoc test and differences were considered significant if p < 
0.05.
AMPCPP was used in an attempt to desensitize the P2x  receptors in this tissue 
using 15 and 30 day animals. 100 pM AMPCPP was added, left in contact with the 
tissue for 10 min, and the dose was repeated after 5 min. Contractions were expressed 
as % of the response obtained to the initial dose of AMPCPP. Statistical analysis was 
carried out using one-way ANOVA followed by Dunnett's two-tailed post-hoc test 
and differences were considered significant if p < 0.05. Cross-desensatisation 
between AMPCPP and 2-Me-S-ATP, ATP or UTP was also investigated in the 
muscularis mucosae. A dose of 2-Me-S-ATP (100 or 3 pM), ATP (100 or 10 pM) or 
UTP (100 or 10 pM) (control response) was first administered followed by the 
desensitizing dose of AMPCPP (100 pM) for 10 min, after which the tissue was 
challenged with the same concentrations of the agonists, and contractions were 
expressed as % of the control response. For tissues from day 15 and day 30 rats, a 
submaximal concentration of 100 pM of the agonists was used, whereas for tissues
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from day 15 rats a lower dose (3 pM 2-Me-S-AT, 10 pM ATP, 10 pM UTP) was also 
tested as 100 pM of the agonists produced a maximum effect. A Student’s t test was 
used to compare the results.
2.3.2.S. Degradation studies
The degradation of ATP, UTP, AMPCPP and 2-Me-S-ATP by the rat 
duodenum muscularis mucosae from rats aged 15 and 30 days was investigated. 
Tissues were mounted in 4 ml organ baths as in the functional studies (see section 
2.3.2). lOOpM ATP, UTP, AMPCPP and 2-Me-S-ATP were added individually to 
the baths and 100 pi aliquots were taken at 0, 2, 5, 10, 15, 20 minutes, stored at -20°C 
and analysed by high pressure liquid chromatography (h.p.l.c.) at a later date. H.p.l.c. 
analysis was carried out using a Shimadzu LC-lOA with an Apex II 5 pm ODS Cig 
column, eluted with 0.1 M KH2PO4 /8  mM tetrabutylammonium hydrogen sulphate 
(pH 6.0) (solvent A) and a 60:40 mixture of solvent A and acetonitrile (pH 6.7) 
(Solvent B), using a non-linear gradient (0-2.5 min 0% B, 2.5-5 min 0-20% B, 5-10 
min 20-40% B, 10-13 min 40%-100% B, 13-18 min 100% B) at a flow rate of 1.3 ml 
min'T The compounds were detected by u.v. absorbance at 259 nm and quantified by 
the area of the absorbance peaks which is linearly related to the concentration. To 
compare the rate of degradation of the agonists a half life was calculated for each 
tissue from a semi log plot of log 10 concentration of agonist versus time. Statistical 
analysis was carried out using a Students t test (for comparison of half lives for 
agonists between the two ages) or a one-way ANOVA followed by Duncan's New 
Multiple Range post-hoc test (for comparison of half lives across the agonists).
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2.5. MATERIALS
DPCPX, CPA, 2-Me-5-HT, MDL 72222, ketanserin, CGS 21680 and 2-Me-S- 
ATP were obtained from Research Biochemicals International, Natick, MA, USA.
ATP, UTP, AMPCPP, 5-HT, bradykinin, imipramine, prazosin, carbachol, NA, 
phenylephrine, atropine, indomethacin and TTX were obtained from Sigma Chemical 
Company, Poole, UK.
The buffer salts were of analytical grade or h.p.l.c. grade and were obtained 
from Fisons, Loughborough, Leicestershire, UK, or BDH, Poole, Dorset, UK. 
Suramin was a generous gift from Bayer, UK. Gas cylinders containing 95% O2 : 5% 
CO2 were obtained from B.O.C., UK. Apex II 5 pm ODS Cig column was obtained 
from Jones Chromatography Ltd., UK.
CPA (10 mM) was dissolved in 20% ethanol and DPCPX (1 mM) was also 
dissolved in 20% ethanol or in 2% aqueous dimethylsulphoxide (DMSG) containing 
NaOH (6  mM). Indomethacin (2.5 mM) was initially dissolved in ethanol and made 
up to 1/19 v/v ethanol/phosphate buffer (pH 7.4). Noradrenaline (10 mM) and 
phenylephrine (10 mM) were dissolved in ascorbic acid solution (20 pg/ml). CGS 
21680 (10 mM) was dissolved in 7% DMSG. The effects of the solvents on the 
tissues were also tested here, and after dilution to the final bath concentration of the 
agonists the solvents had no effect on the tissues. Adenosine, ATP, AMPCPP, UTP 
and 2-Me-S-ATP (10 mM) were dissolved in distilled water and their final 
concentration checked using u.v. spectrometry (the optimal wavelengths and 
extinction coefficients are shown in Table 2.1). All other drugs were dissolved in 
distilled water and stock solutions were stored at -20°C.
Compounds used were greater than 97% pure (as stated by the manufacturer). 
Therefore any errors caused by the impurities on the potency of compounds are 
assumed negligible.
Table 2.1. Optimum wavelengths and extinction coefficients for purines and 
pyrimidines.
Purine/Pyrimidine Optimum Wavelength Extinction coefficient at their
(nm) optimal wavelength at pH 6
(10-3M-lcm-l)
Adenosine 259 15.4
ATP 259 15.4
UTP 262 10.0
AMPCPP 259 15.4
2-Me-S-ATP 273 14.5
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CHAPTER 3
RESULTS
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3.1. ADULT RAT VAS DEFERENS
3.1.1. Inhibition of contractions
The whole adult rat vas deferens had an average wet weight of 80 ± 5 mg (n = 
4-8). Adenosine, NECA and CPA (> 1 pM) inhibited contractions induced by ATP 
(10 pM) in this tissue (Figure 3.1a), with a potency order of NECA (6 .6  ±0.1) > 
adenosine (4.9 ±0.1) = CPA (4.8 ± 0.1) (pEC 50 values in parenthesis, n = 4-5). The 
agonists also inhibited contractions induced by noradrenaline (NA) (10 pM) (Figure 
3.1b), with the same potency order: NECA (5.9 ±0.1) > adenosine (4.9 ±0.1) = 
CPA (4.9 ±0.1) (pECso values in parenthesis, n = 4-5). Nerve-mediated contractions 
were also inhibited by adenosine, NECA and CPA (Figure 3.1c) with a potency order 
of NECA (7.1 ±0.1) = CPA (6.9 ±0.1) > adenosine (4.6 ± 0.1) (pEC4o values in 
parenthesis, n = 4), and nerve-mediated contractions were abolished by tetrodotoxin 
(TTX) (1 pM). A representative trace showing the inhibition by CPA and NECA of 
nerve-mediated contractions is shown in Figure 3.2. For the inhibition of nerve- 
mediated contractions by CPA, DPCPX at concentrations of 10 and 100 nM caused 
rightward shifts (Figure 3.3) with dose ratios of 11.1 and 36.0 corresponding to 
apparent pA2 values of 8.9 and 8.5 respectively (see Table 3.1), and concentration- 
response curves to CPA were not significantly different from curves repeated after 30 
minutes (results not shown).
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Figure 3.1. Inhibitory effects of adenosine (À), NECA (■) and CPA ( • )  on 
contractions of the adult rat vas deferens induced by (a) ATP (10 |xM), (b) NA 
(10 |XM) or (c) nerve stimulation (for stimulation parameters see methods). 
Responses are expressed as % decrease of the control response to (a) ATP, (b) 
NA and (c) nerve-stimulation in the absence of purines. Each point is the mean 
of at least four determinations and the vertical bars show s.e.mean.
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Figure 3.3. Antagonism by (a) 10 nM DPCPX and (b) 100 nM DPCPX of the 
inhibition by CPA of nerve-mediated contractions in the adult rat vas deferens. 
The closed symbols show the effect of CPA alone and the open symbols show the 
effect of CPA in the presence of DPCPX. Results are expressed as % decrease of 
the nerve-mediated contraction. Each point is the mean of at least four 
determinations and the vertical bars show s.e.mean.
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Table 3.1. Antagonism by DPCPX of the effects of CPA in inhibiting nerve- 
mediated contractions in the neonatal and adult rat vas deferens.
Agonist pECso Dose-ratio Apparent pA%
Adult rat vas deferens
CPA alone 7.0 ± 0.1
CPA +10 nM DPCPX 6.0 ±0.1» 11.1 ±0.7 8.9 ±0.1
CPA + 100 nM DPCPX 5.4 ± 0.2* 36.0 ± 9.2 8.5 ±0.1
Neonatal rat vas deferens
CPA alone (day 15) 7.0 ±0.1
CPA +10 nM DPCPX 6.5 ±0.1* 4.0 ±1.1 8.4 ±0.2
CPA alone (day 25) 7.0 ±0.1
CPA +10 nM DPCPX 6.1 ±0.1* 8.2 ±1.3 8 .8  ±0.1
Table showing the potency of CPA in inhibiting nerve-mediated contractions in the 
neonatal and adult rat vas deferens and the apparent pA2 values for DPCPX.
Student's paired t test (for day 25 and adult tissues) and unpaired t test (for day 15
tissues); *p < 0.05, significantly different from control values.
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3.1.2. Bisected rat vas deferens
The epididymal and prostatic portions of the bisected rat vas deferens had an 
average wet weight of 18 ± 1 mg and 35 ± 1 mg respectively. Concentration-response 
curves to NA and ATP in the bisected tissue are shown in Figure 3.4. NA was more 
potent in the epididymal region when compared to the prostatic region where the 
potency values for NA (expressed as pECso) were 6.9 ± 0.4 and 5.8 ± 0 .1  
respectively. However, ATP was more potent in the prostatic region when compared 
to the epididymal region where the potency values for ATP (expressed as pEC2o) 
were 4.2 ±0.1 and 3.5 ± 0.3 respectively. Also the contractile responses to 5-HT (3 
|iM), tyramine (10 jxM) and 2-Me-5-HT (10 pM) were significantly (p < 0.05) more 
pronounced in the epididymal region when compared to the prostatic region (Figure 
3.5), whereas KCl (35 mM) gave similar contractions in both regions of the bisected 
tissue. CPA (0.01-0.3 p,M) enhanced contractions induced by KCl (35 mM) equally 
in both the epididymal and prostatic portions of the bisected tissue, with a maximal 
enhancement at 0.3 |xM CPA of approximately 40% in each case (Figure 3.6). NECA 
(0.01-30 p,M) potently inhibited contractions induced by KCl (35 mM) in the prostatic 
region (pEC20 = 6.3 ± 0.3), but was almost inactive even at 100 p,M in the epididymal 
region of the bisected tissue (Figure 3.7).
Nerve-mediated responses in the epididymal and prostatic regions were 
abolished by TTX (1 pM), whereas KCl-induced responses were unaffected (results 
not shown). CPA and NECA inhibited nerve-mediated contractions in both regions of 
the tissue (Figures 3.8 and 3.9) but CPA (7.4 ± 0.1) was more potent than NECA (6.7 
± 0 .2 ) in inhibiting nerve-mediated contractions in the epididymal region, whereas in 
the prostatic region the order of potency was reversed: NECA (7.3 ±0.1) > CPA (6 .6  
± 0.1) (pECso values in parenthesis, n = 4-5). CGS 21680 also inhibited nerve-
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mediated contractions in the prostatic region but was much less potent than NECA 
(pECso NECA = 7.3 ± 0.1, pECso CGS 21680 = 4.0 ± 0 .2 ) (Figure 3.10). DPCPX (10 
nM) antagonised the inhibition by CPA of nerve-mediated contractions in both 
regions of the bisected tissue (Figure 3.8), giving a dose ratio of 20.8 corresponding to 
an apparent pA2 value of 9.3 in the epididymal region, and a dose ratio of 3.7 
corresponding to an apparent pA2 value of 8.4 in the prostatic region. DPCPX (10 
nM) also antagonised the response to NECA in the epididymal region (Figure 3.9a), 
giving a dose ratio of 5.8 corresponding to an apparent pA2 value of 8 .6 , whereas it 
did not antagonise the response to NECA in the prostatic region (Figure 3.9b). 
However 1 pM DPCPX antagonised responses to NECA in both regions of the 
bisected tissue (Figure 3.9), giving a dose ratio of 155.8 corresponding to an apparent 
pA2 value of 8.2 in the epididymal region, and a dose ratio of 3.5 corresponding to an 
apparent pA2 value of 6.4 in the prostatic region. Concentration-response curves to 
CPA and NECA were not significantly different from curves repeated after 30 
minutes (results not shown). The potency values for CPA and NECA in inhibiting 
nerve-mediated contractions, and the apparent pA2 values for DPCPX are summarised 
in Table 3.2.
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Figure 3.4. Contractile effects of (a) NA and (b) ATP in the prostatic 
(open symbols) and epididymal (closed symbols) portions of the 
bisected adult rat vas deferens. Results are expressed as % contraction 
induced by KCl (35 mM). Each point is the mean of at least three 
determinations and the vertical bars show s.e.mean.
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Figure 3.5. Contractile responses induced by 5-HT (3 |iM), 2-Me-5-HT (10 
fiM) and tyramine (10 jiM) in the epididymal (closed columns) and prostatic 
(open colunms) portions of the bisected adult rat vas deferens. Responses 
are expressed as % contraction induced by KCl (35 mM). Each column is 
the mean of at least four determinations and the vertical bars show s.e.mean. 
Student's unpaired t test; *p < 0.05, significantly different from responses in 
the epididymal region.
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Figure 3.6. Enhancement by CPA of KCl-induced (35 mM) 
contractions in the prostatic (O) and epididymal ( • )  portions of the 
bisected adult rat vas deferens. Responses are expressed as % increase 
of the control response in the absence of CPA. Each point is the mean 
of at least four determinations and the vertical bars show s.e.mean.
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Figure 3.7. Inhibition by NECA of KCl-induced (35 mM) 
contractions in the prostatic (■) and epididymal (□) portions of the 
bisected adult rat vas deferens. Responses are expressed as % 
decrease of the control response in the absence of NECA. Each 
point is the mean of at least four determinations and the vertical bars 
show s.e.mean.
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Figure 3.8. Antagonism by DPCPX (10 nM) of the inhibition by CPA of 
nerve-mediated contractions in the (a) epididymal and (b) prostatic 
portions of the adult rat vas deferens. The closed symbols show the effect 
of CPA in the absence of DPCPX and the open symbols show the effect of 
CPA in the presence of DPCPX. Responses are expressed as % decrease 
of the nerve-mediated contraction. Each point is the mean of at least four 
determinations and the vertical bars show s.e.mean.
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Figure 3.9. Effect of DPCPX (10 nM and 1 jxM) on the inhibition by CPA of nerve- 
mediated contractions in the (a) epididymal and (b) prostatic portions of the adult rat 
vas deferens. Closed symbols show the effect of NECA (■) in the absence of the 
antagonist and open symbols show the effect of NECA in the presence of the 
antagonist; 10 nM DPCPX (□), l|iM DPCPX (T). Responses are expressed as % 
decrease of the nerve-mediated contraction. Each point is the mean of at least four 
determinations and the vertical bars show s.e.mean.
117
100-1
8 0 -
2 0 -
0.001 0.01 0 . 1 1 1 0 1 0 0
Concentration (|XM)
Figure 3.10. Inhibition by CGS 21680 (□) and NECA (■) of nerve- 
mediated contractions in the prostatic portion of the adult rat vas 
deferens. Results are expressed as % decrease of the nerve-mediated 
response. Each point is the mean of at least four determinations and the 
vertical bars show s.e.mean.
118
Table 3.2. Antagonism by DPCPX of the effects of CPA and NECA in inhibiting 
nerve-mediated contractions in the epididymal region and the prostatic region of 
the bisected rat vas deferens.
Agonist pECso Dose-ratio Apparent pA%
Epididvmal region
CPA alone 7.4 ±0.1
CPA +10 nM DPCPX 6.0 ±0.1* 20.8 ±2.1 9.3 ±0.1
NECA alone 6.7 ± 0.2
NECA +10 nM DPCPX 6.0 ±0.1* 5.8 ±0.6 8 .6  ±0.1
NECA + 1 \iM DPCPX 4.7 ± 0.2* 155.8 ± 34.2 8.2 ± 0.1
Prostatic region
CPA alone 6 .6  ±0.1
CPA +10 nM DPCPX 6.1 ±0.1* 3.7 ±0.6 8.4 ±0.1
NECA alone 7.3 ±0.1
NECA + 10 nM DPCPX 7.2 ±0.1
NECA + 1 pM DPCPX 6 .8  ±0.1* 3.5 ± 0.5 6.4 ± 0.1
Table showing the potency of CPA and NECA in inhibiting nerve-mediated 
contractions in the epididymal and prostatic regions of the bisected rat vas deferens 
and the apparent pA% values for DPCPX. Student’s paired t test; *p < 0.05, 
significantly different from control values.
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3.1.3. Enhancement of contractions
The enhancement of contractions induced by a range of contractile agents 
were studied using the whole rat vas deferens. A sub-maximal concentration of the 
agonists were used and was obtained from concentration-response curves constructed 
to NA, ATP, carbachol, bradykinin, tyramine, 2-Me-5-HT, phenylephrine and 5-HT 
(Figure 3.11). KCl (35 mM) also produced a sub-maximal contraction but no 
concentration-response curve was obtained.
Concentrations of CPA ranging from 1 nM to 0.3 pM clearly enhanced 
contractions induced by ATP (10 pM), 5-HT (3 pM), tyramine (10 pM), 2-Me-5-HT 
(10 pM) and KCl (35 mM), maximal enhancement being seen at 0.3 pM CPA for 
each contractile agent (Figure 3.12). There was no enhancement of the contractions 
induced by NA (10 pM), phenylephrine (3 pM), carbachol (10 pM) or bradykinin (0.1 
pM) (Figure 3.12). No enhancement was also observed of contractions induced by a 
lower concentration of NA (1 pM) (results not shown). High concentrations of CPA 
(> 1 pM) inhibited responses to some of the contractile agents (Figure 3.12). In the 
presence of 0.3 pM CPA the concentration-response curves to ATP and tyramine 
were clearly enhanced and the enhancement was significantly different (p < 0.05) at 
concentrations of ATP >10 pM and concentrations of tyramine > 3 pM (Figure 3.13). 
The concentration-response curve to NA on the other hand was unaffected in the 
presence of 0.3 pM CPA (Figure 3.13b). The enhancement by CPA (0.3 pM) of 
contractions induced by ATP (10 pM), 5-HT (3 pM), tyramine (10 pM), 2-Me-5-HT 
(10 pM) and KCl (35 mM) was significantly inhibited (p < 0.05) by DPCPX (3 nM) 
(Figure 3.14).
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TTX (1 pM) did not inhibit contractions induced by ATP (10 pM), 5-HT (3 
pM), 2-Me-5-HT (10 pM) and KCl (35 mM), and did not affect the enhancement of 
these contractions by CPA (0.3 pM) (Figure 3.15). After desensitizing P2X" 
purinoceptors with AMPCPP (100 pM), the responses to 5-HT (3 pM), 2-Me-5-HT 
(10 pM), NA (10 pM), carbachol (10 pM), KCl (35 mM) and bradykinin (0.1 pM) 
were also not affected (Figure 3.16). Atropine (1 pM) inhibited contractions induced 
by carbachol (10 pM) (results not shown). Prazosin (100 nM) significantly inhibited 
contractions induced by NA (10 pM), phenylephrine (3 pM), 2-Me-5-HT (10 pM) 
and tyramine (10 pM), but did not affect the contractions induced by 5-HT (3 pM), 
KCl (35 mM) or ATP (10 pM) (Figure 3.17). In the presence of prazosin (100 nM) 
contractions to 2-Me-5-HT (10 pM) were reduced from 1.0 ± 0.1 g to 0.1 ± 0.05 g (p 
< 0.001). Imipramine (1 pM) almost abolished contractions induced by 2-Me-5-HT 
(10 pM) and tyramine (10 pM) but did not affect contractions induced by NA (10 
pM), 5-HT (3 pM), KCl (35 mM) or ATP (10 pM) (Figure 3.18). In the presence of 
imipramine (1 pM) contractions to 2-Me-5-HT (10 pM) were reduced from 1.4 ± 
0.1 g to 0.1 ± 0.1 g (p < 0.001). Ketanserin (10 nM) caused a shift to the right of the 
concentration-response curve to 5-HT (Figure 3.19a), with a dose-ratio of 12.9 
corresponding to an apparent pA2 of 9.1, and MDL 72222 did not antagonise the 
response to 2-Me-5-HT (Figure 3.19b).
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Figure 3.11. Contractions by various contractile agonists in the adult rat vas 
deferens: (a) ATP (O), 5-HT (V); bradykinin (♦); carbachol (T); (b) NA (O); 
phenylephrine (□); 2-Me-5-HT (•) ; tyramine (■). Each point is the mean of at 
least four determinations and the vertical bars show s.e.mean.
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Figure 3.12. Effect of CPA on contractile responses of rat vas deferens induced 
by (a) ATP (10 |XM)(0), 5-HT (3 pM)(V), KCl (35 mM)(A), bradykinin (0.1 
p,M)(^), carbachol (10 |liM)(T), (b) NA (10 |iM(0), phenylephrine (3 jxM)(D), 2- 
Me-5-HT (10 |iM)(#) and tyramine (10 jiM)(H). Results are expressed as 
percent of control response to each agent in the absence of CPA. Each point is 
the mean of at least four determinations and the vertical bars show s.e.mean.
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Figure 3.13. Contractions to (a) ATP, (b) NA and (c) tyramine in the 
adult rat vas deferens in the presence (open symbols) and absence (closed 
symbols) of CPA. Each point is the mean of at least four determinations 
and the vertical bars show s.e.mean. Student's unpaired t test; *p < 0.05, 
significantly different from results in the absence of CPA.
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Figure 3.14. Antagonism by DPCPX (3 nM) of the enhancement by CPA (0.3 
jxM) of contractions induced by ATP (10 pM), 2-Me-5-HT (10 |xM), 5-H (3 
|iM), KCl (35 mM) and tyramine (10 |iM) in the adult rat vas deferens. Results 
are expressed as percent of control response to each agent in the absence of 
CPA. Results are the mean of at least four determinations and the vertical bars 
show s.e.mean. Student's paired t test; *p < 0.05, significantly different from 
results in the absence of antagonist.
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Figure 3.15. Effect of TTX (1 )liM )  on the enhancement by CPA (0.3 [iM) 
of contractions induced by ATP (10 |xM), 2-Me-5-HT (10 |XM), 5-HT (3 
|xM) and KCl (35 mM) in the adult rat vas deferens. Results are expressed 
as percent of control response to each agent in the absence of CPA. Results 
are the mean of at least four determinations and the vertical bars show 
s.e.mean.
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Figure 3.16. Effect of desensitization with AMPCPP (100 |xM) on contractions 
in the adult rat vas deferens induced by ATP (10 |iM), 2-Me-5-HT (10 |iM), 5- 
HT (3 |iM), KCl (35 mM), carbachol (10 p,M), NA (10 |liM )  and bradykinin 
(0.1 |xM). Results are the mean of at least four determinations and the vertical 
bars show s.e.mean. Student's paired t test; *p < 0.001, significantly different 
from results in the absense of desensitization.
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Figure 3.17. Effect of prazosin (100 nM) on contractions of the adult rat vas 
deferens induced by NA (10 pM), KCl (35 mM), ATP (10 pM), 2-Me-5-HT (10 
pM), 5-HT (3 pM), tyramine (10 pM) and phenylephrine (3 pM). Results are the 
mean of at least four determinations and the vertical bars show s.e.mean. Student's 
paired t test; *p < 0.005, significantly different from results in the absence of 
prazosin.
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Figure 3.18. Effect of imipramine (1 pM) on contractions induced by 5-HT 
(3 pM), KCl (35 mM), ATP (10 pM), NA (10 pM), 2-Me-5-HT (10 pM) and 
tyramine (10 pM) in the adult rat vas deferens. Results are the mean of at least 
four determinations and the vertical bars show s.e.mean. Student's paired t test; 
*p < 0 .0 1 , significantly different from results in the absence of imipramine.
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Figure 3.19. Contractions to (a) 5-HT in the presence (□) and absence 
(■) of ketanserin (10 nM), (b) 2-Me-5-HT in the presence (O) and 
absence ( • )  of MDL 72222 (1 |iM) in the adult rat vas deferens. Each 
point is the mean of at least four determinations and the vertical bars 
show s.e.mean.
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3.2. NEONATAL RAT VAS DEFERENS
The average wet weight of the neonatal rat vas deferens increased with age 
(Figure 3.20a). CPA and NECA inhibited the nerve-mediated contractions of the vas 
deferens from day 15 onwards, day 15 being the earliest age at which nerve-mediated 
contractions could be detected (Figure 3.21). The inhibitory effect of CPA and 
NECA was not significantly different from that determined in the adult at all the 
neonatal ages studied (Figure 3.22). DPCPX (10 nM) caused a rightward shift in the 
dose response curve to CPA at day 15 and day 25 (Figure 3.23), with dose ratios of 
4.0 and 8.2 respectively corresponding to apparent pA2 values of 8.4 and 8 .8  (see 
Table 3.1). NECA and high concentrations of CPA (> 1 p,M) inhibited contractions 
induced by KCl (35 mM) from day 10 onwards, the earliest age at which responses to 
KCl could be detected (Figure 3.24). The contraction induced by KCl (35 mM) in the 
neonatal tissues, expressed as tension (g)/wet weight of tissue (g), was not 
significantly different from adult tissues (3.2 ± 0.6, 2.7 ± 0.5 and 1.8 ± 0.4 for days 
10, 20 and adult tissues respectively, n = 4). The potency values for CPA and NECA 
(expressed as PEC25 values) were not significantly different from adult at any age 
(Figure 3.25), whilst the potency of CPA was always at least 10 fold lower than that 
of NECA (Figure 3.25). In contrast, low concentrations of CPA (< 1 |xM) enhanced 
the contractions induced by KCl from day 20 onwards (Figure 3.26), with the 
maximal enhancement observed at 0.3 p,M CPA and the response to this concentration 
of CPA was therefore used to compare potency at different ages. No enhancement of 
the KCl-induced response by CPA was observed at days 10 and 15 (Figure 3.26), and 
the enhancement of KCl-induced contractions by 0.3 p,M CPA was significant from 
day 30 (p < 0.05). At this concentration of CPA (0.3 |XM), the % enhancement of the 
KCl-induced contractile response increased with an increase in age up to day 40, and
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until day 3 5  the level of enhancement was significantly different from that found in 
the adult (p < 0.05) (Figure 3.27).
*The contractions induced by nerve-stimulation in the neonatal tissues, expressed as 
tension (g)/wet weight of tissue (g), were not significantly different from adult tissues 
(0.02 ± 0.003, 0.03 ± 0.004 and 0.01 ± 0.001 for days 20, 25 and adult tissues 
respectively, n = 4).
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Figure 3.20. Variation in wet tissue weight of (a) rat vas deferens, (b) 
rat duodenum longitudinal muscle and (c) rat duodenum muscularis 
mucosae with age. Each point is the mean of 4-8 determinations and the 
vertical bars show s.e.mean (apparent only when they are greater than 
symbol size).
133
1 0 0  n
75-
§
I 50-
25-
0.001 0.01 0.1 1 
Concentration (|xM)
(c)
(e)
(b) 1 0 0  n
1 0 0  n
75-
§ 50-!
25-
0.001 0.01 0.1 1 
Concentration (|XM)
î
1 0 0 -,
75-
g
I 50-
25-
0.001 0.01 0.1 1 
Concentration (}xM)
75-
50-
25-
0.01 0.1 1 
Concentration (|iM)
S  50-
0.001 0.01 0.1 1 
Concentration (|iM)
(f) 1 0 0  n
75-
g  50-4
25-
0 —T-
0 .10.001 0.01
Concentration (|xM)
n
10
Figure 3.21. Inhibition by CPA ( • )  and NECA (■) of nerve-mediated 
contractions in the (a) 15 day, (b) 20 day, (c) 25 day, (d) 30 day, (e) 40 day and (f) 
adult (>60 day) rat vas deferens. Results are expressed as % decrease of the nerve- 
mediated response. Each point is the mean of at least four determinations and the 
vertical bars show s.e.mean.
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Figure 3.22. Variation with age in potency of CPA (#) and NECA 
(■) in causing inhibition of nerve-mediated contractions in the rat 
vas deferens. Potency is expressed as pECSO (negative logarithm of 
the concentration producing 50% of the response). Each point is the 
mean of at least four determinations and the vertical bars show 
s.e.mean.
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Figure 3.23. Antagonism by DPCPX (10 nM) of the inhibition by CPA of nerve- 
mediated contractions in the (a) 15 day and (b) 25 day and rat vas deferens. The 
closed symbols show agonist alone and the open symbols show the effect of the 
agonist in the presence of DPCPX. Results are expressed as % decrease of the 
nerve-mediated response. Each point is the mean of at least four detrminations 
and the vertical bars show s.e.mean.
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Figure 3,24. Inhibitory effects of CPA ( • )  and NECA (■) on KCl- 
induced (35 mM) contractions of the (a) 10 day, (b) 15 day, (c) 20 day, 
(d) 25 day, (e) 35 day and (f) adult (>60 day) rat vas deferens. Results 
are expressed as % decrease of the control response in the absence of 
purines. Each point is the mean of at least four determinations and the 
vertical bars show s.e.mean.
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Figure 3.25. Variation in potency with age of CPA (#) and NECA (■) 
in causing inhibition of KCl-induced (35 mM) contractions in the rat vas 
deferens. Potency is expressed as pEC25 (negative logarithm of the 
concentration producing 25% of the KCl-induced response). Each point 
is the mean of at least four determinations and the vertical bars show 
s.e.mean.
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Figure 3.26. Effect of CPA on contractile responses induced by KCl (35 mM) in 
10 day (□), 15 day (O), 20 day (A), 25 day (V), 30 day (A), 35 day (■), 40 day 
(▼) 45 day (#) and adult (>60 day) (♦) rat vas deferens. Results are expressed as 
percent of control response in the absence of CPA. Results are the mean of at least 
four determinations and the vertical bars show s.e.mean.
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Figure 3.27. Variation with age in the enhancement by CPA (0.3 
gM) of contractions induced by KCl (35 mM) in the rat vas 
deferens. Results are expressed as % increase of the KCl-induced 
response in the absence of CPA. Each point is the mean of at least 
four determinations and the vertical bars show s.e.mean. ANOVA 
followed by Duncan’s New Multiple Range post hoc test; *p < 0.05, 
significantly different from the adult value.
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3.3. ADULT RAT DUODENUM
3.3.1. Longitudinal muscle
The rat duodenum longitudinal muscle had an average wet weight of 35 ± 4 
mg. A submaximal concentration of carbachol (0.3 |iM) was used to pre-contract the 
tissue (Figure 3.28a). Adenosine, CPA and NECA all caused relaxation (Figure 
3.29), with a potency order of order of CPA (6.4 ± 0.2) = NECA (6.3 ± 0.2) > 
adenosine (5.2 ± 0.2) (PEC35 values in parenthesis, n = 4-5). The concentration- 
response curves to CPA and NECA were inhibited by DPCPX (10 nM) (Figure 3.30), 
giving dose ratios of of 20.7 and 10.5, corresponding to apparent pA2 values of 9.3 
and 9.2 respectively. However, a higher concentration of DPCPX (1 gM), abolished 
the responses to CPA, whereas it antagonised the response to NECA (Figure 3.30), 
giving a dose ratio of of 158.2 and an apparent pA% value of 8.2. The concentration- 
response curves to CPA and NECA in this tissue were not significantly different from 
curves repeated after 30 minutes (results not shown). The effects of DPCPX on the 
concentration response curves to CPA and NECA in the longitudinal muscle are 
summarised in Table 3.3.
3.3.2. Muscularis mucosae
The rat duodenum muscularis mucosae had an average wet weight of 237 ±10 
mg. Adenosine, CPA and NECA all caused contractions in this tissue (Figure 3.31), 
with a potency order of NECA (6.7 ± 0.2) = CPA (6.5 ± 0.3) > adenosine (4.8 ± 
0.1) (pEC4o values in paranthesis, n = 4-5). CGS 21680 (10 jxM) had no effect on this 
tissue (results not shown). 10 nM DPCPX had no effect on the concentration-
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response curves to CPA and NECA (results not shown), but 1 jxM DPCPX 
antagonised the responses to CPA and NECA (Figure 3.32), giving dose-ratios of 4.1 
and 5.5, corresponding to apparent pA2 value of 6.4 and 6 .6  respectively. 
Indomethacin (25 gM) had no effect on the contractile response to CPA (Figure 3.33), 
and the EC40 value in the presence and absence of indomethacin was 0.1 gM. The 
concentration-response curves to CPA and NECA in this tissue were not significantly 
different from curves repeated after 30 minutes (results not shown). The effects of 
DPCPX on the concentration response curves to CPA and NECA in the muscularis 
mucosae are summarised in Table 3.3.
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Figure 3.28. Contractions induced by carbachol on (a) adult and (b) 20 
day rat duodenum longitudinal muscle. Each point is the mean of four 
determinations and the vertical bars show s.e.mean.
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Figure 3.29. Relaxations to CPA (•) , NECA (■) and adenosine 
(A) in the adult rat duodenum longitudinal muscle. Results are 
expressed as % decrease of the carbachol-induced (0.3 |iM) 
contraction. Each point is the mean of at least four determinations 
and the vertical bars show s.e.mean.
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Figure 3.30. Antagonism by DPCPX of the relaxant responses in the adult 
rat duodenum longitudinal muscle to (a) CPA in the presence and absence of 
10 nM DPCPX, (b) NECA in the presence and absence of 10 nM DPCPX and
(c) NECA in the presence and absence of 1 pM DPCPX. The closed symbols 
show the effect in the absence of the antagonist and the open symbols show 
the effect in the presence of the antagonist. Results are expressed as % 
decrease of the carbachol-induced (0.3 mM) contraction. Each point is the 
mean of at least four determinations and the vertical bars show s.e.mean.
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Figure 3.31. Contraction to CPA (•) , NECA (■) and adenosine (A) 
in the adult rat duodenum muscularis mucosae. Results are expressed 
as % contraction induced by KCl (35 mM). Each point is the mean of 
at least four determinations and the vertical bars show s.e.mean.
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Figure 3.32. Antagonism by DPCPX (1 |xM) of the contractions caused 
by (a) CPA and (b) NECA in the adult rat duodenum muscularis 
mucosae. The closed symbols show the effect in the absence of DPCPX 
and open symbols show the effect in the presence of DPCPX. Results 
are expressed as % contraction induced by KCl (35 mM). Each point is 
the mean of at least four determinations and the vertical bars show 
s.e.mean.
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Figure 3.33. Effect of indomethacin (25 |liM) on the contractions 
induced by CPA in the adult rat duodenum muscularis mucosae. 
Responses are expresed as % contraction induced by KCl (35 mM). 
The closed symbols show results in the absence of indomethacin and 
the open symbols show results in the presence of indomethacin. 
Results are expressed as % contraction induced by KCl (35 mm). 
Each point is the mean of at least four determinations and the vertical 
bars show s.e.mean.
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Table 3.3. Antagonism by DPCPX of the effects of CPA and NEC A in the 
longitudinal myscle and the muscularis mucosae of the adult rat duodenum.
Agonist Potency Dose-ratio Apparent pA%
Longitudinal muscle pECgg
CPA alone 6.4 ± 0.4
CPA + 10 nM DPCPX 5.4 ± 0.2 20.7 ± 10.2 9.3 ± 0.3
NECA alone 6.5 ± 0.2
NECA + 10 nM DPCPX 5.7+ 0.3 10.5 ± 5.5 8.9 ± 0.3
NECA + 1 pM DPCPX 4.1 ± 0.4* 158.2 ± 62.7 8.2 ± 0.4
Muscularis mucosae PEC40
CPA alone 6.5 ± 0.3
C P A + lpM  DPCPX 6.3 ±0.3 4.1 ±2.1 6.4 ±0.3
NECA alone 6.7 ± 0.2
NEC A +1 pMDPCPX 6.1 ±0.1* 5.5 ±2.2 6 .6  ±0.2
Table showing the potency of CPA and NECA in the rat duodenum longitudinal 
muscle causing relaxation (expressed as PEC35 values) and in the muscularis mucosae 
causing contraction (expressed as pEC^o values). The effect of DPCPX and the 
apparent pA2 values are also shown here. Student's paired t test; *p < 0.05, 
significantly different from control values.
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3.4. NEONATAL RAT DUODENUM
3.4.1. Longitudinal muscle
The average wet weight of the rat duodenum longitudinal muscle increased 
with age (Figure 3.20b). Carbachol (0.3 pM) gave a sub-maximal contraction at day 
20 (Figure 3.28b) and was used to pre-contract the tissue. The contraction induced by 
carbachol (0.3 pM) in the neonatal tissues, expressed as tension (g)/wet weight of 
tissue (g), was not significantly different from adult tissues (0.11 ± 0.08, 0.13 ± 0.04 
and 0.21 ± 0.05 for days 15, 20 and adult tissues respectively, n = 4). CPA caused a 
relaxation from day 25 onwards (Figure 3.34). At day 15 no relaxations to CPA were 
observed, whereas small relaxations to CPA (less than 15%), were seen at day 20 
(Figure 3.34). Day 15 was the earliest age relaxations could be tested due to the 
fragility of the tissue. Relaxations to NECA were observed in this tissue from day 15 
onwards (Figure 3.35). The maximum relaxation achieved by NECA at day 15 
(approximately 50%) in this tissue was less than that observed for NECA at days 20, 
25 or in adult preparations (approximately 75%) (Figure 3.35). A representative trace 
showing the effects of CPA and NECA in this tissue is shown in Figure 3.36. CGS 
21680 also caused a weak relaxation (less than 15%) in this tissue at day 15 but only 
at concentrations > 10 pM (Figure 3.37a).
10 nM DPCPX antagonised the response to CPA at day 25 (Figure 3.38a), 
giving a dose ratio of 18.4 and an apparent pA2 value of 8.9. 10 nM DPCPX also 
antagonised the response to NECA at day 25 (Figure 3.38b), giving a dose ratio of 
14.1 corresponding to an apparent pA2 value of 8.9, however in the presence of the 
antagonist a suppresion of the maximal response was observed. The responses to 
NECA at days 15,20 and 25 were also antagonised by a higher concentration of
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DPCPX (1 pM) (Figure 3.39), giving dose ratios of 4.6, 49.3 and 144.9, 
corresponding to apparent pA% values of 6 .8 , 7.5 and 8.0 respectively. The effects of 
DPCPX in the longitudinal muscle are summarised in Table 3.4.
The potency of CPA in causing relaxations (expressed as PEC35) after day 25 
was not significantly different from the potency in the adult at any age (Figure 3.40a). 
The potency of NECA (expressed as PEC35) in causing relaxations increased with 
age, NECA being least potent at day 15 (p < 0.05) and equipotent with adult by day 
20 (Figure 3.40b). However the potency of NECA in causing relaxations in the 
presence of 1 pM DPCPX was not significantly different from adult throughout the 
ages (Figure 3.40b).
2-Me-S-ATP and AMPCPP also relaxed the carbachol contracted tissue from 
day 15 onwards (Figure 3.41). Weak relaxations were observed to both the agonists 
at day 15, but only at high concentrations of agonists (Figure 3.41). The 
concentration response curve to 2-Me-S-ATP reached a lower maximum than that for 
AMPCPP in this tissue (Figure 3.41). The potency of 2-Me-S-ATP and AMPCPP in 
causing relaxations (expressed as PEC30) increased with age being lowest at day 15 
(p < 0.05) and reaching values not significantly different from adult by day 25 (Figure 
3.42). The potency order of agonists was 2-Me-S-ATP > AMPCPP at all ages 
except at day 15 where the agonists were equipotent (Table 3.5).
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Figure 3.34. Relaxation caused by CPA in the rat duodenum longitudinal 
muscle at (a) day 15, (b) day 20, (c) day 25, (d) day 30, (e) day 35 and (f) adult 
(> 60 day) tissues. Results are expressed as % reduction of the carbachol- 
induced (0.3 |xM) contraction. Each point is the mean of at least four 
determinations and the vertical bars show s.e.mean.
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Figure 3.35. Relaxation caused by NECA in the rat duodenum longitudinal 
muscle at (a) day 15, (b) day 20, (c) day 25 and (d) adult (> 60 day) tissues. 
Results are expressed as % reduction of the carbachol-induced (0.3 |iM) 
contraction. Each point is the mean of at least four determinations and the 
vertical bars show s.e.mean.
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Figure 3.37. (a) Relaxation caused by NECA (■) and CGS 21680 (A) in the 
15 day rat duodenum longitudinal muscle (no relaxation to CPA was 
observed) and (b) contraction caused by CPA (•) , NECA (■) and CGS 21680 
(A) in the 20 day rat duodenum muscularis mucosae. Results are expressed as
(a) % reduction of the carbachol-induced (0.3 jiiM) contraction and (b) % 
contraction induced by KCl (35 mM). Each point is the mean of at least four 
determinations and the vertical bars show s.e.mean.
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Figure 3.38. Antagonism by DPCPX (10 nM) of the relaxant responses 
by (a) CPA and (b) NECA in the 25 day rat duodenum longitudinal 
muscle. Responses are expresed as % reduction of the carbachol- 
induced (0.3 p,M) contraction. The closed symbols show results in the 
absence of DPCPX and the open symbols show results in the presence 
of DPCPX. Each point is the mean of at least four determinations and 
the vertical bars show s.e.mean.
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Figure 3.39. Antagonism by DPCPX (1 |iM) of the relaxation caused by 
NECA in (a) 15 day, (b) 20 day and (c) 25 day rat duodenum longitudinal 
muscle. Results are expressed as % reduction of the carbachol-induced (0.3 
|xM) contraction. The closed symbols show the effect of NECA alone and 
the open symbols show the effect of NECA in the presence of DPCPX. 
Each point is the mean of at least four determinations and the vertical bars 
show s.e.mean.
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Figure 3.40. Variation in potency with age of (a) CPA (#) and (b) NECA 
(■) causing relaxation of the rat duodenum longitudinal muscle. The 
potency of NECA in the presence of DPCPX (1 jiM) is also shown in (b) 
(□). Potency is expressed as pEC35 values (negative logarithm of the 
concentration of the agonist producing 35% reduction of the carbachol- 
nduced (0.3 jiM) response). Each point is the mean of at least four 
determinations and the vertical bars show s.e.mean. ANOVA followed by 
Duncan's New Multiple Range post hoc test; *p < 0.05, significantly 
different from the adult value.
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Figure 3.41. Relaxation caused by 2-Me-S-ATP ( • )  and AMPCPP (■) in the rat 
duodenum longitudinal muscle at (a) day 15, (b) day 20, (c) day 25, (c) day 30, (e) 
day 40 and (f) adult (> 60 day). Results are expressed as % reduction of the 
carbachol-induced (0.3 pM) contraction. Each point is the mean of at least four 
determinations and the vertical bars show s.e.mean.
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Figure 3.42. Variation in potency with age of 2-Me-S-ATP ( • )  and AMPCPP 
(■) causing relaxation in the rat duodenum longitudinal muscle. Potency is 
expressed as pECBO values (negative logarithm of the concentration of the 
agonist producing 30% reduction of the of the carbachol-induced (0.3 |XM) 
response). Each point is the mean of at least four determinations and the 
vertical bars show s.e.mean. ANOVA followed by Duncan's New Multiple post 
hoc test; *p < 0.05, significantly different from the adult value.
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Table 3.5. Potency order of agonists causing relaxation in the rat duodenum 
longitudinal muscle at various ages.
Age (days) Potency order
(pECao values in parentheses)
15 2-Me-S-ATP (4.2 + 0.1) = AMPCPP (4.3 ± 0.1)
20 2-Me-S-ATP (5.5 ±0.2) > AMPCPP (5.0 ±0.1)
25 2-Me-S-ATP (5.8 ± 0.2) > AMPCPP (5.5 ±0.1)
30 2-Me-S-ATP (6.0 ± 0.2) > AMPCPP (5.5 ±0.1)
40 2-Me-S-ATP (6.2 ± 0.2) > AMPCPP (5.7 ±0.1)
Adult (> 60) 2-Me-S-ATP (6.3 ± 0.2) > AMPCPP (5.7 ±0.1)
Potency is expressed as pECgo values ± s.e.mean (n = 4).
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3.4.2. Muscularis mucosae
The average wet weight of the rat duodenum muscularis mucosae increased 
with age (Figure 3.20c). The contraction induced by KCl (35 mM) in the neonatal 
tissues, expressed as tension (g)/wet weight of tissue (g), was not significantly 
different from adult tissues (3.2 ± 1.3, 3.3 ± 1.1 and 2.5 ±1.2  for days 10, 20 and 
adult tissues respectively, n = 4). CPA caused contractions from day 10 onwards 
(Figure 3.43). Day 10 was the earliest age that could be tested due to the fragility of 
the tissue. CGS 21680 and NECA also caused a contraction in the neonatal tissue at 
day 20 (Figure 3.37b), and the potency order of agonists was CPA (7.4 ± 0.6) = 
NECA (7.4 ± 0.2) »  CGS 21680 (5.6 ± 0.1) (pEC4o values in parenthesis, n = 4-6).
1 gM DPCPX antagonised the response to CPA at days 15 (Figure 3.44a) and 
10, giving dose ratios of 9.6 and 6.8, corresponding to apparent pA2 values of 6.7 and 
6.6 respectively. Responses to NECA were also shifted to the right in the presence of 
DPCPX (1 |xM) in the neonates at day 20 (Figure 3.44b) giving a dose ratio of 7.3 
corresponding to an apparent pA2 value of 6.8. The effects of DPCPX in the 
muscularis mucosae are summarised in Table 3.4. The potency of CPA in causing 
contractions (expressed as pEC4 o) was not significantly different from adult 
throughout the ages (Figure 3.45).
Contractions were also observed to AMPCPP, 2-Me-S-ATP, ATP and UTP in 
the rat duodenum muscularis mucosae from day 10 onwards (Figures 3.46 and 3.47). 
The potency of ATP and UTP in causing contractions (expressed as pECgo) decreased 
with age being greatest at days 10 and 15 (p < 0.05) and reaching values not 
significantly different from adult by day 20 (Figure 3.48a). The potency of AMPCPP 
and 2-Me-S-ATP in causing contractions (expressed as pECgo) also decreased with
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age being greatest between days 10-25 (p < 0.05) and reaching values not 
significantly different from adult by day 30 (Figure 3.48b). The potency orders at all 
the ages are summarised in Table 3.6. Repeated administration of AMPCPP (100 
|liM) did not desensitize the response to AMPCPP at day 15, although a 45% 
reduction of the initial response to AMPCPP was observed at day 30 (p < 0.05) 
(Figure 3.49). Cross-desensitization between 100 p,M AMPCPP and 2-Me-S-ATP (3 
p.M), ATP (10 |iM) or UTP (10 |im) was not observed at day 15 (Figure 3.50 ), 
whereas at day 30 a 40% reduction of the control response to 100 |iM 2-Me-S-ATP 
was observed (p < 0.05) while contractions to 100 pM ATP and UTP were unaffected 
(Figure 3.50 ).
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Figure 3.43. Contraction caused by CPA in the rat duodenum muscularis 
mucosae at (a) day 10, (b) day 15, (c) day 20, (d) day 25 and (e) adult (> 60 
day) tissues. Results are expressed as % contraction induced by KCl (35 mM). 
Each point is the mean of at least four determinations and the vertical bars show 
s.e.mean.
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Figure 3.44. Antagonism by DPCPX (1 fiM) of the contraction caused by
(a) CPA on 15 day and (b) NECA on 20 day rat duodenum muscularis 
mucosae. Results are expressed as % contraction induced by KCl (35 mM).
The closed symbols show the effect of the agonists alone and the open 
symbols show the effects in the presence of DPCPX. Each point is the 
mean of at least four determinations and the vertical bars show s.e.mean.
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Figure 3.45. Variation in potency with age of CPA causing contraction in 
the rat duodenum muscularis mucosae. Potency is expressed as pEC40 
values (negative logarithm of the concentration of the agonist producing 
40% contraction induced by KCl (35 mM)). Each point is the mean of at 
least four determinations and the vertical bars show s.e.mean.
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Figure 3.46. Contraction by 2-Me-S-ATP (#) and AMPCPP (■) in the rat duodenum 
muscularis mucosae at (a) day 10, (b) day 15, (c) day 20, (d) day 25, (e) day 30, (f) day 40 
and (g) adult (> 60 day). Results are expressed as % contraction induced by KCl (35 mM). 
Each point is the mean of at least four determinations and the vertical bars show s.e.mean.
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Figure 3.47. Contractile effect by ATP (O) and UTP (□) in the rat duodenum muscular; 
mucosae at (a) day 10, (b) day 15, (c) day 20, (d) day 25, (e) day 30, (f) day 40 and (g) adu 
(> 60 day). Results are expressed as % contraction induced by KCl (35 mM). Each point : 
the mean of at least four determinations and the vertical bars show s.e.mean.
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Figure 3.48. Variation in potency with age of (a) ATP (O) and UTP (□) and
(b) 2-Me-S-ATP (#) and AMPCPP (■) causing contraction in the rat 
duodenum muscularis mucosae. Potency is expressed as pEC60 values 
(negative logarithm of the concentration of the agonist producing 60% 
contraction induced by KCl (35 mM). Each point is the mean of at least four 
determinations and the vertical bars show s.e.mean. ANOVA followed by 
Duncan's New Multiple post hoc test; *p < 0.05, significantly different from the 
adult value.
170
150n
125-
Exposure to agonist
Figure 3.49. Contractions of the rat duodenum muscularis mucosae to 
repeated administrations of AMPCPP (100 jiM) at day 15 (closed columns) 
and day 30 (open columns). Contractions are expressed as % response to 
initial dose of AMPCPP. Each column is the mean of at least four 
determinations and the vertical bars show s.e.mean. ANOVA followed by 
Dunnett's two-tailed post-hoc test; *p < 0.05, significantly different from 
control value.
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Figure 3.50. Contractions of the rat duodenum muscularis mucosae to
(b) 2-Me-S-ATP (3 gM), ATP (10 |iM) and UTP (10 \iM) at day 15 and 
(a) 2-Me-S-ATP (100 [iM), ATP (100 jiM) and UTP (100 \lM) at day 30 
following exposure to a desensitizing dose of AMPCPP (100 jiM). 
Contractions are expressed as % response to initial dose of agonist. 
Each column is the mean of at least four determinations and the vertical 
bars show s.e.mean. Student's paired t tests; *p < 0.05, significantly 
different from control value.
172
i
I
egI
I
I
I
I
I
I*o
I
I
I
I
I
%
%
I
I
f
I
0  
+1
5
1
0  
+1 
VO
6
1
A
A
CO
d
4-1
0
6
1
cs
d
4-1
I
CO
d
i
s
A
d
4-1Os
vdICO
i
CO
d
4-1
00
s
B
CO
d
4-100
s
I
AI
CO
d
4-1
04
6
I
1
A
in
d
4-100
s
I
O '
d
4-1
VO
s
in
d
4-1
in
s
COi
00 in CO
d d d
4-1 4-1 4-1
00 CO o
04 04 cd
p4 Cl. Cl.
H H H
< <F <
CO CO CO
À Ô
04 04 CN
AI A A
04 VO
d d d
4-1 4-1 4-1
04 0- p
cd
Cl. Cl. Cl.
H H H
D P
II II II
CO (S 04
d d d
4-1 "H -HI
04 04
Tf- CO
Cl. Cl.
H H H
< < <
A A A
CO m
d d d
4-1 4-1 4-1
CO o oo
in in
Cl. Oh Cl4Cl. Cl. Cl.
u V ud. d. Cl.
m O
CO ?
S
A
I
CO
I
ÔC/5
4-1
i
I
'SI
I
173
3.4.2.I. Degradation studies in the neonatal rat duodenum muscularis mucosae
The degradation of ATP, UTP, 2-Me-S ATP and AMPCPP by tissues from rats 
aged 15 and 30 days were tested and experiments were carried out in triplicate. ATP 
(lOOjiM) was rapidly degraded by the muscularis mucosae to ADP, AMP and inosine 
with no adenosine being detected at days 15 and 30 (Figure 3.51). However at day 15 
the half life of ATP was 8.9 ± 3.0 min (Figure 3.51a), whereas at day 30 it was 
significantly lower, 0.4 ± 0.2 min (p < 0.05) (Figure 3.51b). A similar rate of 
degradation was seen for UTP and 2-Me-S-ATP at days 15 and 30, UTP being 
degraded to UMP, UDP and uridine (Figure 3.52), and 2-Me-S-ATP being degraded 
to 2-Me-S-ADP, 2-Me-S-AMP and 2-Me-S-adenosine (Figure 3.53). At day 15 the 
half lives of UTP and 2-Me-S-ATP were 11.4 ± 3.8 min and 13.5 ± 3.9 min 
respectively (Figures 3.52a and 3.53a), whereas at day 30, the values were 
significantly lower (p < 0.05), 0.2 ±0.1 min and 0.3 ±0.1 respectively (Figures 3.52b 
and 3.53b). The half lives of ATP, UTP or 2-Me-S-ATP at day 30 or at day 15 were 
not significantly different from each other. AMPCPP was also degraded by the 
muscularis mucosae at days 15 and 30 with only AMPCP being detected (Figure 
3.54). The half life of AMPCPP at days 30 and 15 was 12.2 ±1.5 min and 26.0 ± 7.0 
min respectively, the difference between these values does not quite reach 
significance. The half life of AMPCPP at day 30 was significantly higher than the 
half life values of ATP, UTP, or 2-Me-S-ATP at that age (p < 0.05), whereas at day 
15, the half life value of AMPCPP was not significantly different from ATP, UTP or 
2-Me-S-ATP. The half lives for all the agonists are summarised in Table 3.7. 
Representative h.p.l.c. traces for ATP, ADP, AMP, adenosine and inosine are shown 
in Figure 3.55 and retention times are summarised in Table 3.8.
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Figure 3.51, Degradation of ATP (100 |iM) ( • )  to ADP (■), AMP (O) and inosine 
(□) by the (a) 15 day and (b) 30 day rat duodenum muscularis mucosae. Each point is 
the mean of three determinations and the vertical bars show s.e.mean.
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Figure 3.52. Degradation of UTP (100 |iM) ( • )  to UDP (■), UMP (O) and uridine 
(□) by the (a) 15 day and (b) 30 day rat duodenum muscularis mucosae. Each point is 
the mean of three determinations and the vertical bars show s.e.mean.
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Figure 3.53. Degradation of 2-Me-S-ATP (100 |xM) (#) to 2-Me-S-ADP (■), 
2-Me-S-AMP (O) and 2-Me-S-adenosine (□) by the (a) 15 day and (b) 30 day 
rat duodenum muscularis mucosae. Each point is the mean of three 
determinations and the vertical bars show s.e.mean.
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Figure 3.54. Degradation of AMPCPP (100 jiM) ( • )  to AMPCP (■) by the (a) 15 
day and (b) 30 day rat duodenum muscularis mucosae. Each point is the mean of three 
determinations and the vertical bars show s.e.mean.
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Figure 3.55. Separation of ATP, ADP, AMP, adenosine and 
inosine (100 pM) by h.p.l.c.
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Table. 3.7. Half lives for ATP, UTP, 2-Me-S-ATP and AMPCPP degraded by 15 
and 30 day rat duodenum muscularis mucosae.
Agonist ATP UTP 2-Me-S-ATP AMPCPP
Half lives using 15 8.9 ±3.0 11.4 ±3.8 13.5 ±3.9 26.0 ±7.0
day tissues (minutes)
Half lives using 30 0.4 ± 0.2*^ 0.3 ±0.1*^ 0.3 ±0.1*^ 12.2 ±1.5
day tissues (minutes)
Student's unpaired t test; *p < 0.05, significantly different from values obtained using 
15 day tissues, and ANOVA followed by Duncan's New Multiple range post hoc test; 
^p < 0.05, significantly different from the value for AMPCPP obtained using 30 day 
tissues.
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Table 3.8. H.p.l.c. retention times for purines and pyrimidines.
Purine/Pyrimidine Retention Time (minutes)
ATP 12.7
ADP 9.9
AMP 6.5
Adenosine 4.1
Inosine 1.9
UTP 11.8
UDP 7.7
UMP 2.5
Uridine 1.5
2-Me-S-ATP 16.1
2-Me-S-ADP 15.4
2-Me-S-AMP 13.3
2-methylthioadenosine 8.4
AMPCPP 11.9
AMPCP 8.4
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CHAPTER 4
DISCUSSION
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4.1. RAT VAS DEFERENS
4.1.1. Distribution of Pi-purinoceptors in the epididymal and 
proststic portions of the rat vas deferens
In the rat vas deferens the presence of pre-junctional Ai receptors has been 
established (Paton, 1981; Hourani et ah, 1993b). The results discussed in this thesis 
also confirm this finding as CPA inhibited nerve-mediated contractions and was 
antagonised by a nanomolar concentration of DPCPX. NECA and adenosine also 
inhibited nerve-mediated contractions and the agonist potency order was CPA = 
NECA > adenosine. This order of potencies was also shown by Hourani and co­
workers (1993b), who proposed that NECA and adenosine activated A2 receptors in 
the rat vas deferens, antagonised by a micromolar concentration of DPCPX, to cause 
inhibition of nerve-mediated contractions. Contractions induced by NA and ATP 
were inhibited by NECA, CPA and adenosine with a potency order of NECA > CPA 
= adenosine suggesting the activation of post-junctional A2 receptors in this tissue 
(Hourani et al., 1993b). On the other hand, excitatory post-junctional Ai receptors 
have also been shown in the rat vas deferens as contractions induced by ATP have 
been shown to be enhanced by CPA and the enhancement was abolished by a 
nanomolar concentration of DPCPX (Hourani and Jones, 1994). In the present study 
the distribution of adenosine receptors in the bisected rat vas deferens was examined.
In the bisected rat vas deferens ATP was more potent in eliciting contractions 
in the prostatic region than in the epididymal region, whereas NA was more potent in 
the epididymal region than in the prostatic region. This has also been reported 
previously, where the purinergic component of the nerve-mediated response has been 
shown to be associated with the prostatic region and the adrenergic component has
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been associated with the epididymal region of the rat vas deferens (Sneddon & 
Machaly, 1992). Also, contractions induced by 5-HT, tyramine and 2-Me-5-HT 
varied along the length of the tissue, all agents being more potent in the epididymal 
region. However contractions induced by KCl were similar at both ends of the tissue. 
Therefore to study the distribution of Pi-purinoceptors along the length of the tissue, 
KCl was used as the contractile agent.
CPA clearly enhanced contractions induced by KCl equally in the epididymal 
and prostatic regions of the bisected rat vas deferens, presumably due to the activation 
of the previously reported post-junctional Ai receptor (Hourani and Jones, 1994). 
Responses to KCl were unaffected by TTX suggesting that responses were a direct 
effect on the smooth muscle and not due to stimulation of excitatory nerves. 
Therefore these results suggest that post-junctional Ai receptors are evenly distributed 
along the length of the rat vas deferens. In contrast NECA potently inhibited 
contractions induced by KCl in the prostatic region, presumably due to the activation 
of post-junctional A2 receptors (Hourani et al., 1993b). However, the lack of an 
appreciable response to NECA in the epididymal region suggests that the A2  receptors 
are localised mainly in the prostatic region of the tissue.
In the bisected tissue nerve-mediated contractions were also inhibited by CPA 
in both regions, and these effects were antagonised by a nanomolar concentration of 
DPCPX, suggesting the activation of pre-junctional Ai receptors. However the 
potency of CPA in activating the pre-junctional Ai receptors in the epididymal region 
is almost 10-fold higher than that for the prostatic region. This may be due to a larger 
population of pre-junctional A% receptors in the epididymal region when compared to 
the prostatic region, or may reflect differences in post-receptor events. Like CPA, 
NECA also inhibited nerve-mediated contractions in both regions of the bisected
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tissue, but unlike CPA the potency of NECA in inhibiting the nerve-mediated 
contractions was higher at the prostatic region than at the epididymal region. The 
inhibitory effect of NECA on nerve-mediated responses was antagonised by a 
nanomolar concentration of DPCPX in the epididymal region, and this together with a 
potency order of CPA > NECA suggests the activation by NECA of pre-junctional 
Ai receptors here. There was no antagonism of the effect of NECA by this 
concentration of DPCPX in the prostatic region, as previously shown for the whole 
tissue (Hourani et al., 1993b), suggesting that NECA was acting via A2 receptors not 
A%. A micromolar concentration of DPCPX antagonised the response to NECA in 
both regions, and yielded an apparent pA2 in the nanomolar range in the epididymal 
region, supporting the activation by NECA of pre-junctional Ai receptors. However 
in the prostatic region the apparent pA2 for DPCPX was in the micromolar range, 
similar to the situation in the whole tissue, supporting the activation by NECA of 
post-junctional A2 receptors here. In the whole tissue NECA activated A2 receptors 
rather than pre- or post-junctional Ai receptors (Hourani et al., 1993b; Hourani & 
Jones, 1994), but the activation by NECA of pre-junctional Ai receptors in the 
epididymal region of the bisected tissue can be explained by the lack of post­
junctional A2 receptors in this region of the rat vas deferens. NECA is > 1000 times 
more potent than CGS 21680 in causing inhibition of nerve-mediated contractions in 
the prostatic region of the tissue, suggesting that the A2 receptor is of the A2b subtype. 
This is also in agreement with findings of Major and co-workers who suggested the 
presence of A2b receptors in the rat vas deferens due to the lack of activity of by CV 
1808 (Major et al., 1989).
In conclusion, this work has shown a differential distribution of adenosine 
receptor subtypes along the length of the rat vas deferens, with pre and post-junctional
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Al receptors being present over both regions of the bisected tissue, whereas post­
junctional A2 receptors, of the A2b subtype, were only present in the prostatic region.
4.1.2. Selective enhancement by an adenosine Ai receptor agonist of 
agents inducing contractions of the rat vas deferens
The results obtained in this study confirm the previous conclusion that there is 
a post-junctional A% receptor enhancing contractions to ATP in the rat vas deferens 
(Hourani & Jones, 1994). This study was performed in order to establish whether the 
Ai receptor-mediated enhancement was selective for certain agonists, or whether it 
could be explained by a non-specific increase in the contractility of the tissue. 
Various contractile agonists were used and a submaximal concentration was selected 
for comparing the effects of CPA. The enhancement by CPA of contractions induced 
by ATP, 5-HT, tyramine, 2-Me-5-HT and KCl, but not by NA, phenylephrine, 
carbachol or bradykinin, suggests that the effect is clearly selective for some of the 
contractile agents, and not due to a general increase in contractility. The enhancement 
by CPA of contractions induced by ATP, 5-HT, tyramine, 2-Me-5-HT and KCl was in 
each case due to an interaction with the Ai receptor as it was inhibited by an Ai- 
selective concentration of DPCPX. At higher concentrations of CPA (> 1 |iM), 
inhibition of contractions to some of the contractile agents was observed, as had 
previously been seen with ATP (Hourani & Jones, 1994), and this may be due to 
interaction of CPA with the post-junctional inhibitory A2 receptor.
One possible explanation for the enhancement by CPA of 5-HT, tyramine, 2- 
Me-5-HT and KCl could be that they all act via release of ATP, either from the 
excitatory nerves or from the muscle (Vizi & Bumstock, 1988). However, none of
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these contractile agents were acting by neuronal stimulation as their effects were not 
inhibited by TTX. In addition they were unaffected by desensitization of P2X- 
purinoceptors with AMPCPP, showing that they did not act via released ATP.
This selective interaction between agonists is similar to the results previously 
reported for DDTi MF-2 cells (Dickenson & Hill, 1993b), although the mechanism is 
unlikely to be the same, as in DDT 1 MF-2 cells ATP, adenosine and histamine all act 
via G-protein coupled receptors, and the interaction may be due to cross-talk between 
G-proteins. However in the rat vas deferens the mechanism is not so clear. 
Responses to NA, phenylephrine, carbachol and bradykinin, which were unaffected 
by CPA, are all thought to be mediated via G-protein coupled receptors: carbachol 
acts via a muscarinic receptor as it was blocked by atropine in this tissue; NA and 
phenylephrine act via a  1-adrenoceptors; and both BKi and BK2 receptors for 
bradykinin are also G-protein coupled (Hall, 1992; Levesque et al., 1993). In contrast 
responses to ATP and KCl, which are both enhanced by CPA, are thought to result 
from depolarisation of the membrane in each case followed by opening of voltage- 
dependent calcium channels (Morishita et al., 1987; Bean & Friel, 1990; Kennedy, 
1990; Dubyak & El-Moatassim, 1993). Although this could imply that CPA 
selectively enhanced agents acting via membrane depolarisation, CPA also enhanced 
responses induced by 5-HT. Although 5-HTg receptors are receptor-operated cation 
channels, in this tissue 5-HT acts via 5 -HT2 receptors which are G-protein coupled 
receptors rather than 5-HTg receptors, as responses to 5-HT were antagonised by 
ketanserin with an apparent pA2 of 9.1, which is similar to the reported affinity of 
ketanserin at 5 -HT2 receptors (Hoyer et al., 1994). In addition, although 2-Me-5-HT, 
which has been reported to be selective for 5 -HT3 receptors, is active in this tissue, 
this compound was not acting at 5 -HT3 receptors as it was not antagonised by the 5- 
HT3 receptor antagonist MDL 72222 (Martin & Humphrey, 1994).
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Like tyramine, 2-Me-5-HT appears to act indirectly on ai-adrenoceptors via 
release of endogenous NA in the rat vas deferens, as the effect of both these drugs was 
blocked by the a  i-adrenoceptor antagonist prazosin or by the uptake blocker 
imipramine. Contractions induced by both tyramine and 2-Me-5-HT were enhanced 
by CPA. In contrast, contractions induced by NA and phenylephrine, which act 
directly via ai-adrenoceptors as they were blocked by prazosin, were not enhanced by 
CPA. Adenosine has been reported to produce a relatively small enhancement (20 
±10%) of contractions of the rat vas deferens induced by NA (> 10 jiM) (Long & 
Stone, 1986). However no significant enhancement of NA-induced contractions by 
CPA was obtained in this study using either 1 or 10 |iM NA. Adenosine was not used 
as the Ai agonist here, as in the previous study adenosine and NECA were only 
observed to inhibit ATP-induced contractions, presumably due to lower selectivity for 
Ai receptors over A2 . The ability of CPA to enhance contractions induced by 
endogenously released NA but not by exogenous NA or phenylephrine is perhaps 
surprising. However, Mallard et al. (1992) suggested that exogenous and endogenous 
NA act on two different a  1-adrenoceptor receptor subtypes in the rat vas deferens. 
They used chloroethylclonidine (CEC) as an antagonist at aiB receptors, and showed 
that it selectively inhibited the contractions induced by endogenous NA released by 
electrical nerve stimulation, but did not antagonise contractions induced by 
exogenously added NA. They proposed that endogenous NA acts on aiB receptors 
which are localised in the synaptic region, whereas exogenous NA may activate 
another subtype of the ai-adrenoceptor, the aiA  receptor, distributed over the extra- 
synaptic region of the muscle. This proposed difference in subtypes could explain the 
finding that CPA enhances endogenously released NA but not exogenously added a i  
agonists, but due to the current lack of selective agonists and antagonists at the 
proposed a i  subtypes further investigation would be difficult. In addition, doubt has
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been cast on the suggestion of a  i-adrenoceptor subtypes in the rat vas deferens as 
CEC has also been shown to act as an agonist at the pre-junctional 0C2 receptors to 
cause inhibition of NA release (Bultmann & Starke, 1993). CEC may therefore not be 
acting solely as a selective antagonist at the post-junctional aiB receptor, but instead 
its differential effects on contractions induced by exogenous NA and contractions 
induced by nerve stimulation may be due to this Œ2 agonist action. Whatever the 
explanation of the differential effect of CPA on endogenously released and exogenous 
NA, it seems likely that the post-junctional Ai receptor would also enhance the effects 
of NA released by neuronal stimulation, although this enhancement cannot be 
detected due to the concomitant inhibition of NA release by pre-junctional A% 
receptors.
Since responses of the vas deferens to NA and ATP vary along the length of 
the tissue, with NA being more potent at the epididymal and ATP more potent at the 
prostatic end, it seemed possible that the differential enhancement by CPA of 
responses to contractile agents could reflect a differential distribution of receptor 
types along the length of the tissue. However, as shown previously, CPA produced 
similar enhancement of contractions induced by KCl on both epididymal and prostatic 
regions of the tissue. Therefore the selectivity of the Ai receptor mediated 
enhancement for certain agents cannot be due to gross differences in distribution of 
adenosine A% receptors along the length of the tissue. However, receptor 
heterogeneity within each individual smooth muscle cell or within small areas of the 
tissue cannot be excluded.
In conclusion the Ai receptor-mediated enhancement of contractions of the rat 
vas deferens is clearly selective for certain contractile agents, but the reason for the 
selectivity, and the mechanism of the enhancement, requires further study. However,
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the probable enhancement of the two sympathetic co-transmitters in this tissue, NA 
and ATP, may have functional significance, and demonstrates the complexity of the 
interactions in the rat vas deferens and of the neuromodulatory effects of adenosine.
4.1.3. Ontogeny of Pi-purinoceptors in the rat vas deferens
Previous ontogenetic studies in the rat vas deferens have shown adenosine to 
be more potent in the neonates than in the adults, with the potency of adenosine in 
inhibiting nerve mediated contractions decreasing with an increase in age (Hourani et 
al., 1993b). However, the receptor involved had not been characterized in the 
neonates. Therefore this study was performed to demonstrate the development of Pi- 
purinoceptors in the rat vas deferens using tissues from neonatal animals. CPA 
inhibited nerve-mediated contractions throughout the ages studied (from day 10 
onwards, day 10 being the earliest age it could be tested), and as shown in the adult, 
responses to CPA were antagonised by a nanomolar concentration of DPCPX, 
suggesting the activation of pre-junctional A% receptors in the neonates. The potency 
of CPA in activating this receptor in the neonates was similar to the adult throughout 
the ages studied and the early appearance of this functional response suggests that this 
inhibitory pre-junctional Ai receptor is as important in the neonate as it is in the adult 
vas deferens.
To follow the development of post-junctional Ai and A2 receptors in the rat 
vas deferens, KCl was used as the contractile agent instead of NA or ATP, as 
responses to ATP and NA have been shown to vary with age (Hourani et al., 1993b). 
NECA and high concentrations of CPA (> 1 pM) inhibited KCl-induced contractions 
from as early as they could be detected (day 10) with a potency order of NECA >
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CPA. The potency of agonists causing inhibition was similar to the adult throughout 
the ages studied, showing that the inhibitory post-junctional A2 receptor is present as 
early as day 10 and the receptor population is constant throughout the ages. NECA 
also inhibited nerve-mediated contractions acting via A2 receptors in this tissue 
(Hourani et al., 1993b) and the potency of NECA in mediating this response was 
constant throughout the ages, and this too suggests that the post-junctional A2 
receptor population is similar to the adult throughout the ages.
The presence of an excitatory post-junctional A% receptor in the adult rat vas 
deferens enhancing contractions induced by KCl has been discussed. In the neonates, 
at days 10 and 15, no enhancement by CPA of KCl-induced contractions were 
observed, suggesting the absence of post-junctional A% receptors here. However from 
day 20 onwards CPA enhanced contractions induced by KCl, achieving statistical 
significance by day 30. Here responses to CPA increased with an increase in age and 
the levels of the enhancement was not significantly different from that observed in the 
adult by day 35, implying that this receptor subtype is more important in the later 
stages of development. The late development of this excitatory post-junctional Ai 
receptor may explain why the overall inhibitory effect of adenosine on nerve 
stimulation was shown to decrease with age (Hourani et al., 1993b). Binding studies 
using [^HJDPCPX on the rat vas deferens, which were carried out in parallel to these 
functional studies also showed that in tissues from days 10 and 15 animals no Ai 
binding sites were observed, whereas from day 20 onwards [^H] DPCPX binding to an 
Ai receptor was observed (Peachey et al., 1995). Therefore the binding studies using 
[^HJDPCPX have been shown only to identify post-junctional A% receptors but not Ai 
receptors present on the nerve terminals. The reasons for this apparent preferential 
binding to the post-junctional Ai receptors are unknown, but it may simply be a
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consequence of the greater mass of smooth muscle than nerve tissue present in the vas 
deferens.
The presence of post-junctional A% receptors in the rat vas deferens which are 
only functionally significant in the later stages of the development (after day 20) of 
the rat is somewhat intriguing. It has been reported that the process of sexual 
maturation in the male rat starts at around 4 weeks of age, with an increase in the 
number of Leydig cells per testes from the fourth to the tenth week of age, and a 
corresponding rise in plasma testosterone concentration (Pahnke et al., 1975). 
Therefore the appearance of the post-junctional Ai receptors on the vas deferens at 
post-natal day 20, although earlier than the reported start of sexual maturation in the 
rat, may have some involvement in this process.
In conclusion, this work has shown that the pre-junctional Ai and the post­
junctional Pi-2 receptors on the rat vas deferens are present from day 15 and day 10 
respectively, the earliest ages at which responses can be measured, and that the 
potency of the adenosine analogues acting at these receptor subtypes is constant with 
an increase in age. In contrast, the excitatory post-junctional Ai receptors exhibit 
delayed development and may be associated with the sexual maturation of the rat.
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4.2. RAT DUODENUM
4.2.1. Characterization of Pi-purinoceptors in the longitudinal 
muscle and the muscularis mucosae of the rat duodenum
Pl-purinoceptors have been characterized in the whole duodenum where the 
presence of Ai and A2b receptors both mediating relaxation has been shown (Nicholls 
et al., 1992). The aim of this study was to investigate the location of Pi-purinoceptors 
receptors in the separated layers of the rat duodenum which contract in the 
longitudinal plane, the longitudinal muscle and the muscularis mucosae. In the rat 
duodenum longitudinal muscle adenosine, CPA and NECA all caused relaxation, with 
an agonist potency order of CPA = NECA > adenosine. Responses to CPA and 
NECA were antagonised by a nanomolar concentration of DPCPX suggesting that the 
agonists were activating A% receptors. In the whole rat duodenum, CPA was also 
shown to relax the tissue via a direct action on Ai receptors, whereas responses to 
NECA and adenosine were shown to be due to the activation of A2b receptors 
(Nicholls et al., 1992). Relaxation via an A% receptor is unusual as A2 receptors are 
generally considered to cause relaxant effects (for review see Collis and Hourani, 
1993) and in fact the rat duodenum is the only smooth muscle preparation to have 
been shown to relax directly via Ai receptors (Nicholls et al., 1992). In the rat 
duodenum longitudinal muscle, NECA, but not CPA, may also be activating A2 
receptors as responses to CPA were abolished by 1 |xM DPCPX whereas responses to 
NECA were antagonised by 1 jim DPCPX giving an apparent pA2 of 8.4. Even 
though this apparent pA2 for DPCPX is more suggestive of an A 1 rather than an A2 
receptor in this tissue, Schild analysis for DPCPX versus CPA, which was carried out 
in parallel to the present study (results not shown), gave a slope that did not differ 
from unity suggesting that CPA was acting on one receptor type (Ai receptors).
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whereas the Schild analysis for DPCPX versus NECA gave a slope that was much 
lower than unity suggesting that NECA was acting on a mixed population of receptors 
presumably on Ai and A2 receptors (Nicholls et al., 1996). The reason for the high 
potency of NECA (being equipotent with CPA) in this tissue and the higher maximum 
response of the NECA concentration-response curves when compared to CPA may 
also indicate the activation of more than one receptor by NECA. The A2 receptor has 
also been shown to be of the A2b subtype as CGS 21680 was much less potent than 
adenosine in relaxing the tissue (Nicholls et al., 1996).
The rat duodenum muscularis mucosae preparations contracted to Pi- 
purinoceptor agonists with a potency order of CPA = NECA > adenosine. A 
micromolar concentration of DPCPX was required to antagonise the effects of CPA 
and NECA suggesting the activation of A2 receptors in this tissue, even though this 
may not be so clear from the potency order of agonists in this tissue. Contractions 
were not due to the synthesis of prostaglandins as they were not blocked by 
indomethacin. The purines were also not acting via A3 receptors in the rat duodenum 
muscularis mucosae as responses to CPA and NECA were antagonised by 8 -SPT (10 
pM) with an apparent pA2 of 6 .6  (Nicholls et al., 1996) whereas the rat A3 receptor 
has been shown to be resistant to blockade by this antagonist (Van Galen et al., 1994). 
CGS 21680 was inactive in this tissue suggesting the A2 receptor is of the A2 b 
subclass.
The findings of contractile Pi-purinoceptors in the muscularis mucosae and 
relaxant Pi-purinoceptors in the longitudinal muscle of the rat duodenum are 
consistent with studies performed in other areas of the gastrointestinal tract such as in 
the rat colon. In the rat colon adenosine analogues cause a relaxation in the 
longitudinal muscle and a contraction in the muscularis mucosae (Bailey et al., 1992;
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Bailey & Hourani, 1990). However, whereas in the rat colon contractions and 
relaxations are mediated via Ai and A2b receptors respectively, unusually in the rat 
duodenum muscularis mucosae contractions are mediated via A2b receptors and not 
via Ai receptors as would be normally be expected, and in the rat duodenum 
longitudinal muscle relaxations are mediated via a mixture of Ai and A2b receptors.
In conclusion, the presence of a mixture of Ai and A2b receptors in the 
longitudinal muscle of the rat duodenum is shown in this study. CPA appears to 
activate the A% subtype whereas NECA has been shown to activate both Ai and A2b 
receptors. The A2 receptor-mediated relaxation is only apparent in this tissue when 
the Ai receptor-mediated effect is blocked by DPCPX. On the rat duodenum 
muscularis mucosae there are A2b receptors mediating contraction and in the whole 
rat duodenum it appears that responses of the longitudinal muscle dominate as no 
contractions were detected (Nicholls et al., 1992).
4.2.2. Ontogeny of Pi-purinoceptors in the longitudinal muscle and 
the muscularis mucosae of the rat duodenum
In the previous study, CPA was shown to activate Ai receptors and NECA to 
activate a mixture of A% and A2b receptors to cause relaxations of the adult rat 
duodenum longitudinal muscle. In tissues from neonatal rats CPA caused a relaxation 
in a concentration dependent manner after day 20, with small relaxations being 
observed at day 20 (less than 15%), but no relaxations at day 15. 10 nM DPCPX 
antagonised the response to CPA at day 25 with an apparent pA2 of 8.9, whereas 1 
|xM DPCPX abolished the response, suggesting that CPA was solely acting via Ai 
receptors as previously observed for the adult tissue. Binding studies using
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pH]DPCPX in the whole rat duodenum have shown that DPCPX binds with high 
affinity to a single site after day 20, whereas no binding was observed at days 10 or 15 
(Peachey et al., 1996), thus supporting the suggestion that there are no Ai receptors in 
the rat duodenum at day 15 and below. The potency of CPA in causing relaxations 
was not significantly different from adult from day 25 onwards, suggesting that, once 
the Ai receptor has developed (between days 20-25) there is no further increase in the 
receptor population with age.
NECA also caused a relaxation in neonatal rat duodenum longitudinal muscle, 
but was active earlier, from day 15 onwards. The potency of NECA increased with 
age, with NECA being least potent at day 15 and equipotent with adult by day 20, and 
the concentration-response curve to NECA at day 15 reached a lower maximal 
response (50%) than at days 20 or 25 (75%). This increase in potency and maximal 
response of NECA concentration-response curves may be due to the development 
between days 20 and 25 of Ai receptors which are also activated by NECA. 
Consistent with the lack of A% receptors in this tissue at day 15, responses to NECA 
were antagonised by 1 pM DPCPX with an apparent pA2 of 6.8, showing the 
activation of only A2 receptors by NECA at this age. In the previous study on the 
adult tissue, DPCPX (1 pM) antagonised the response to NECA with an apparent pA2 
value of 8.4, and the Schild plot slope was much lower than unity, suggesting that 
NECA activates a mixture of Ai and A2 receptors in this tissue. The results with 
DPCPX (1 pM) at days 20 and 25 giving apparent pA2 values of 7.5 and 8.0 
respectively suggests that in the neonatal tissues too NECA may activate a mixture of 
Ai and A2 receptors as is the case in the adult. This was further confirmed by the fact 
that at day 25, as in the adult, 10 nM DPCPX antagonised the response to NECA with 
an apparent pA2 of 8.9, indicating an A1-mediated effect of NECA at this age. The 
results with NECA therefore confirm that at ages below day 20 there are no functional
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Al receptors but that around day 20 an Ai receptor population begins to develop, as 
shown also by the development of the responses to CPA at this age. The potency of 
NECA in causing relaxations in the presence of 1 pM DPCPX (to abolish any Ai- 
mediated effect) was not significantly different from the potency in the adult 
suggesting that the A% receptor is fully developed by day 15. CGS 21680 also caused 
some relaxations (less than 15%) in the rat duodenum longitudinal muscle at day 15, 
but only at concentrations greater than 10 pM, suggesting that the A2 receptor in the 
neonates is of the A2b subtype as is the case in the adult. The results in the whole rat 
duodenum (Nicholls et al., 1990) showing that adenosine was less potent in the 
neonates (below day 15) than in the adult is also similar to the results found in this 
study with NECA, suggesting that adenosine, like NECA, may activate A2b receptors 
at day 15 and below and a mixture of Ai and A2b receptors from day 20 onwards.
In the neonatal rat duodenum muscularis mucosae CPA, NECA and CGS 21680 
all caused contractions with a potency order of CPA = NECA »  CGS 21680 (at 
day 20), similar to the situation in the adult tissue where all the purines activated A2b 
receptors to cause contractions. Since contractions via A2b receptors rather than A% 
receptors are unexpected and CPA was equipotent with NECA, the ontogeny of this 
contractile A2b receptor was followed in this tissue using CPA instead of NECA. 
This would also allow the determination of Ai receptor mediated components in this 
tissue at various ages. However 1 pM DPCPX antagonised the response to NECA as 
well as to CPA in the neonates with an apparent pA2 value for DPCPX in the 
micromolar range, confirming that CPA activated only A2b receptors in the neonatal 
tissues as is the case for the adult. This is supported by the lack of detectable Ai 
receptors in radioligand binding studies to the whole duodenum before day 20 
(Peachey et al., 1996). The potency of CPA in causing contractions was not 
significantly different from adult throughout the ages, suggesting that the contractile
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A2b receptor population is fully developed as early as day 10 in this tissue. In an 
ontogenetic study of the whole rat duodenum no contractile responses were observed 
and only relaxations were seen, with CPA activating Ai receptors from day 20 
onwards and NEC A activating only A2b receptors at days 10-15 and a mixture of Ai 
and A2b receptors from day 20 onwards (Peachey et al., 1996). The results in the 
whole duodenum are therefore similar to those reported in this study for the 
longitudinal muscle of the rat duodenum.
In conclusion, the contractile A2b receptor in the rat duodenum muscularis 
mucosae and the relaxant A2b receptor in the rat duodenum longitudinal muscle are 
present as early as days 10 and 15 respectively (the earliest ages which could be 
studied), whereas the relaxant Ai receptor in the rat duodenum longitudinal muscle 
appears between days 20-25. One possible explanation of this late development of the 
relaxant Ai receptor in the rat duodenum longitudinal muscle may be due to the 
physiological maturation of the gut associated with weaning which takes place at day 
20, showing that the roles of adenosine in controlling smooth muscle function can 
vary with age.
4.2.3. Ontogeny of P2-purinoceptors in the longitudinal muscle and 
the muscularis mucosae of the rat duodenum
Relaxations were observed in the rat duodenum longitudinal muscle to 2-Me-S- 
ATP and AMPCPP from day 20 onwards, with a potency order of 2-Me-S-ATP > 
AMPCPP, whereas only weak relaxations were observed at day 15 and at this age 
both the agonists appear to be equipotent. This could be explained by the fact that 
day 15 was the earliest age that the tissue could be separated from the muscularis
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mucosae and if a clean separation of the tissues had not been made this may 
complicate the results. The potency order of 2-Me-S-ATP > AMPCPP in the 
neonatal tissues from day 20 onwards is similar to that reported for the adult tissue 
(Johnson & Hourani, 1996), suggesting the activation of P2Y receptors to elicit 
relaxations. The potency of the agonists in causing relaxation increased with age 
being least potent at days 15 and 20, and reaching values not significantly different 
from adult by day 25, suggesting that the P2Y receptor population becomes fully 
developed at day 25. Relaxations have also been observed in the whole rat duodenum 
to ATP and 2-Me-S-ATP acting via P2Y receptors, and in the whole tissue the potency 
of agonists was also least at day 20 and was similar to the adult by day 25 (Nicholls et 
al., 1990). The concentration-response curves obtained for 2-Me-S-ATP and 
AMPCPP in this tissue appear to cross over at high concentrations and this may 
reflect the breakdown of the less stable agonist, 2-Me-S-ATP.
Contractile responses were observed in the muscularis mucosae of the rat 
duodenum to ATP, UTP, 2-Me-S-ATP and AMPCPP. The potency order of agonists 
above day 25 was AMPCPP > ATP = UTP > 2-Me-S-ATP. A similar order was 
also observed in a previous study for the adult tissue by Johnson and co-workers 
(1996) where the activation of P2X receptors by AMPCPP and 2-Me-S-ATP and the 
activation of P21J receptors by ATP and UTP has been shown. Therefore above day 
25, since AMPCPP is much more potent than 2-Me-S-ATP, the activation of P2 X 
receptors is suggested, and similarly since ATP is equipotent with UTP, the activation 
of P2U receptors in this tissue is suggested. Responses to AMPCPP were desensitized 
at day 30 and cross-desensitization was observed between AMPCPP and 2-Me-S- 
ATP, also showing that both the agonists activate P2X receptors. On the other hand 
no cross-desensitization was observed at day 30 between AMPCPP and ATP or UTP, 
suggesting that the latter agonists were not acting via P2X receptors, but via P2U
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receptors as in the adult. However below day 25, 2-Me-S-ATP was more potent in 
eliciting contractions than AMPCPP, and at days 10 and 15 the order was 2-Me-S- 
ATP > AMPCPP > ATP = UTP. At day 15, unlike day 30, responses to AMPCPP 
were not desensitized and no cross desensitization was observed with AMPCPP and 
2-Me-S-ATP. This suggests that AMPCPP and 2-Me-S-ATP were not acting via P2X 
receptors and as 2-Me-S-ATP was more potent than ATP in eliciting contractions in 
this tissue, contractions may be mediated via P2Y receptors at this age. In contrast the 
potency order of ATP being equipotent with UTP were unaffected at day 15 and again 
no cross-desensitization was observed between AMPCPP and ATP or UTP, 
suggesting the activation of P2U receptors, as observed at day 30. Therefore in the rat 
duodenum muscularis mucosae, a different P2-purinoceptor subtype is activated in the 
neonates compared to the adult mediating the same response. Indeed in a previous 
study by Nicholls and co-workers (1992) using the whole rat duodenum, contractile 
responses were shown below day 20, mediated via P2Y receptors. However in the 
whole tissue above day 20, only relaxations via P2Y receptors could be detected 
(Nicholls et al., 1992). This can be explained by the fact that as the relaxant response 
observed in the rat duodenum longitudinal muscle develops to adult levels by day 20 
(discussed earlier) it begins to predominate thus masking the contractile response 
observed in the muscularis mucosae.
The potency of all the agonists in eliciting contractions in the rat duodenum 
muscularis mucosae decreased with age. The potency of AMPCPP and 2-Me-S-ATP 
in causing contractions in this tissue was greatest in the neonates below day 25 and 
reached values similar to adult by day 30. The potency of ATP and UTP causing 
contractions also decreased with age being greatest at days 10 and 15 and reached 
values similar to adult by day 20. This drop in potency of agonists may be due to the 
breakdown of compounds by ectonucleotidases present on the muscularis mucosae.
200
Indeed in the adult rat duodenum muscularis mucosae the presence of 
ectonucleotidases causing breakdown of ATP, UTP and AMPCPP was shown. The 
rate of breakdown of ATP was similar to that of UTP, whereas the breakdown of 
AMPCPP was much slower (Johnson et al., 1996). Therefore the development of 
ectonucleotidases in the rat duodenum muscularis mucosae was investigated using 
tissue preparations from rats aged day 15 and day 30 in order to investigate the drop 
in potency of the agonists.
At day 30, ATP, 2-Me-S-ATP and UTP were broken down at a similar rate and 
the half lives were not significantly different from each other. However the half lives 
of ATP, UTP or 2-Me-S-ATP were significantly lower at day 15 than at day 30, 
indicating that the ectonucleotidase activity is lower in the neonatal rat duodenum 
muscularis mucosae at day 15 than at day 30. The major breakdown products of 
ATP, UTP and 2-Me-S-ATP at both ages were AMP, UMP and 2-Me-S-AMP 
respectively. This indicates that there may be differences in the ecto ATPase enzyme 
levels found on this tissue. For example the levels of ecto 5'-nucleotidase which 
converts AMP to adenosine may be lower than the levels of other degradative 
enzymes found on the muscularis mucosae. AMPCPP was the most stable agonist at 
day 30 as the half life for AMPCPP was significantly greater than that for ATP, UTP 
or AMPCPP. This is similar to the degradation observed by the adult rat duodenum 
muscularis mucosae (Johnson et al., 1996) where AMPCPP was also the most stable 
agonist. At day 15 AMPCPP was also degraded by the muscularis mucosae, but the 
differences in the half life of AMPCPP compared to those of ATP, UTP or 2-Me-S- 
ATP did not quite reach significance.
The potency of ATP and UTP in eliciting contractions in this tissue decreased 
with age by approximately 1.5 log units, whereas the potency of 2-Me-S-ATP, also
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eliciting the same response, decreased more dramatically with a drop of greater than 3 
log units. Since the relative rates of degradation of ATP, UTP and 2-Me-S-ATP are 
similar at days 15 and 30, the difference in the drop in the potency of 2-Me-S-ATP 
compared to ATP or UTP cannot be explained by the greater rate of breakdown of 2- 
Me-S-ATP at day 30. Therefore it is likely that the reason for the high potency of 2- 
Me-S-ATP observed at days 10 and 15 compared to adult or day 30 tissue 
preparations is due to the activation of a P2Y receptor in the neonates (at which 2-Me- 
S-ATP has high potency) and a P2X receptor after day 25. As there are low levels of 
ectonucleotidase activity in the neonatal tissue preparations compared to the adult 
ones the drop in potency of ATP and UTP may be partly due to the increase in the rate 
of breakdown. However as there was no difference in the breakdown of AMPCPP by 
15 day tissues compared to 30 day tissues, while there was also a drop in potency of 
AMPCPP with age, it seems likely that this decrease in potency of this agonist may be 
due to a change in receptor number.
In conclusion, this work has supported the presence of a P2Y receptor in the rat 
duodenum longitudinal muscle mediating relaxation and has shown that this receptor 
is present as early as day 15 (the earliest age it could be studied), and is fully 
developed by day 25. In the adult rat duodenum muscularis mucosae there are P2X 
and P21J receptors both mediating contractions. The contractile P21J receptor in the 
muscularis mucosae is present as early as day 10 (the earliest age it could be studied) 
and the receptor population may be highest in the neonates below day 20. However 
the results here suggest that P2Y receptors mediate contractions in this tissue below 
day 20 whereas P2X receptors mediate the same response above day 25, implying a 
switch in the P2 -purinoceptors with age. The ectonucleotidase activity in the rat 
duodenum muscularis mucosae also increase with age and this may at least partly 
explain the decrease in potency of agonists with age.
202
4.3. CONCLUSION AND FURTHER WORK
It is thus apparent from the work of this thesis that there are different subtypes 
of purinoceptors involved in the functioning of the rat vas deferens and the rat 
duodenum. The results in the rat vas deferens confirm the presence of pre-junctional 
Ai receptors causing an inhibition of nerve-mediated contractions. In this tissue ATP 
acts as a co-transmitter with NA (Sneddon and Bumstock, 1984; Meldrum and 
Bumstock, 1983), and responses to the two sympathetic transmitters have been shown 
to vary along the length of the tissue (Brown et al., 1979; Sneddon & Machaly, 1992). 
In the epididymal region of the rat vas deferens NA is more potent than ATP and in 
the prostatic region ATP is more potent than NA in eliciting contractions (Sneddon & 
Machaly, 1992). However the pre-junctional A% receptors are apparent in both 
regions of the tissue, but CPA was more potent (10 fold) in inhibiting nerve-mediated 
contractions in the epididymal region than at the prostatic region, suggesting that 
there may be a larger population of pre-junctional Ai receptors in the epididymal 
region of the tissue. The neuronally released ATP activates pre-junctional Ai 
receptors via its breakdown product, adenosine, as a feed back mechanism to inhibit 
further release of transmitters (Paton, 1981). Therefore the larger population of pre­
junctional Ai receptors found in the epididymal region of the tissue where the 
adrenergic, but not purinergic, component of the nerve-mediated response 
predominates is somewhat surprising. However the fact that pre-junctional Ai 
receptors also inhibit NA release (Paton, 1981), which is the prominent transmitter in 
the epididymal region of the tissue. Post-junctional effects of adenosine are also 
apparent in the rat vas deferens. Here adenosine inhibits contractions induced by ATP 
and NA acting via A2 receptors in the muscle. In contrast to the pre-junctional Ai 
receptor this post-junctional A2 receptor appears to be present mainly in the prostatic 
region of the tissue, showing that the A2 -mediated effect is only apparent in the
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prostatic region of the rat vas deferens where the prominent transmitter in this region 
is ATP. An excitatory Ai receptor on the smooth muscle of the rat vas deferens is 
also shown here, however this receptor is present equally on both regions of the 
bisected tissue.
ATP is thought to exert effects on adenosine receptors in the rat vas deferens 
after metabolism of ATP to adenosine. Therefore the differential distribution of 
adenosine receptors in the rat vas deferens might be explained in terms of 
ectonucleotidase activity in this tissue. Indeed the smooth muscle of the rat vas 
deferens contains high levels of ecto ATPases as the potency order of P2-purinoceptor 
agonists obtained by pharmacological studies (Bumstock and Kennedy, 1985) has 
been shown to be markedly different from that obtained at cloned P2X receptors 
(Valera et al., 1994). This has been suggested to be due to the breakdown of agonists 
by ectonucleotidases found on smooth muscle cells, whereas on cultured cells 
ectonucleotidases are absent or much less active (Kennedy and Leff, 1995b). 
Therefore the degradation of ATP by ectonucleotidases in the bisected tissue needs 
investigation in order to explain the significance of the differential distribution of 
adenosine receptors along the length of the rat vas deferens. Autoradiographic studies 
of adenosine receptors in the rat vas deferens can also be carried out to show if 
receptor numbers are similar in the prostatic and epididymal portions of the tissue or 
whether the differences observed in functional studies can simply be explained by the 
functional uncoupling of the receptors in one region over another.
The post-junctional Ai receptor in the rat vas deferens has been shown to 
enhance contractions induced by a variety of contractile agents, but the effect has 
been shown to be selective. For example it does not enhance the contractions induced 
by NA, but ATP-induced contractions are clearly enhanced. This selective interaction
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between receptors have been shown in other systems such as in the DDTi MF-2 
smooth muscle cells where it has been shown to be due to cross-talk at the G-protein 
levels. In the DDTi MF-2 cells Ai receptors can interact with receptors at which 
ATP and UTP act (P2U receptors) and histamine Hi receptors (both of which are 
coupled to phospholipase C via pertussis toxin insensitive G-protein), to raise IP3 
levels mediating an increase in intracellular calcium (Gerwins and Fredholm, 1992; 
Dickenson and Hill, 1993a). Here Ai receptors are negatively coupled to adenylate 
cyclase and the A% mediated calcium response may be due to the Py subunit of Gi 
activating phospholipase C (Dickenson and Hill, 1993b). In contrast there is no 
synergism between Hi and P21J receptors in the DDTi MF-2 cells (Dickenson and 
Hill, 1993b). Therefore the interaction between Ai receptors and P2-purinoceptors 
but not between Ai receptors and adrenoceptors in the rat vas deferens could be been 
explained in terms of second messenger systems in the rat vas deferens. However 
ATP acts in this tissue via an ion channel (P2X receptors) (Bean & Friel, 1990; 
Kennedy, 1990; Dubyak & El-Moatassim, 1993) rather than a G-protein coupled 
receptor. Therefore in this tissue the second messenger interactions are not so clear, 
and measurements of intracellular calcium levels for example may provide some 
useful information in an attempt to explain this phenomenon.
The location of Pi-purinoceptors in the rat duodenum at which adenosine act 
has also been shown in this study. In the longitudinal muscle there are relaxation- 
mediating Ai and A2 b receptors, and in the muscularis mucosae contraction- 
mediating A2 b receptors have been shown. Contraction via A2 receptors and 
relaxation via Ai receptors is unusual, as generally contractions are mediated via Ai 
receptors and relaxation via A2 receptors on smooth muscle (for review see Collis and 
Hourani, 1993). Therefore the investigation of the second messenger systems 
underlying these phenomena in the rat duodenum would provide more information
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about the nature of this mechanism. A2b receptors in human erythroleukemia cells are 
positively coupled to Ca^+ channels thereby increasing intracellular Ca^+ levels, and 
this mechanism is not through a Gg mediated cAMP mechanism, but may involve a 
Gq mediated IP3 dependent mechanism (Feoktistov et al., 1996). A similar 
mechanism may also operate in the rat duodenum muscularis mucosae where A2b 
receptors are involved in this tissue mediating contraction.
Ontogenetic studies of purinoceptors in the rat vas deferens and the rat 
duodenum have been carried out in this study. In the rat vas deferens post-junctional 
A2 receptors and pre-junctional Ai receptors were present as early as they could be 
studied (days 10 and 15 respectively). However the post-junctional Ai receptor 
showed delayed development and appeared at the start of sexual maturation of the rat, 
, (after day 20). A direct link between the development of the post-junctional Ai 
receptor and the sexual maturation of the rat can be investigated if this study were 
performed using animals with suppressed sexual maturation, to see if the development 
of this excitatory post-junctional Ai receptor is affected. Adenosine receptors in the 
rat duodenum also show differential development, relaxation-mediating A2b receptors 
in the longitudinal muscle and contraction-mediating A2b receptors in the muscularis 
mucosae are present as early as they could be studied (day 15 and day 10 
respectively), whereas the relaxation-mediating Ai receptor in the longitudinal muscle 
appears between days 20-25. This late development of the relaxant A% receptor in the 
rat duodenum longitudinal muscle may be due to the physiological maturation of the 
gut associated with weaning which takes place at day 2 0 , and thus could be 
investigated further using age matched non-weaned animals. The weaning process 
has also been shown to be linked to the development of other receptor systems such as 
the 6 -opioid receptor subtypes in the rat central nervous system (Kitchen et al., 1995).
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The ontogeny of P2-purinoceptors in the separated layers of the rat duodenum 
obtained in this study has given a more complex picture. Here relaxation-mediating 
?2Y receptors in the longitudinal muscle and P2u receptors in the muscularis mucosae 
are present from as early as they could be studied (days 15 and 10 respectively). 
However in the adult muscularis mucosae preparations there are P2X receptors also 
mediating contraction of the tissue, but in the neonatal tissues there is a switch in the 
receptor type and a P2Y receptor was shown to mediate this effect. Therefore the 
involvement of a G-protein coupled receptor (P2Y receptor) in the neonates but an ion 
channel receptor (P2X receptor) in the adult to mediate the same response in the 
muscularis mucosae is intriguing. In the development of opioid receptors a switch in 
receptors has also been noted. Here the swim-stress induced antinociception is 
mediated via p receptors in rats below day 20 whereas after that age a Ô receptor is 
involved in mediating this response, both of which are G-protein coupled receptors 
(Muhammad and Kitchen, 1993).
The characterization of P2-purinoceptor subtypes in this study has been based 
on the potency order of agonists and the susceptibility to desensitization by AMPCPP. 
However with the presence of ectonucleotidases on the muscularis mucosae (Johnson 
et al., 1996) the potency orders obtained in this study may be somewhat distorted. 
Indeed the activity of the ecto enzymes is greatly reduced in the neonates compared to 
the adult, suggesting that the enzymes develop with age, whereas the potency of 
agonists decreased with age. For example, a decrease in potency of 1000 fold was 
obtained for 2-Me-S-ATP whereas the decrease was only 10 fold for ATP or UTP 
with an increase in age. However the rate of degradation of 2-Me-S-ATP, ATP and 
UTP were similar to each other at days 30 and 15. Therefore while the drops in 
potency of UTP and ATP with age may well be explained in terms of increased 
ectonucleotidase activity, the larger drop in potency for 2-Me-S-ATP cannot simply
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be due to the activity of ecto enzymes but may indeed be due to the activation of 
different P2 -purinoceptor subtypes between the two ages (a P2 Y receptor at day 15 
and a P2 X receptor at day 30). The potency of AMPCPP also decreased with age (10 
fold), but the rate of degradation of this compound at day 15 was not significantly 
different from that observed at day 30, therefore the drops in potency of this agonist 
may be due to differences in receptor number. These suggestions would be further 
strengthened if experiments were carried out in the presence of ectonucleotidase 
inhibitors. Indeed suramin has been shown on the adult muscularis mucosae to act as 
an ectonucleotidase inhibitor (Johnson et al., 1996), but this compound is also a P2 - 
purinoceptor antagonist, thus complicating interpretation of results. When selective 
potent ectonucleotidase inhibitors are commercially available this problem can be 
addressed directly.
Overall, this study has shown that purinoceptors are present in neonatal and 
adult smooth muscle preparations contributing to the normal functioning of the tissues 
and these receptors appear at different stages of the development of the animal.
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Differential distribution of adenosine receptors in the epididymal and 
prostatic portions of the rat vas deferens
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A b s tr a c t
In the rat vas deferens there are prejunctional A j receptors mediating inhibition of transmitter release and post-junctional A j and A 2 
receptors mediating enhancement and inhibition of contractions respectively. In this study the distribution of adenosine receptors in the 
prostatic and epididymal portions of the bisected rat vas deferens was investigated. The pre- and post-junctional A j receptors were 
present on both portions of the bisected tissue. However, post-junctional A 2 receptors appear to be present only in the prostatic region, 
showing that adenosine receptors are differentially distributed along the length of the rat vas deferens.
Keywords: Vas deferens, rat; Adenosine receptor; Receptor distribution
1. Introduction
Stimulation of the sympathetic nerves of the rat vas 
deferens produces a biphasic response, which is thought to 
be due to adenosine 5'-triphosphate (ATP) and noradrena­
line released as cotransmitters (White, 1988; Bumstock, 
1990; Von Kligelgen and Starke, 1991). It is well docu­
mented that there is regional variation in the contractile 
responses to nerve stimulation along the length of the rat 
vas deferens, with the prostatic region showing the 
purinergic component and the epididymal region showing 
the adrenergic component (Sneddon and Machaly, 1992). 
Adenosine has been shown to have a neuromodulatory role 
mediating inhibition of neurotransmitter release acting via 
pre-junctional Aj receptors in this tissue (Muller and 
Paton, 1979; Paton, 1981). ATP has also been shown to 
have a neuromodulatory role acting via pre-junctional 
purinoceptors, and this may be due to a direct effect of 
nucleotides on the Aj receptor (Forsyth et al., 1991; Kurz 
et al., 1993). It was therefore of interest to investigate the 
distribution of adenosine receptors on the prostatic and 
epididymal portions of the bisected rat vas deferens, to see 
whether these receptors are also localised in the prostatic 
region of the tissue where the purinergic component pre­
dominates. In the rat vas deferens there are pre-junctional
* Corresponding author. Tel.: (44) (1483) 259707; fax: (44) (1483) 
576978.
Aj receptors, mediating inhibition of transmitter release 
(Muller and Paton, 1979; Paton, 1981), and post-junctional 
A 2 receptors mediating inhibition of contractions induced 
by ATP or noradrenaline (Hourani et al., 1993). Recently, 
the presence of an excitatory post-junctional Aj receptor 
mediating enhancement of contractions has also been 
shown (Hourani and Jones, 1994). In this study, we exam­
ined the distribution of adenosine receptors along the 
length of the rat vas deferens using the A j-selective ago­
nist V ^ -cyclopentyladenosine (CPA), the non-selective ag­
onist 5'-A-ethylcarboxamidoadenosine (NBCA) and the se­
lective antagonist l,3-dipropyl-8-cyclopentylxanthine 
(DPCPX) which shows nanomolar affinity at A j receptors 
compared to micromolar affinity at A 2 receptors (for 
review, see Collis and Hourani, 1993).
2. Materials and methods
Male Wistar rats (200-250 g) were killed by cervical 
dislocation. Equal portions (1.0-1.5 cm) of the epididymal 
and prostatic ends of the vas deferens were removed, freed 
of any connective tissue, and mounted in 4 ml organ baths 
containing Mg '^^-free Krebs of the following composition, 
118 mM NaCl, 25 mM NaHCOg, 1.2 mM KH2PO4, 4.8 
mM KCl, 2.5 mM CaClj, 11 mM glucose, gassed with 
95% O2 :5% CO2, and maintained at 37°C. A resting 
tension of 0.5 g was applied, and contractile responses
0014-2999/96/$ 15.00 © 1996 Elsevier Science B.V. All rights reserved 
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were measured isometrically with a Grass FT03 transducer 
and recorded on a Grass model 79D polygraph. Tissues 
were equilibrated for 90 min before the addition of drugs 
and concentration-response curves were obtained non- 
cumulatively.
To measure the inhibition of nerve-stimulated contrac­
tions, tissues were field stimulated (Grass S48 stimulator, 
twin pulses of 1 ms duration, 75 ms apart, 70 V) via 
parallel platinum electrodes at a frequency of 0.1 Hz 
resulting in regular contractions 10 s apart. The purines 
were added when the response to the nerve stimulation had 
stabilised, and left in contact with the tissue until maxi­
mum inhibition of the contractions were observed. The 
inhibition was expressed as percent reduction of the 
nerve-mediated response. To investigate the effect of 
DPCPX (10 nM or 1 /aM), concentration-response curves 
for agonists were obtained in the same tissue before and 
after incubation for 30 min with the antagonist. To mea­
sure the inhibitory effect of NECA or the enhancement by 
CPA of KCl-induced (35 mM) contractions, the tissues 
were pre-incubated with the purines for 1 min before the 
addition of KCl. Responses were expressed as percent 
reduction (% inhibition) or increase (% enhancement) of 
control response in the absence of the purines, calculated 
as the mean of several control contractions obtained in 
each tissue over the course of the experiment. To investi­
gate the effect of tetrodotoxin (1 / j M )  on the nerve-media­
ted or KCl-induced contractions, responses were obtained 
to nerve stimulation or KCl (35 mM) in the same tissue 
before and after incubation for 30 min with tetrodotoxin.
For inhibition of nerve-mediated responses, pD2 values 
were calculated as the negative logjo of the molar concen­
tration of the agonist producing 50% inhibition and dose 
ratios were calculated using these values. Apparent pAj 
values were estimated as the negative logjo of the molar 
concentration of the antagonist divided by the dose ratio — 
1. For inhibition of KCl-induced contractions, a pECjo 
value was calculated as the negative logjo of the molar 
concentration of the agonist producing 2 0 % inhibition.
DPCPX and CPA were obtained from Research Bio­
chemicals International (USA) and NECA was obtained 
from Sigma Chemical Company (UK). The buffer salts 
were of analytical grade and were obtained from BDH 
(UK). CPA (10 mM) was dissolved in 20% ethanol and 
DPCPX (1 mM) was dissolved in 6 % aqueous dimethyl- 
sulphoxide (DMSG) containing NaOH (6  mM), and after 
dilution to the final bath concentration the solvents had no 
effect.
3. Results
Nerve-mediated responses were abolished by tetrodo­
toxin (1 /iM) in the prostatic and epididymal portions of 
the bisected rat vas deferens, whereas KCl-induced re­
sponses were unaffected (results not shown). CPA (0.01- 
0.3 fiM)  enhanced contractions induced by KCl (35 mM) 
equally in both the epididymal and prostatic portions of the 
bisected tissue, with a maximal enhancement at 0.3 /xM 
CPA of approximately 40% in each case (Fig. la). NECA 
(0.01-30.0 fJiM) potently inhibited contractions induced 
by KCl (35 mM) in the prostatic portion (pEC^g = 6.3 ±  
0.3), but was almost inactive even at 100 / j M  in the 
epididymal portion of the bisected tissue (Fig. lb).
CPA and NECA inhibited nerve-mediated contractions 
in both the epididymal and prostatic portions of the bi­
sected rat vas deferens (Fig. 2). The pD  ^ values for CPA 
and NECA for the epididymal region were 7.4 +  0.1 and 
6.7 ±  0.2 respectively, whereas the order of potency was 
reversed at the prostatic end, where the pDj values were
6.6 ±0.1  and 7.3 ±0.1  respectively. DPCPX (10 nM) 
antagonised the inhibition by CPA of nerve-mediated con­
tractions on both regions of the bisected tissue (Fig. 2a,b), 
giving a dose ratio of 20 .8  ± 2.1 and an apparent pAg 
value of 9.3 ±0.1  for the epididymal region, and for the 
prostatic region a dose ratio of 3.7 ±  0.6 and an apparent 
pAj value of 8.4 ±  0.1. DPCPX (10 nM) antagonised the 
response to NECA in the epididymal region (Fig. 2c), 
giving a dose ratio of 5.8 ±  0.6 and an apparent pA^ value
(b)(a)
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Fig. 1. Effect of (a) CPA and (b) NECA on KCl-induced (35 mM) contractions of the epididymal ( • )  and prostatic (■ )  portion of the bisected rat vas 
deferens. Results are expressed as (a) % enhancement of KCl-induced contraction in the absence of CPA and (b) % inhibition of KCl-induced contraction 
in the absence of NECA. Results are the mean of three to four determinations and the vertical bars show S.E.M.
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Fig. 2. The effect of DPCPX on the inhibition of nerve-mediated contractions by CPA and NECA. (a) CPA in the absence of DPCPX ( • )  and in the 
presence of DPCPX (10 nM) (O ) in the epididymal portion; (b) CPA in the absence of DPCPX (■ ) and in the presence of DPCPX (10 nM) (□ )  in the 
prostatic portion; (c) NECA in the absence of DPCPX ( • )  and in the presence of DPCPX, 10 nM (O ) and 1 pM  ( v )  in the epididymal portion; (d) 
NECA in the absence of DPCPX (■ ) and in the presence of DPCPX, 10 nM (□ ) and 1 /x.M ( a )  in the prostatic portion of the rat vas deferens. Results 
are expressed as % inhibition of nerve-mediated contractions. Results are the mean of four determinations and the vertical bars show S.E.M.
of 8.6 ± 0 .1, whereas it did not antagonise the response to 
NECA in the prostatic region (Fig. 2d). In the epididymal 
region, 1 / j l M  DPCPX antagonised the response to NECA 
(Fig. 2c), giving a dose ratio of 155.8 ±  34.2 and an 
apparent pA^ value of 8.2 ±  0 .1, whereas it was much less 
effective at the prostatic region (Fig. 2d), giving a dose 
ratio of 3.5 ±  0.5 and an apparent pAj value of 6.4 ±0.1 .
4. Discussion
CPA clearly enhanced contractions induced by KCl in 
the epididymal and prostatic regions of the bisected rat vas 
deferens, presumably due to the activation of the previ­
ously reported post-junctional Aj receptor (Hourani and 
Jones, 1994). In this study KCl was used as the contractile 
agent instead of ATP, as used in the previous study 
(Hourani and Jones, 1994), as ATP-induced contractions 
have been shown to vary along the length of the tissue, 
predominating at the prostatic region (Sneddon and 
Machaly, 1992). Responses to KCl were unaffected by 
tetrodotoxin suggesting that these responses were due to a 
direct effect on the smooth muscle and not to stimulation 
of excitatory nerves. These results suggest that post-junc­
tional Aj receptors are evenly distributed along the length 
of the rat vas deferens. NECA potently inhibited contrac­
tions induced by KCl in the prostatic region, presumably 
due to the activation of post-junctional A 2 receptors 
(Hourani et al., 1993). However, the lack of an appreciable 
response to NECA in the epdidymal region suggests that
the A 2 receptors are localised mainly in the prostatic 
region of the tissue.
In the whole rat vas deferens, CPA inhibited nerve- 
mediated contractions via pre-junctional Aj receptors, an­
tagonised by a nanomolar concentration of DPCPX, 
whereas NECA inhibited nerve-mediated contractions via 
post-junctional A 2 receptors, antagonised by a micromolar 
concentration of DPCPX (Hourani et al., 1993). In the 
bisected tissue nerve-mediated contractions were inhibited 
by CPA in both regions, and CPA was acting via pre-junc­
tional Aj receptors as it was antagonised by a nanomolar 
concentration of DPCPX. However, the potency of CPA in 
activating the pre-junctional A  ^ receptors in the epididy­
mal region (pD2 =  7.4 ±  0.1) is almost 10-fold higher than 
that for the prostatic region (pD2 =  6 .6  ±0 .1). This may 
be due to a larger population of pre-junctional Aj recep­
tors in the epididymal region when compared to the pro­
static region, or may reflect differences in post-receptor 
events. Like CPA, NECA also inhibited nerve-mediated 
contractions in both regions of the bisected tissue, but 
unlike CPA the potency of NECA in inhibiting the nerve- 
mediated contractions was higher at the prostatic region 
(pD2 =  7.3 ±  0.1) than at the epididymal region (pD2 =
6.7 ±  0.2). The inhibitory effect of NECA on nerve-media­
ted responses was antagonised by a nanomolar concentra­
tion of DPCPX in the epididymal region, and this together 
with a potency order of CPA > NECA suggests the activa­
tion by NECA of pre-junctional Aj receptors here. There 
was no antagonism of the effect of NECA by this concen­
tration of DPCPX in the prostatic region, as previously
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shown for the whole tissue (Hourani et al., 1993), suggest­
ing that NECA was acting here via A 2 receptors not Aj. A 
micromolar concentration of DPCPX antagonised the re­
sponse to NECA in both regions, and yielded an apparent 
PA2 in the nanomolar range in the epididymal region, 
supporting the activation by NECA of pre-junctional Aj 
receptors. However, in the prostatic region the apparent 
PA2 for DPCPX was in the micromolar range, similar to 
the situation in the whole tissue, supporting the activation 
by NECA of post-junctional A 2 receptors here. In the 
whole tissue NECA activated A 2 receptors rather than pre- 
or post-junctional Aj receptors (Hourani et al., 1993; 
Hourani and Jones, 1994), but the activation by NECA of 
pre-junctional Aj receptors in the epididymal region of the 
bisected tissue can be explained by the lack of post-junc­
tional A 2 receptors in this region of the rat vas deferens.
In conclusion, this work has shown a differential distri­
bution of adenosine receptor subtypes along the length of 
the rat vas deferens, with pre- and post-junctional Aj 
receptors being present over both regions of the bisected 
tissue, whereas post-junctional A 2 receptors were only 
present in the prostatic region.
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Selective enhancement by an adenosine receptor agonist 
of agents inducing contraction of the rat vas deferens
Reeeived: 3 August 1995/Aceepted: 22 D ecem ber 1995
Abstract The adenosine analogue N®-cyclopen- 
tyladenosine (CPA), acting via postjunctional Ai recep­
tors, has been shown to enhance contractions of the rat 
vas deferens induced by adenosine 5'-triphosphate 
(ATP), the sympathetic cotransmitter in this tissue. The 
aim of the present study was to examine the ability of 
CPA to enhance contractions induced by other con­
tractile agents. CPA (0.01-0.3 pM) enhanced contrac­
tions induced by exogenous ATP (10 pM), 5-hydroxy- 
tryptamine (5-HT) (3 pM), tyramine (10 pM), 2-methyl- 
5-hydroxytryptamine (2-Me-5-HT) (10 pM) and KCl 
(35 mM) and this enhancement was blocked by an 
Ai-selective concentration (3 nM) of l,3-dipropyl-8- 
cyclopentylxanthine (DPCPX). CPA failed to enhance 
contractions induced by exogenous noradrenaline 
(NA) (1 pM or 10 pM), bradykinin (0.1 pM), 
phenylephrine (3 pM) or carbachol (10 pM).
The contractions induced by ATP (10 pM), 5-HT 
(3 pM), 2-Me-5-HT (10 pM) and KCl (35 mM) were 
unaffected by tetrodotoxin (1 pM) as well as by desen­
sitisation of the Pix-purinoceptors with the ATP ana­
logue adenosine 5'-(a, j9-methylene) triphosphonate. 
The contractions induced by tyramine (10 pM) and 
2-Me-5-HT (10 pM) were blocked by prazosin 
(100 nM) or by imipramine (1 pM). Ketanserin (10 nM) 
antagonised the response to 5-HT giving a dose-ratio 
of 12.9 corresponding to an apparent pAz of 9.1.
In conclusion, the Ai-mediated effect was clearly 
selective for certain contractile agents and not due to 
a non-specific increase in contractility of the tissue. 
CPA enhanced contractions induced by both ATP and
V.R. Brownhill • S.M.O. Hourani ( E l ) - I. Kitchen 
Receptors and Cellular Regulation Research Group, 
School of Biological Sciences, University of Surrey, 
Guildford GU2 5XH, UK
indirect sympathomimetics which release endogenous 
NA, and this enhancement of the two sympathetic 
cotransmitters may have a functional significance, and 
demonstrates the complexity of the neuromodulatory 
effects of adenosine in the rat vas deferens.
Key words Rat vas deferens • Adenosine receptors • 
Purinoceptors • Adenosine 5'-triphosphate • 
Noradrenaline • Contraction
Introduction
The rat vas deferens has been widely used as a model to 
investigate the actions of purinoceptor agonists. The 
effects of adenosine on smooth muscle are mediated by 
specific Pi-purinoceptors, of which four major classes 
Ai, Aga, Azb and A 3 have been cloned and can be 
distinguished in pharmacological and binding studies 
(Collis and Hourani 1993; Fredholm et al. 1994). On 
Ai receptors N^-substituted analogues of adenosine 
such as N^-cyclopentyladenosine (CPA) are more po­
tent than 5'-substituted analogues such as 5'-N-ethyl- 
carboxamidoadenosine (NECA), and the antagonist 
l,3-dipropyl-8-cyclopentylxanthine (DPCPX) has 
nanomolar affinity, whereas on A2 receptors NECA is 
more potent than CPA and DPCPX has micromolar 
affinity (Collis and Hourani 1993). The adenine nucleo­
tide adenosine 5'-triphosphate (ATP) also has effects on 
smooth muscle which are mediated by P 2-purinocep- 
tors, of which at least two major classes exist, 
P 2X (ligand gated ion channels) and P 2Y (G-protein 
coupled), generally causing contraction and relaxation 
respectively (Bumstock and Kennedy 1985; Fredholm 
et al. 1994).
In the rat vas deferens the P 2-purinoceptor is of the 
P 2X subtype causing contraction of the smooth muscle, 
and the cotransmitter role of ATP released from sym­
pathetic nerves with noradrenaline (NA) is well esta­
blished (White 1988; Bumstock 1990; von Kligelgen
500
and Starke 1991). There are pre-junctional receptors 
on the sympathetic nerves of the rat vas deferens caus­
ing inhibition o f transmitter release (Paton 1981), as 
well as post-junctional A^y receptors inhibiting con­
tractions (Hourani et al. 1993). Recently the A  ^ agonist 
CPA (but not N E C A  and adenosine) has been shown to  
enhance contractions of the rat vas deferens induced by 
ATP, and this enhancement was blocked by 1 nM  
D P C P X , suggesting the presence of an excitatory post­
junctional A i receptor (Hourani and Jones 1994). 
These results are similar to those reported by D ick­
enson and Hill (1993) on the DDT^ M F-2 hamster vas 
deferens cell line, where A  ^ receptors enhance increases 
in cytosolic calcium induced by agonists such as ATP, 
histamine and bradykinin. However, in this cell line 
ATP induces m obilisation of calcium by a G-protein  
coupled receptor rather than by a ligand gated ion  
channel. In the DDT^ M F-2 cells enhancement of the 
responses of one agonist by another has been suggested 
to be due to cross talk at the G-protein level and 
depends on the agonists used, enhancement being seen 
between adenosine and ATP or adenosine and hista­
mine for example, but not between ATP and histamine 
(D ickenson and Hill 1993).
It was therefore of interest to examine the ability of 
a selective A i agonist to enhance contractions of the rat 
vas deferens to a variety of agents, to see if the enhance­
ment was non selective or whether it was agonist de­
pendent. In this study we used ATP, noradrenaline 
(NA), phenylephrine, 5-hydroxytryptamine (5-HT), 2- 
m ethyl-5-hydroxytryptamine (2-M e-5-HT), brady­
kinin, carbachol, tryamine and KCl to contract the rat 
vas deferens, and the effect o f CPA on the contractions 
induced by these agents was investigated.
with various concentrations of CPA, before addition of the contrac­
tile agent at intervals of 10-20 min. The response in the presence of 
CPA was calculated as % of the response in the absence of CPA, 
calculated as the mean of several control contractions obtained in 
each tissue over the course of the experiment. The control contrac­
tions to each agent were stable throughout the course of the experi­
ment. To investigate further the enhancement by CPA, concentra­
tion-response curves to ATP, NA and tyramine were carried out 
either in the presence or absence of 0.3 pM CPA pre-incubated with 
the tissue for 1 min as above.
In experiments to investigate the effect of tetrodotoxin (TTX) 
(1 pM), imipramine (1 pM), prazosin (100 nM), atropine (1 pM), 
ketanserin (10 nM), 3-tropanyl-3,5-dichlorobenzoate (MDL 72222) 
(1 pM) and DPCPX (3 nM), these were incubated with the tissue for 
1 h before challenge with the contractile agents. In experiments to 
investigate the effect of desensitising the Pj^-purinoceptor, contrac­
tions to the ATP analogue adenosine 5'-(a, ^-methylene) triphos­
phonate (a, jS-meATP) (100 pM), were induced repeatedly until no 
response to ATP (10 pM) was obtained. In each case responses to 
the contractile agents were obtained in the same tissue before and 
after treatment with TTX, imipramine, antagonists, or a, ^-meATP. 
In the case of 5-HT, a dose-ratio was calculated from the concentra­
tion of 5-HT inducing a contraction of 0.75 g tension in the absence 
and presence of ketanserin. The apparent pA^ value for ketanserin 
was calculated as the negative logj^ of the molar concentration of 
the antagonist divided by the dose-ratio — 1. All data were present­
ed as means + SEM of at least four determinations. Student’s t tests 
were used to compare results, and a value of P <  0.05 was con­
sidered significant.
Drugs. DPCPX, MDL 72222, ketanserin (tartrate salt), 2-Me-5-HT 
(maleate salt), CPA (D isomer) and a, jg-meATP (D isomer, 
dilithium salt) were obtained from Research Biochemicals, Natick, 
MA, USA. 5-HT (hydrochloride salt), bradykinin (acetate salt), 
imipramine (hydrochloride salt), prazosin (hydrochloride salt), car­
bachol (chloride salt), NA (( — ) isomer, bitartrate salt), phenyleph­
rine (( — ) isomer, hydrochloride salt), atropine (sulphate salt) and 
TTX were obtained from Sigma, Poole, Dorset, UK. The buffer salts 
were of analytical grade and were obtained from Fisons, Lough­
borough, Leicestershire, UK, or BDH, Poole, Dorset, UK. CPA 
(10 mM) was dissolved in 20% ethanol and DPCPX (1 mM) was 
dissolved in 6% aqueous dimethylsulphoxide (DMSO) containing 
NaOH (6 mM) or in 20% ethanol.
Methods
Male Wistar rats (200-250 g) were killed by cervical dislocation. The 
whole vasa deferentia were removed, freed of any connective tissue, 
and mounted in 4 ml organ baths containing Mg^ free Krebs of the 
following composition: 118 mM NaCl, 25 mM NaHCO^, 1.2 mM 
KH2PO4, 4.8 mM KCl, 2.5 mM CaCl^, 11 mM glucose, gassed with 
95% O^: 5% CO2, and maintained at 37° C. A resting tension of
0.5 g was applied, and contractile responses were measured isometri­
cally with a Grass FT03 transducer and recorded on a Grass model 
79D polygraph after incubation for 90 min during which Krebs 
buffer was replaced every 20 min. Non-cumulative concentration- 
response curves were constructed with a 10 min dose cycle for ATP, 
NA, phenylephrine, 5-HT, 2-Me-5-HT and tyramine and a 20 min 
dose cycle for carbachol and bradykinin. For each agonist a concen­
tration was selected which gave consistent submaximal contractile 
responses, and this concentration (10 pM ATP, 1 and 10 pM NA, 
3 pM phenylephrine, 10 pM carbachol, 3 pM 5-HT, 10 pM 2-Me- 
5-HT, 10 pM tyramine and 0.1 pM bradykinin) was used in further 
experiments. KCl (35 mM) was also used, and the contraction in­
duced by this concentration was submaximal, as it was lower than 
that induced by 70 mM KCl, although no concentration-response 
curve was constructed.
To measure the enhancement by CPA of contractions induced 
by the contractile agents, the tissues were pre-incubated for 1 min
Results
The rat vas deferens contracted in a concentration  
dependent manner to N A , ATP, CCh, bradykinin, 
tyramine, 2-M e-5-HT, phenylephrine and 5-HT  
(Fig. 1). K Cl (35 mM) also contracted the rat vas de­
ferens but no concentration-response curve was ob­
tained.
Concentrations of CPA ranging from 1 nM  to 
0.3 pM  clearly enhanced contractions induced by ATP  
(10 pM), 5-HT (3 pM), tyramine (10 pM), 2-M e-5-H T  
(10 pM) and KCl (35 mM), maximal enhancement be­
ing seen at 0.3 pM  CPA in each case. There was no 
enhancement of the contractions induced by N A  
(10 p M ), phenylephrine (3 p M ), carbachol (10 pM) or 
bradykinin (0.1 pM) (Fig. 2). Contractions induced by 
a lower concentration of N A  (1 pM) were also not 
enhanced by CPA (results not shown). High concentra­
tions of CPA ( >  1 pM) inhibited responses to some of 
contractile agents (Fig. 2). In the presence of 0.3 pM
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Fig, 1 Concentration-response curves to various contractile ago­
nists in the rat vas deferens: (a) ATP (O), 5-HT (V); bradykinin (♦); 
carbachol (T); (b) NA (O); phenylephrine (□); 2-Me-5-HT (•); 
tyramine (■). Each point is the mean of at least four determinations 
and the vertical bars show SEM
o>
0^  60
(b) 180-1
2
160-
§ 140-
o
o 120-
' i
(D
a
loor
o
&
80-
60-
40-
CPA concentration (|iM)
0.001 0.01 0.1 1 
CPA concentration (|iM)
Fig. 2 Effect of preincubation for 1 min with CPA on contractile 
responses of rat vas deferens induced by (a) ATP (10 pM) (O), 5-HT 
(3 pM) (V), KCl (35 mM) (A), bradykinin (0.1 pM) (♦), carbachol 
(10 pM) (▼), (b) NA (10 pM (O), phenylephrine (3 pM) (□), 2-Me-5- 
HT (10 pM) (•) and tyramine (10 pM (■). Results are expressed as 
percent of control response to each agent in the absence of CPA. 
Each point is the mean of at least four determinations and the 
vertical bars show SEM
CPA the concentration-response curves to ATP and 
tyramine were clearly enhanced and the enhancement 
was significantly different (F <  0.05) at concentrations 
of ATP >  10 pM and concentrations of tyramine 
>  3 pM (Fig. 3a, c). A lthough no maximal response 
was obtained it appeared that rather than a leftward 
shift in the concentration-response curves there would  
be an increase in the maximal response. The concentra­
tion-response curve to N A  was unaffected in the pre­
sence of 0.3 pM CPA (Fig. 3b). The enhancement by 
CPA (0.3 pM) of contractions induced by ATP (10 pM), 
5-HT (3 pM), tyramine (10 pM), 2-M e-5-H T (10 pM) 
and KCl (35 mM ) was inhibited by D P C P X  (3 nM ) 
(Fig. 4).
TTX (1 pM) did not inhibit contractions induced by 
ATP (10 pM), 5-HT (3 pM), 2-M e-5-H T (10 pM) and 
KCl (35 mM), and did not affect the enhancement of 
these contractions by CPA (0.3 pM) (n =  4). After de­
sensitising Pix-purinoceptors with a, )?-meATP 
(100 pM), the responses to 5-HT (3 pM), 2-M e-5-H T
(10 pM), N A  (10 pM), carbachol (10 pM), K Cl (35 mM ) 
and bradykinin (0.1 pM) were also not affected (n =  4) 
(results not shown). Atropine (1 pM) inhibited contrac­
tions induced by carbachol (10 pM). Prazosin (100 nM ) 
significantly inhibited contractions induced by N A  
(10 pM), phenylephrine (3 pM), 2-M e-5-H T (10 pM) 
and tyramine (10 pM), but did not affect the contrac­
tions induced by 5-HT (3 pM), KCl (35 mM ) or ATP  
(10 pM) (n =  4-5) (results not shown). In the presence 
of prazosin (100 nM ) eontractions to 2-M e-5-H T  
(10 pM) were reduced from 1.0 +  0.1 g to 0.1 ±  0.05 g 
(P <  0.001) (n =  4) . Imipramine (1 pM ) alm ost abo­
lished contractions induced by 2-M e-5-H T (10 pM) 
and tyramine (10 pM) but did not affect contractions 
induced by N A  (10 pM), 5-HT (3 pM), K Cl (35 mM ) or 
ATP (10 pM) {n =  4-5) (results not shown). In the 
presence of imipramine (1 pM) contractions to 2-M e-5- 
H T (10 pM) were redueed from 1.4 +  0.1 g to  
0.1 ±  0.1 g (P <  0.001) (n =  4). Ketanserin (10 nM) 
caused a parallel shift to the right of the concentration-
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Fig. 3 Concentration-response curves to (a) ATP, (b) NA and (c) 
tyramine in the rat vas deferens in the presence (open symbols) and 
absence (closed symbols) of CPA (0.3 pM) pre-incubated for 1 min. 
Each point is the mean of at least four determinations and the 
vertical bars show SEM. * Significantly different from results in the 
absence of CPA, Students unpaired t test; P < 0.05
response curve to 5-HT, with a dose-ratio of 12.9 cor­
responding to an apparent pAz of 9.1, and M D L  72222 
did not antagonise the response to 2-M e-5-H T {n =  4) 
(results not shown).
Discussion
These results confirm our previous conclusion that 
there is a post-junctional A^ receptor enhancing con­
tractions to ATP in the rat vas deferens (Hourani and 
Jones 1994), as well as the pre-junctional A  ^ receptor 
inhibiting transmitter release (Paton 1981) and the 
post-junctional Azb receptor inhibiting contractions 
(Hourani et al. 1993). These studies were performed in 
order to establish whether the A  ^ receptor-mediated 
enhancem ent was selective for certain agonists, or 
whether it could be explained by a non-specific increase
o 100
o 60
ATP 5-HT KCl Tyr, 2-Me-5-HT
Fig. 4 Effect of DPCPX (3 nM) on contractions of the rat vas 
deferens induced by ATP (10 pM), 5-HT (3 pM), KCl (35 mM), 
tyramine (Tyr) (10 pM) and 2-Me-5-HT (10 pM) in the presence of 
CPA (0.3 pM). Open columns show results in the absenee of DPCPX 
and closed columns show results in the presence of DPCPX. Results 
are expressed as percent of control response to each agent in the 
absence of CPA. Results are the mean of at least four determinations 
and the vertical bars show SEM. Significantly different from results 
in the absence of DPCPX, Students paired t test; *P < 0.05, 
**P < 0.01
in the contractility of the tissue. Various contractile 
agents were used and a submaximal concentration was 
selected for comparing the effects of CPA. The en­
hancement by CPA of contractions induced by ATP, 
5-HT, tyramine, 2-M e-5-H T and KCl, but not by NA, 
phenylephrine, carbachol or bradykinin, shows that the 
effect is selective for som e of the contractile agents, and 
not due to a general increase in contractility. The en­
hancement by CPA of contractions induced by ATP, 
5-HT, tyramine, 2-M e-5-H T and KCl was in each case 
due to an interaction with the A  ^ receptor as it was 
inhibited by an A^-selective concentration of D PC PX . 
At higher concentrations of CPA ( >  1 pM), inhibition  
of contractions to som e of the contractile agents was 
observed, as had previously been seen with ATP  
(Hourani and Jones 1994), and this is presumably due 
to interaction of CPA with the post-junctional inhibit­
ory Agb receptor (Hourani et al. 1993), although this 
was not investigated further.
One possible explanation for the enhancement by 
CPA of 5-HT, tyramine, 2-M e-5-H T and KCl could be 
that they all act via release of ATP, either from the 
excitatory nerves or from the muscle (Vizi and Burn- 
stock 1988). However, none of these contractile agents 
was acting by neuronal stim ulation as their effects were 
not inhibited by TTX. In addition they were unaffected 
by desensitization of Pzx-purinoceptors with a, P~ 
meATP, showing that they did not act via released 
ATP.
This selective interaction between agonists is sim i­
lar to the results previously reported for DDT^ M F-2  
cells (D ickenson and Hill 1993), although the m echa­
nism is unlikely to be the same, as in DDT^ M F-2 cells 
ATP, adenosine and histamine all act via G-protein  
coupled receptors, and the interaction may be due to
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cross-talk between G-proteins. H owever in the rat vas 
deferens the mechanism is not so clear, although it is 
unlikely to be due to an increase in affinity of the 
receptors as CPA did not cause a leftward shift o f the 
concentration-response curves. Responses to NA, 
phenylephrine, carbachol and bradykinin, which were 
unaffected by CPA, are all thought to be mediated via 
G-protein coupled receptors; carbachol acts via a m us­
carinic receptor as it was blocked by atropine in this 
tissue; N A  and phenylephrine act via ai-adrenoceptors; 
and both B K i and B K 2 receptors for bradykinin are 
also G-protein coupled (Hall 1992; Levesque et al.
1993). In contrast responses to ATP and KCl, which 
are both enhanced by CPA, are thought to result from  
depolarisation of the membrane in each case followed  
by opening of voltage-dependent calcium channels 
(M orishita et al. 1987; Bean and Friel 1990; Kennedy 
1990; Dubyak and El-M oatassim  1993). Although this 
could imply that CPA selectively enhanced agents act­
ing via membrane depolarisation, CPA also enhanced 
responses induced by 5-HT. Although 5-H T 3 receptors 
are receptor-operated cation channels, in this tissue 
5-HT acts via 5-H T 2 receptors which are G-protein 
coupled receptors rather than 5-H T 3 receptors, as res­
ponses to 5-HT were antagonised by ketanserin with 
an apparent pA 2 o f 9.1, which is similar to the reported 
affinity of ketanserin at 5-H T2 receptors (Hoyer et al.
1994). In addition, although 2-M e-5-HT, which has 
been reported to be selective for 5-H T 3 receptors, is 
active in this tissue, this com pound was not acting at 
5-H T 3 receptors as it was not antagonised by the 
5-H T 3 receptor antagonist M D L  72222 (Martin and 
Humphrey 1994).
Like tyramine, 2-M e-5-H T appears to act indirectly 
on (%1-adrenoceptors via release of endogenous N A  in 
the rat vas deferens, as the effect of both these drugs 
was blocked by the ai-adrenoceptor antagonist 
prazosin or by the uptake blocker imipramine. C on­
tractions induced by both tyramine and 2-M e-5-H T  
were enhanced by CPA. In contrast, contractions 
induced by N A  and phenylephrine, which act here 
directly via a 1-adrenoceptors as they were blocked by 
prazosin, were not enhanced by CPA. Adenosine has 
been reported to produce a small enhancement of con­
tractions of the guinea pig and rat vas deferens induced 
by N A  (Hoick and Marks 1978; Long and Stone 1986). 
However we did not observe any significant enhance­
m ent of N A  by CPA. We did not use adenosine itself as 
the A i agonist, as in our previous study adenosine and 
N EC A  were only observed to inhibit ATP-induced  
contractions, presumably due to lower selectivity for 
A i receptors over A 2 (Hourani and Jones 1994; 
Hourani et al. 1993). The ability of CPA to enhance 
contractions induced by endogenously released N A  but 
not by exogenous N A  or phenylephrine is perhaps 
surprising. It has been suggested that exogenous and 
endogenous N A  act on two different a 1-adrenoceptor 
subtypes (Mallard et al. 1992), however more recent
work has cast doubt on this suggestion and has shown  
that the receptor involved in mediating contraetions 
induced by exogenous and endogenous N A  is the
receptor (Bültman and Starke 1993: Biiltman et al. 
1994). W hatever the explanation of the differential eff­
ect o f CPA on exogenous N A  and on N A  released by 
tyramine and 2-M e-5-HT, it seems likely that activa­
tion of post-junctional A^ receptors would also en­
hance the effects of N A  released by neuronal stimula­
tion. However experimentally no enhancement of 
nerve-mediated contractions can be detected due to the 
presence of pre-junctional Aj receptors inhibiting 
transmitter release.
It is well known that the responses of the vas de­
ferens to N A  and ATP vary along the length of the 
tissue, with N A  being more potent at the epididymal 
and ATP more potent at the prostatic end (Sneddon 
and M achaly 1992). It seemed possible therefore, that 
the differential enhancement by C PA  of responses to 
contractile agents could refiect a differential distribu­
tion of receptor types along the length of the tissue. 
Indeed, responses to 5-HT, 2-M e-5-H T and tyramine, 
like these to N A , were more pronounced at the epi­
didymal end (results not shown). However, CPA pro­
duced similar enhancement of contractions induced by 
KCl on both epididymal and prostatic regions (Brown­
hill et al. 1996), so the selectivity of the A  ^ receptor 
mediated enhancement for certain agents cannot be 
due to gross differences in distribution of adenosine 
A i receptors along the length of the tissue. However, 
receptor heterogeneity within each individual sm ooth  
muscle cell or within small areas of the tissue cannot be 
excluded.
In conclusion the A i receptor-mediated enhance­
ment of contractions of the rat vas deferens is clearly 
selective for certain contractile agents, but the reason 
for the selectivity, and the mechanism  of the enhance­
ment, requires further study. However, the probable 
enhancement of the two sympathetic cotransmitters in 
this tissue, N A  and ATP, m ay have functional signifi­
cance, and demonstrates the com plexity o f the interac­
tions in the rat vas deferens and of the neurom odula­
tory effects of adenosine.
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Characterization of Pi-purinoceptors on rat isolated duodenum 
longitudinal muscle and muscularis mucosae
J. Nicholls, V.R. Brownhill & ^S.M.O. Hourani
Receptors and Cellular Regulation Research Group, School of Biological Sciences, University o f Surrey, Guildford, Surrey 
GU2 5XH
1 Pi-purinoceptors mediating relaxation of the rat duodenum longitudinal muscle and contraction of 
the rat duodenum muscularis mucosae were characterized by the use of adenosine and its analogues, 5'- 
N-ethylcarboxamidoadenosine (NECA), NCcyclopentyl-adenosine (CPA), N®-(phenylisopropyl)adeno- 
sine (R-PIA), 2-chloroadenosine (2-CADO) and 2-p-((carboxyethyl)phenethylamino)-5'-carboxamidoa- 
denosine (CGS21680), as well as the Pi-purinoceptor antagonist 8-phenyltheophylline (8-PT) and the Ai- 
selective antagonist, l,3-dipropyl-8-cyclopentylxanthine (DPCPX).
2 In the rat duodenum longitudinal muscle, the order of potency of the adenosine agonists was 
CPA >  NECA >  adenosine > C G S 21680. DPCPX antagonized responses to CPA and NECA at a 
concentration of 1 nM suggesting that they are acting at Ai receptors. A Schild plot versus CPA gave a 
slope near to unity (slope =  0.955) and a pAg of 9.8 confirming that CPA was acting via Ai receptors.
Schild analysis for DPCPX versus NECA, however, gave a slope of 0.674 suggesting that NECA was 
acting on both Ai and Az receptors. CGS21680, a selective A2a agonist, was much less potent than 
adenosine suggesting that the A2 receptors are o f the A2b subtype.
3 In the rat duodenum muscularis mucosae, the order of potency of the adenosine agonists was 
NECA ^  R-PIA =  CPA >  2-CADO >  adenosine, and DPCPX antagonized responses to CPA and NECA 
at a concentration of 1 ^M. CGS21680, at a concentration of 10 fiu , had no effect on this tissue. This 
suggests the presence of A2 receptors in this tissue and that they are of the A2b subtype.
4 These results are in agreement with previous studies in the whole duodenum showing the presence of 
Ai and A2b receptors causing relaxation, and this shows that the longitudinal muscle dominates the 
response of the whole tissue. In addition, a contractile A2b receptor has been revealed on the muscularis 
mucosae, the first time this subtype has been reported to elicit an excitatory response in a smooth muscle 
preparation.
Keywords: Adenosine receptors; purinoceptors; rat duodenum; smooth muscle
Introduction
Adenosine has pharmacological actions on a variety of 
smooth muscle preparations and mediates its effects by acting 
at Pi-purinoceptors (Bumstock, 1978). The Pi-purinoceptor 
was originally subdivided into Ai and A2 (van Calker et al., 
1979), and in smooth muscle, adenosine usually causes a re­
laxation via A2 receptors but can also contract some tissues 
via Ai receptors (for review, see Collis & Hourani, 1993). 
Since this original Pi-purinoceptor classification, it has been 
shown that the A2 receptor can be subdivided into A2a (high 
affinity receptor) and A2b (low affinity receptor) and that a 
third receptor type, the A 3 receptor, also exists (Fredholm et 
a l, 1994).
Pi-purinoceptors have been classified from the relative po­
tency of agonists and antagonists. For the Apreceptor, N®- 
substituted analogues such as N^-cyclopentyladenosine (CPA) 
and N®-(phenylisopropyl)adenosine (R-PIA) are more potent 
than 5'-N-ethylcarboxamidoadenosine (NECA) and the C2 
substituted analogues such as 2-chloroadenosine (2-CADO), 
and the Apselective antagonist, l,3-dipropyl-8-cyclopentyl- 
xanthine (DPCPX) has a dissociation constant in the nano­
molar range. On À2 receptors NECA and 2-CADO are more 
potent than CPA and R-PIA, and DPCPX has a dissociation 
constant in the micromolar range (Bruns, 1990; Collis & 
Hourani, 1993). The A2a and A2b subtypes can be distinguished 
by the selective binding of some C2-substituted analogues such 
as 2 - ( (carboxyethyl) phenethylamino)-5'-carboxamidoaden- 
osine (CGS-21680) to the high affinity A2a subclass of A2 re-
' Author for correspondence.
ceptors (Jarvis et a l,  1989). For the rat, A 3 receptor radi­
oligand binding experiments have shown tha t NECA is 
equipotent with R-PIA and that CGS21680 is a relatively weak 
agonist. The rat A3 receptor is also highly resistant to certain 
xanthine antagonists such as DPCPX and 8-phenyltheophyl­
line (8-PT) (van Galen et a l,  1994) but is sensitive to other 
xanthine antagonists such as BW-A522 (Fozard & Hannon, 
1994).
Previous functional studies on the rat duodenum showed 
that this tissue contained a mixture of Ai and A2b receptors 
both mediating relaxation (Nicholls et a l,  1992). The pre­
sence of Ai receptors has also recently been confirmed by 
radioligand binding experiments with pH]-DPCPX (Peachey 
et a l, 1994). The significance of two Pi-purinoceptor sub­
classes both mediating an inhibitory response was unclear, 
and relaxations mediated by Ai receptors have not been re­
ported elsewhere. Several tissues, such as the rat colon and 
the guinea-pig trachea and aorta, have been shown to possess 
both Ai and A2 receptors; however, in each case the Ai re­
ceptor mediated contraction while only the A 2 receptor 
mediated relaxation (Farmer et a l,  1988; Stoggall & Shaw, 
1990; Bailey & Hourani, 1990; Bailey et at., 1992). In  the case 
of the rat colon, Ai and A2 receptors were localized at dif­
ferent sites, contractile Ai receptors being present on the 
muscularis mucosae and relaxant A2b receptors on the long­
itudinal muscle.
The aim of this work was to study Pi-purinoceptors on the 
two layers o f the rat duodenum which contract in the long­
itudinal plane, the longitudinal muscle and the muscularis 
mucosae. We investigated whether the Ai and A2 receptors 
were localized at two distinct sites.
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M ethods
Male W istar rats, University of Surrey strain, (200-250 g) 
were killed by cervical dislocation. The duodenum was dis­
sected out by cutting at the base of the pyloris and 1.5 cm from 
this point, cleared of any connective tissue and placed over a 
fine bore (diameter: 5 mm) pipette and a longitudinal cut 
made. The two preparations were separated in the same way as 
previously described for the rat colon (Bailey & Hourani, 1990; 
1992; Bailey et a i, 1992). The longitudinal muscle was sepa­
rated by gently rubbing the layer with moist cotton wool, 
leaving a thick walled tube of mucosal tissue which contains 
the muscularis mucosae. The tissues were mounted in 4 ml 
organ baths by threads tied around each end, so that in the 
case of the muscularis mucosae the lumen was sealed, and 
maintained in Krebs solution of the following composition 
(mM): NaCl 118, KCl 4.8, MgS04  1.2, CaClz 2.5,
K H 2PO4 1.2, NaHCOs 25 and glucose 11. The Krebs solution 
was aerated with 95% O2: 5% CO2 and maintained at 3 5 -  
36°C, and the tissues were equilibrated for at least 45 min 
before addition of drugs. A resting tension of 1 g was applied 
to the tissues and force was recorded isometrically with Grass 
FT03 transducers and displayed on Grass 79D polygraphs.
Concentration-response curves were obtained non-cumula- 
tively, and for the longitudinal muscle the inhibitory responses 
were quantified by precontracting the tissues with carbachol 
(0.3 ^m) before challenge with the purines. Contractions to 
carbachol were measured from the peak of spontaneous ac­
tivity to the highest point of carbachol contraction. Relaxa­
tions were measured as the reduction in this peak height and 
expressed as % inhibition of carbachol contraction. For the 
muscularis mucosae preparation, contractions were observed 
by adding purine directly to the bath without precontraeting 
the tissue and contractions were expressed as % of contraction 
induced by KCl (35 mM). The dose-cycle for both tissue types 
was 10-15 min, and no taehyphylaxis was observed to either 
carbachol or any of the purines used. After concentration- 
response curves to purines had been obtained, tissues were 
incubated for 30 min with DPCPX or 8-PT and the con­
centration-response curves were then repeated in the presence 
of the antagonist. In some muscularis mucosae preparations
after concentration-response curves to CPA had been ob­
tained, tissues were incubated with 25 fiM indomethacin for 
45 min and the concentration-response curves were repeated in 
the presence of indomethacin.
Dose-ratios were calculated from the ratio of the individual 
EC40 values (concentration of agonist producing 40% of the 
response) in the absence and presence of antagonist. For 
NECA on rat duodenum longitudinal muscle, EC40 values 
were estimated from extrapolation of the concentration-re­
sponse curves. Apparent pA2 values were calculated as the 
negative logarithm of the molar coneentration of the antago­
nist divided by the dose-ratio — 1.
Materials
Adenosine, NECA, carbaehol, 2-CADO, R-PIA, in­
domethacin and 8-PT were obtained from Sigma Chemicals., 
U.K. CPA, CGS21680 and DPCPX were obtained from Re­
search Biochemicals Inc., and the buffer salts were of analytical 
grade and were obtained from BDH.
CPA (1 mM) was dissolved in 2% ethanol, DPCPX (1 mM) 
in 20% ethanol or in 6% aqueous dimethylsulphoxide 
(DMSO) containing 6 mM NaOH, and indomethacin (2.5 mM) 
was initially dissolved in ethanol and made up to 1/19 v/v 
ethanol/ 0.1m phosphate buffer. The pH of the indomethacin 
was 7.4 and the drug should therefore be stable for 24 h (Curry 
& Brown, 1982).
Results
Longitudinal muscle
On the longitudinal muscle preparation adenosine, NECA and 
CPA all relaxed the carbachol-contracted tissue, the order of 
potency being CPA >  NECA >  adenosine > C G S 21680 with 
mean ÉC40 values of 0.1 /iM, 0.3 ^M, 8.8 /iM and 41.8 /zM re- 
speetively (« = 4 -6 )  (Figure 1). DPCPX (I nM) inhibited re­
sponses to CPA and NECA, giving dose-ratios of 7.5 and 3.9, 
corresponding to apparent pA2 values of 9.8 and 9.5 respec-
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Figure 1 Relaxations of rat duodenum longitudinal muscle induced 
by CPA (#), NECA (■), adenosine (A) and CGS21680 (♦). Each 
point is the mean with s.e.mean of at least four determinations. For 
abbreviations see text.
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Figure 2 Relaxations of the rat duodenum longitudinal muscle 
induced by CPA in the absence (# )  or presence (O) of DPCPX, (a) 
1 nM, (b) 10 nM, (c) 100 nM. Each point is the mean with s.e.mean of 
at least four determinations. For abbreviations see text.
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lively (Figures 2a and 3a). DPCPX (10 nM) caused a parallel 
shift to the right o f the concentration-response curves to CPA 
and NECA, giving dose-ratios o f 34.9 and 8.9, corresponding 
to apparent pAz values of 9.5 and 8.9 respectively (Figures 2b 
and 3b). DPCPX (100 nM) gave an even greater shift to the 
right of the concentration-response curves to CPA and NECA 
with dose-ratios of 527.9 and 67.3, corresponding to apparent 
pAz values of 9.7 and 8.8 (Figures 2c and 3c). DPCPX (1 fiM) 
shifted the concentration-response curve to NECA further to 
the right, giving an estimated dose-ratio of 254.8, corre­
sponding to an apparent pA% value of 8.4 (Figure 3d). Vehicle 
alone had no effect on the concentration-response curves to 
CPA or NECA (results not shown). Schild analysis of the re­
sults with DPCPX versus CPA gave a linear plot (r = 0.990) 
with a slope of 0.955, corresponding to a pAz of 9.8. For 
DPCPX versus NECA, Schild analysis gave a linear plot 
(r = 0.991) with a slope of 0.674 (Figure 4). Since the slope was 
much lower than unity, no pAz could be calculated.
M uscularis m ucosae
Adenosine, NECA, CPA, R-PIA and 2-CADO all contracted 
the rat duodenum museularis mucosae and the order o f po­
tency was NECA ^  R-PIA = CPA >  2-CADO >  adenosine with 
mean EC40 values of 0.2 piM, 0.5 piM, 0.5 pM, 2.1 pM and 
33.5 /IM respectively (n = 4 -6 )  (Figure 5). CGS21680 (10 /im) 
had no effect on this tissue (results not shown). DPCPX 
(10 nM) had no effect on the concentration-response curve to 
CPA (results not shown) but DPCPX (1 /im) caused a small 
parallel shift to the right of the concentration-response curves 
to CPA and NECA, giving dose-ratios o f 3.8 and 4.9, corre­
sponding to apparent pAz values of 6.6 and 6.4 respectively 
(Figure 6a,b). 8-PT (10 /iM) caused a parallel shift to the right 
of the concentration-response curves to CPA and NECA giv­
ing dose-ratios o f 36.6 and 38.5, corresponding to apparent 
pAz values of 6.6 (Figure 6c,d). Indomethacin (25 /im) had no 
effect on CPA-induced contractions, with concentration-re­
sponse curves to CPA in the absence and presence of in­
domethacin (25 /iM) giving mean EC40 values of 0.05 /iM and 
0.04 /iM respectively (results not shown).
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Figure 4 Schild plots of the effect of DPCPX against CPA (# )  and 
NECA (■) in rat duodenum longitudinal muscle, from results shown 
in Figures 2 and 3. Each point is the mean of at least four 
determinations. For abbreviations see text.
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Figure 5 Contraction of rat duodenum muscularis mucosae induced 
by NECA (H), R-PIA (♦), CPA (#), 2-CADO (▼) and adenosine 
(A). Each point is the mean with s.e.mean of at least four 
determinations. For abbreviations see text.
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Figure 3 Relaxations of rat duodenum longitudinal muscle induced 
by NECA in the absence (■) or presence (□) of DPCPX, (a) 1 nM, 
(b) 10 nM, (c) 100 nM, (d) 1 /im. Each point is the mean with s.e.mean 
of at least four determinations. For abbreviations see text.
The results show that on the rat duodenum longitudinal 
muscle all the adenosine receptor agonists used caused re­
laxation. The order of potency of the Pi-purinoceptor agonists 
was CPA >  NECA >  adenosine > C G S 21680 and DPCPX had 
nanomolar affinity for this receptor suggesting that the ago­
nists are acting on Aj receptors (Collis & Hourani, 1993). The 
presence of a relaxant A; receptor is unusual as adenosine 
normally relaxes smooth muscle via Az receptors (White, 1988; 
Olsson & Pearson, 1990; Collis & Hourani, 1993) and in fact 
the rat duodenum is the only smooth muscle preparation to 
have been shown to relax directly via Ai receptors (Nicholls et 
a/., 1992).
Previous studies on intact rat duodenum showed that a 
mixture of Ai and Az receptors were present both causing re­
laxation of the tissue and that NECA and adenosine acted via
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Figure 6 Contraction of rat duodenum muscularis mucosae induced 
by Pi-agonists in the absence (solid symbols) or presence (open 
symbols) of DPCPX or 8-PT. (a) CPA + DPCPX (1/uvi); (b) 
NECA±DPCPX (l/xM); CPA± 8-PT (lO/iM); (d) NECA± 8-PT 
(10/im ). Each point is the mean with s.e.mean of at least four 
determinations. For abbreviations see text.
the A; receptors whilst CPA acted on A% receptors (Nicholls el 
a l, 1992). In the current studies of the longitudinal muscle, 
NECA initially appeared to be acting via Ai receptors as 
DPCPX at 1 nM and 10 nM shifted the concentration-response 
curve to the right with an apparent pA2 of around 9. However, 
qualitatively the relaxations of the intact rat duodenum were 
similar to those observed in the rat duodenum longitudinal 
muscle, suggesting that when the whole tissue was examined 
responses of the longitudinal muscle dominate. It therefore 
seemed likely that NECA would also act via A2 receptors on 
this tissue. Indeed, Schild analysis showed that DPCPX versus 
CPA gave a slope that did not differ significantly from unity 
suggesting that CPA was acting on one receptor type, and 
since the pA2 for DPCPX versus CPA was 9.8 this confirms 
that CPA was acting via Ai receptors. Schild analysis for 
DPCPX versus NECA, however, gave a slope that was much 
lower than unity suggesting that NECA was acting on a mixed 
population of receptors, presumably A, and A2, to mediate 
relaxation of the rat duodenum longitudinal muscle. Since 
CGS21680 was much less potent than adenosine on this tissue 
it would suggest that the À2 receptors are of the A2b-subtype.
The rat duodenum muscularis mucosae preparation con­
tracted to the Pi-purinoceptor agonists with a potency order 
for the analogues of NECA ^  R-PIA =  CPA >  2-CADO > 
adenosine, although it should be noted that concentration-
response curves to CPA and R-PIA did not achieve the same 
maximal response as NECA and 2-CADO within the con- 
centration-range tested. This agonist potency order did not fall 
clearly into either the Ai or A2 classification as NECA and R- 
PIA were almost equipotent, and in fact the potency order was 
more like that reported for an A3 receptor (Zhou et al., 1992). 
However it is known that on the rat A3 receptor, CGS21680 
has a Ki of approximately 0.5 /iM and that the receptor is 
highly resistant to DPCPX and 8-PT even at concentrations of 
10 /iM and 100 /iM respectively (van Galen et a l, 1994). The 
results in this study indicate that the contractile Pi-pur­
inoceptor on the rat duodenum muscularis mucosae is not an 
A3 receptor as CGS21680 at 10 /iM had no contractile effect 
and both DPCPX (1 /im) and 8-PT (10 pM) inhibited re­
sponses to NECA and CPA, the pA2 derived for 8-PT being 
consistent with Ai or A 2  receptors. Since DPCPX (1 /im) gave 
about a 4 fold shift in the concentration-response curves to 
NECA and CPA it would suggest that the agonists are acting 
via A2 receptors, in spite of the high potency of the N^-sub- 
stituted analogues, and the observation that CGS21680 
(10 /im) had no effect on this tissue would suggest that the A2 
receptors are of the A2b subtype (Lupica et a l, 1990).
The findings of a relaxant Pi-purinoceptor on the rat duo­
denum longitudinal muscle and a contractile Pi-purinoceptor 
on the muscularis mucosae are consistent with our previous 
studies in the rat colon where adenosine analogues cause re­
laxation of the longitudinal muscle and contraction of the 
muscularis mucosae (Bailey & Hourani, 1990; 1992; Bailey et 
a l, 1992). However, whereas in the rat colon contraction and 
relaxation are mediated by Ai and A2b receptors respectively, 
unusually in the rat duodenum muscularis mucosae, contrac­
tions were mediated via A2 receptors and not Ai receptors as 
would normally be expected, and in the rat duodenum long­
itudinal muscle, relaxations were predominantly mediated by 
Al not A2 receptors. The receptor subtypes mediating the re­
sponses in the two layers of the duodenum are therefore the 
opposite of those mediating the same responses in the colon. In 
some tissues such as the guinea-pig taenia caeci, purines 
(namely ATP) have been shown to cause prostaglandin- 
mediated rebound contractions following relaxations (Burn- 
stock et a l, 1975). However, the contractions in the rat duo­
denum muscularis mucosae were never preceded by relaxations 
and were not mediated by prostaglandins as they were not 
blocked by indomethacin.
In conclusion, we have shown that a mixture of A% and A2b 
receptors mediate relaxation of the rat duodenum longitudinal 
muscle, with CPA acting on the Ai subtype and NECA acting 
on both Al and A2b receptors. The relaxant A2 receptors 
however are only clearly observed when the Ai receptors have 
been blocked by DPCPX. On the rat duodenum muscularis 
mucosae, adenosine analogues cause contraction by acting at 
Pi-purinoceptors of the A2b subtype. In the rat whole duode­
num it appears that the responses of the longitudinal muscle 
dominate, as in our previous work no contractile A2b receptors 
were detected (Nicholls et a l, 1992).
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The ontogenetic profiles of the pre- and postjunctional adenosine 
receptors in the rat vas deferens
J.A. Peachey, V.R. Brownhill, ^S.M.O. Hourani & I. Kitchen
Receptors and Cellular Regulation Research Group, School o f Biological Sciences, University o f Surrey, Guildford, Surrey 
GU2 5XH
1 The ontogenetic profiles o f the prejunctional Ai and postjunctional Ai and A2 receptors on the rat 
vas deferens were investigated, using a combination of functional and radioligand binding assays to 
follow the Ai receptors and functional assays alone to follow the development of the A; receptors.
2 The prejunctional Ai receptor, assessed by the inhibitory action of N^-cyclopentyladenosine (CPA)
(3 n M -3  ^m) on nerve-mediated contractions, was present from day 15 onwards, day 15 being the 
earliest age. at which nerve-mediated contractions could be detected. The potency of CPA was constant 
across the ages studied, with pDz values ranging from 6 .4-7 .1 , not significantly different from that 
previously observed in adult rat vas deferens.
3 The postjunctional A2 receptors, assessed by the inhibitory action of 5'-N-ethylcarboxamidoadenosine 
(NECA) (10 n M -3 0  /im) on KCl-induced contractions were present from day 10 onwards, day 10 being 
the earliest age at which responses to KCl could be observed. The potency of NECA remained constant 
with an increase in age, with potency values, expressed as PEC25 values, ranging from 6.5- 7 .0 .
4 The postjunctional Ai receptor displayed a different development profile from that of the 
prejunctional Ai and postjunctional A2 receptors. Postjunctional Ai receptors were identified by the 
enhancement of KCl-induced contractions by CPA (10 n M -0 .3  ^m). At 10 and 15 days, CPA failed to 
enhance KCl-induced contractions. From  day 20 to day 40, this enhancement increased with an increase 
in age and the level of enhancement achieved statistical significance from day 30.
5 Radioligand binding studies using l,3-pH]-dipropyl-8-cyclopentylxanthine (pH]-DPCPX) revealed 
binding sites characteristic o f A, receptors on the vas deferens from rats aged 20 days onwards. The 
density (R^ax) of A, receptors expressed relative to protein content was greatest at day 20 (153 ±
33 fmol m g“ ' protein) and declined at day 30 (43.9 +  3.7 fmol m g“ ' protein) to a level commensurate 
with that previously determined in adult rat vas deferens (43.3 + 1 2 fm olm g“ ‘ protein). However, when 
expressed relative to tissue wet weight little variation in receptor density was observed between these ages 
(Rmax 0.13 +  0.02 fmol mg~^ wet weight at 20 days; 0.17 +  0.01 fmol mg~* wet weight at 30 days). The 
binding affinity (Kd) remained constant with an increase in age and was similar to the value 
previously generated for adult rat vas deferens ( ~  1 nM). At ages 10 and 15 days no reproducible binding 
could be detected.
6 These results show the differential development of the adenosine receptors on the rat vas deferens 
with postjunctional Ai receptors demonstrating delayed development, while prejunctional Ai and 
postjunctional A2 receptors were present from the earliest ages studied. In addition, comparison of 
binding studies and functional studies suggests that the binding studies detect only the A; receptors 
present on the smooth muscle and not those present on the nerve terminals.
Keywords: Rat vas deferens; ontogeny; adenosine receptors; radioligand binding; [^H]-DPCPX
Introduction
The extracellular effects o f adenosine are mediated by specific 
cell surface receptors classified as Pj- and P2-purinoceptors, 
recognising adenosine and adenosine 5'-triphosphate (ATP) 
respectively (Burnstock, 1978). The Pi receptors have been 
further subdivided into Ai and A2 receptors and these receptor 
subtypes can be clearly distinguished by the potency of various 
adenosine analogues, N®-substituted adenosine analogues such 
as N^-cyclopentyladenosine (CPA) being more potent at Ai 
receptors whereas 5'-substituted analogues such as 5'-N- 
ethylcarboxamidoadenosine (NECA) are more potent at A2 
receptors. The antagonist l,3-dipropyl-8-cyclopentylxanthine 
(DPCPX) is highly selective for A% receptors with a dissocia­
tion constant (Xd) around 1 nM, whereas at A2 receptors it has 
a Kd around 1 im  and thus effectively discriminates between 
the two receptor subtypes. The A2 receptor has been further 
subdivided into high affinity A2a and low affinity A2b receptors, 
each of which has been cloned as has the previously un-
 ^Author for correspondence.
recognised A3 receptor (for review see Collis & Hourani, 1993). 
In general in smooth muscle A] receptors are said to exist 
prejunctionally where they act to inhibit transm itter release, 
whereas A2 receptors are postjunctional and inhibit contrac­
tion (Burnstock, 1990; Kennedy, 1990). In addition, A% re­
ceptors have been shown to mediate the contractile effects of 
adenosine in some smooth muscle preparations such as the rat 
colon muscularis mucosae (Bailey et al., 1992).
The rat vas deferens is a tissue which has been widely used 
for adenosine research. It has been assumed that the inhibitory 
actions of adenosine on the nerve-induced contractions are 
mediated via a prejunctional A% receptor where adenosine acts 
to inhibit transmitter release (Paton, 1981). However, we have 
recently identified an inhibitory postjunctional A2 receptor and 
have shown that adenosine and NECA but not CPA act pri­
marily via this receptor, as shown by the inhibitory action of 
NECA and adenosine on contractions induced by ATP and 
noradrenaline (Hourani et al., 1993a). Further support for the 
existence of this inhibitory A2 receptor was provided by the 
high concentrations of DPCPX required to antagonize the
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effects of both NECA and adenosine. Another study has also 
demonstrated the presence of an excitatory postjunctional A% 
receptor on the rat vas deferens (Hourani & Jones, 1994). Low 
concentrations (< 1  fiM) o f the Ai adenosine agonists CPA 
and (R)-N^-phenylisopropyladenosine (R-PIA) were shown to 
enhance contractions induced by ATP, and this effect was 
sensitive to nanomolar concentrations of DPCPX confirming 
the involvement of A% receptors.
The ontogeny of responses to adenosine in the rat vas de­
ferens has also been studied (Hourani et a l, 1993a). Nerve 
stimulated contractions were detectable from day 15, and 
adenosine inhibited these contractions, the potency of adeno­
sine decreasing with an increase in age. However, in this study 
no attempt was made to distinguish between the Ai and the Aa 
receptor subtypes and therefore the possibility o f differential 
development o f the receptors was not explored. However, in 
the rat duodenum we have recently shown that the Ai and Az 
receptors develop at different times, with the Az receptor pre­
sent from day 5 and the A% receptor evident from day 20 only 
(Peachey et al., unpublished observation).
We have recently established a radioligand binding assay to 
identify adenosine Ai receptors in a number of adult rat 
smooth muscle preparations including the rat vas deferens 
(Peachey et al., 1994). Using the Ai-selective radioligand pH]- 
DPCPX we have identified high affinity binding sites com­
mensurate with A] receptors in the adult rat vas deferens, as 
shown by a Kq value in the low nM range and inhibition stu­
dies using adenosine receptor ligands which yielded a poteney 
order characteristic of an Ai receptor.
As part of a continuing project to study the development of 
receptors in smooth muscle we have followed the ontogenetic 
profile o f the pre- and postjunctional Aj and postjunctional Ag 
receptors in the rat vas deferens by studying the response to the 
Ai-selective analogue, CPA and the Ag agonist, NECA, using 
traditional functional assay methods. In addition, we have 
followed the ontogenetic profile o f Aj receptors using binding 
assays with pH]-DPCPX as the radioligand to complement the 
functional studies on Ai receptors.
Some of our findings have been presented previously in 
abstract form (Peachey et al., 1995).
M ethods
Animals and tissue preparation
Isolated vasa deferentia from male W istar albino rats (Uni­
versity of Surrey strain) aged 10, 15, 20, 25, 30 and 40 days old 
and adult ( > 6 0  days, 200-250 g) were used in these experi­
ments. The day of birth was designated as day 1 and animals 
were culled to litters o f eight to ten pups (mixed sexes) to each 
m other to maintain a standard litter size. The animals were 
killed by cervical dislocation. In each case whole vasa defer­
entia were dissected out by cutting just below the epididymis 
and above the urethra and cleared of any connective tissue.
Functional assays
The vasa deferentia were mounted in 4 ml organ baths con­
taining Mg^'^ -free Krebs of the following composition (mM); 
N aC l 118, NaCOs 25, K H 2PO4 1.2, KCl 4.8, CaClz 2.5, glucose 
11, gassed with 95% O^SVo CO2, and maintained at 37°C. 
Mg^^-free Krebs was used as omitting Mg^'^ enhances neu­
rogenic contractions and allows nerve-mediated responses to 
be detected earlier in postnatal development. A resting tension 
o f 0.5 g was applied and tissues were allowed to equilibrate for 
90 min, during which time the Krebs buffer was replaced every 
20 min. Responses were recorded isometrically via an FT03 
force displacement transducer and displayed on a Grass 
polygraph model 79D.
The presence of prejunctional Ai receptors was assessed by 
the inhibitory effects of CPA (3 nM -3  pM) on nerve-mediated 
contractions (field stimulation; Grass S48 stimulator, twin
pulses o f 1 ms duration, 75 ms delay, 70 V) via parallel plati­
num electrodes. To measure the inhibitory effects of CPA, the 
tissues were field-stimulated at a frequency of 0.1 Hz and CPA 
was added to the bath when the response to the nerve stimu­
lation had stabilized and maintained in contact with the tissue 
until maximal inhibition of contraction was observed. The 
inhibition was expressed as % reduction of the nerve mediated 
response, and potency estimates calculated as EC50 values and 
expressed as pDz values (negative logio o f the EC50 value). To 
investigate the effects of DPCPX (10 nM) on the inhibition of 
nerve-mediated contractions by CPA, control concentration- 
response curves to CPA were constructed followed by in­
cubation with the antagonist for 30 min prior to obtaining a 
second concentration-response curve to CPA. In the case of 
animals aged 15 days however, tissue fragility prevented two 
concentration-response curves from being constructed on one 
tissue preparation, therefore experiments in the absence and 
presence of DPCPX were performed in parallel. The effect of 
CPA on the nerve-mediated response was studied from day 15 
onwards, day 15 being the earliest age at which nerve-mediated 
responses could be detected. In adult and 15 day old vas de­
ferens, nerve-mediated responses were neurogenic in origin as 
responses were abolished in the presence of tetrodotoxin 
(1 pM). The presence of the excitatory postjunctional Ai re­
ceptor was assessed as outlined in Hourani & Jones, (1994), 
with minor modifications. The effects of CPA (10 nM - 
300 nM) on the contractile response induced by submaximal 
concentrations of KCl (35 mM) were assessed. KCl was used as 
the contractile agent in preference to ATP as it was found that 
responses to KCl were evident from postnatal day 10, whereas 
responses to ATP were evident only from 15 days (Hourani et 
al., 1993a). Tissues were pfeincubated with CPA for 1 min 
before the addition of KCl, and responses were expressed as 
the % enhancement by CPA of the KCl-induced contraction in 
the absence of CPA. A 1 min preincubation with CPA was 
used as this was previously found to be optimal for the de­
tection of enhancement of contractions (Hourani & Jones, 
1994). The inhibitory effects o f NECA (10 nM -30 pM) and 
high concentrations of CPA (1 -3 0  pM) on the contractile re­
sponse induced by KCl (35 mM) were assessed to study the 
postjunctional inhibitory Az receptor. NECA or CPA were 
incubated with the tissue for 1 min before the addition of KCl, 
responses were expressed as % inhibition of the KCl-induced 
contraction and potency estimates were expressed as pECzs 
values (the negative logio of the ECzs value). In all cases re­
sponses were obtained non-cumulatively and a dose cycle of 
10 min maintained. Statistical analysis across the ages was 
carried out by one-way ANOVA followed by Duncan’s New 
Multiple Range post-hoc test. For the inhibitory effect of CPA 
on the nerve-stimulated response the pDz value was compared, 
for the inhibitory effect of CPA and NECA on KCl-induced 
contractions the pECz; value was compared and for the en­
hancement by CPA of KCl-induced contractions the % en­
hancement at 0.3 ^M CPA (the concentration giving maximal 
enhancement) was compared. For statistical analysis of the 
enhancement by CPA, a Student’s paired t test was used at 
each age to compare the contractions induced by KCl in the 
absence and presence of CPA. For statistical analysis of the 
effect of DPCPX (10 nM) on the inhibition of nerve-mediated 
contractions by CPA, the pDz value for CPA in the absence 
and presence of antagonist was compared by Student’s t test.
Membrane preparation fo r  binding assays
Tissues were placed in ice-cold 50 mM TrisHCl (pH 7.4) buffer. 
Tissues from at least 15 age-matched animals were pooled for 
each assay. All tissues were blotted dry to remove excess buf­
fer, weighed and roughly scissor chopped. Homogenization 
and centrifugation were performed as in Peachey et al. (1994). 
The resulting pellet was resuspended in 50 mM TrisHCl and 
incubated with 5 u m l“  ^ adenosine deaminase for 30 min at 
room temperature before use. Protein estimations were per­
formed according to the method of Lowry et al. (1951).
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Saturation binding assays
Saturation experiments were performed in duplicate in 
polypropylene tubes using a total assay volume of 250 /il. 
Saturation assays were undertaken only on 15, 20, 25 and 30 
day old vas deferens and were carried out according to the 
method of Peachey et al. (1994). Eight concentrations of 
pH]-DPCPX (0.05-10 nM) (specific activity 109 Ci mm ol“ ') 
were used and the non-specific binding was defined by 1 
CPA. The limited homogenate obtained from 10 day old 
neonates prevented saturation assays from being performed, 
therefore homologous displacement assays were undertaken. 
A single concentration of [^H]-DPCPX (1 nM) was used in 
the presence of increasing concentrations of unlabelled 
DPCPX (0.1-100 nM) and incubations performed as out­
lined above. Results were analysed using LIGAND (Munson 
& Rodbard, 1980) and the specific binding subjected to 
Scatchard transformation (Scatchard, 1949) for estimation of 
Kjy and
Materials
NECA, CPA and adenosine deaminase (ADA) (TypeVI) were 
obtained from Sigiria UK. Ltd, Poole, Dorset; DPCPX from 
Research Biochemicals, Natick, MA (U.S.A.) and pH]- 
DPCPX from N EN  DuPont UK. Ltd., Stevenage, Hertford­
shire. CPA (10 mM) was dissolved in 20% ethanol and 
DPCPX (10 mM) was dissolved in either 20% ethanol or 6% 
dimethylsulphoxide containing 6 mM NaOH and all drugs 
were diluted in buffer for use. All stock solutions were stored 
frozen a t — 18°C. The ADA solution was supplied in 50% 
glycerol-0.01 M potassium phosphate solution at a concentra­
tion of 1000 units in 0.6 ml.
Results
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Functional assays
CPA inhibited the nerve-mediated contractions of the vas 
deferens from day 15 onwards, day 15 being the earliest age 
at which nerve-mediated contractions could be detected. The 
inhibitory effect of CPA was similar at all ages studied with 
pDz values between 6.4  and 7.1, and these values were not 
significantly different from that determined in the adult 
( f  > 0 .0 5 )  (Figure la). DPCPX (10 nM) caused a significant 
( f  < 0 .0 5 )  rightward shift in the dose-response curve to CPA 
at day 15 and day 25, with dose-ratios of 3.5 and 8.0 re­
spectively corresponding to apparent pA% values of 8.4 and 
8.9 (Figure 2). NECA (10 n M -3 0  ^M) inhibited the con­
tractions induced by KCl (35 mM) from day 10 onwards, the 
earliest age at which responses to KCl could be detected, 
with pECz; values between 6.5 and 7.0 and these were not 
significantly different from adult at any age (Figure lb). In 
contrast, CPA (10 n M -0 .3  jum) enhanced the contractions 
induced by KCl from day 20 onwards (Figure 3), with the 
maximal enhancement observed at 0.3 gM CPA and the re­
sponse to this concentration of CPA was therefore used to 
compare potency at different ages. No enhancement o f the 
KCl-induced response by CPA was observed at days 10 and 
15 (Figure 3), and the enhancement o f KCl-induced con­
tractions by 0.3 /rM CPA achieved statistical significance 
from day 30 (P < 0 .0 5 ) . At this concentration of CPA 
(0.3 ^m), the % enhancement o f the KCl-induced contractile 
response increased with an increase in age up to day 40, and 
until day 35 the level of enhancement was significantly dif­
ferent from that found in the adult ( f  < 0 .0 5 )  (Figure Ic). At 
concentrations > 0 .3  yM CPA inhibited contractions induced 
by KCl (Figure 3), and the potency of CPA for this effect 
was not significantly different from the adult at any age, and 
was always at least 10 fold lower than that of NECA 
(Figure lb).
40 -
^  O  3 0 -
C M
0  o  2 0 -
10-
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Figure 1 Variations in the responses of the rat vas deferens with 
age. (a) Variation in the potency of CPA as an inhibitor of nerve- 
stimulated contractions expressed as pDg values, showing the 
development of the prejunctional A, receptor, (b) Variations in the 
potency of NECA (■) and CPA (# )  as inhibitors of KCl-induced 
contractions, expressed as PEC25 values, showing development of the 
postjunctional Â2 receptor, (c) Variation in the % enhancement of 
KCl-induced contraction by CPA (0.3 yu), showing development of 
the postjunctional A, receptor. Each point is the mean with s.e.mean 
of as least four determinations. Statistical analysis was performed by 
one-way ANOVA and Duncan’s New Multiple Range post-hoc test, 
*P<0.05 significantly different from adult values.
Binding assays
At days 10 and 15 no specific binding to [^H]-DPCPX could be 
detected. A t day 20, specific binding was observed (Figure 4),
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but transformation of the specific binding yielded Scatchard 
plots with poor regression coefficients ranging from 0.37-0.74. 
However, measures of affinity (Xd) and density (5max) of re­
ceptors derived from these plots resulted in values (K^ 
0.74 +  0.09 nM; 0.11+0.01 fmol m g " ' wet weight) not 
dissimilar from those determined at 25 days (ATd 0.6 +  0.03 nM; 
Smax 0.17 +  0.03 fmol mg^^ wet weight). From  day 25 pH]- 
DPCPX bound with high affinity to the vas deferens from 
neonatal rats (Figure 4b). Scatchard transformation of the 
specific binding yielded monophasic plots and Hill coefficients 
which were not significantly different from unity, indicating 
that [^H]-DPCPX binds to an apparently homogeneous po­
pulation of receptors. The affinity of pH]-DPCPX for the vas 
deferens from animals aged 25 (0.6 +  0.03 nM) and 30 
(0.91+0.2 nM) days was similar and values were not sig­
nificantly different to the Kd value previously determined for 
adult vas deferens (0.93 +  0.2 nM) (Peachey et a l,  1994). The 
protein content of the tissue homogenate from 20 day old 
animals (69.1 +10.9 jUg protein m l“  ^ homogenate) was ap­
proximately half that from animals aged 25 days 
(174.3 +  35.2 jUg protein m l“ ' homogenate) and when receptor 
density was expressed relative to protein content pH]-DPCPX 
binding decreased three fold from day 20 to day 30 (Figure 5a). 
However, when expressed per wet weight of tissue the density 
of A, receptors showed a small increase from day 20 to day 30 
(Figure 5b).
Discussion
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Figure 3 Effect of preincubation with CPA for Imin on the 
contractile response induced by KCl (35 mM) at 10 days (Q), 15 days 
(□), 20 days (A), 25 days (V), 30 days (#), 35 days (■), 40 days 
(A), 45 days (T) and adult (♦ )  rat vas deferens. Each point is the 
mean of at least four determinations. Statistical analysis was 
performed by Student’s paired t test to compare the contractions 
induced by KCl in the absence and presence of 0.3 pM CPA, 
*P<0.05. Error bars have been removed for clarity.
Previous ontogenetic studies of the Pi-purinoceptors on the rat 
vas deferens revealed adenosine to be more potent in the 
neonate than the adult, with the potency of adenosine in in­
hibiting nerve mediated contractions decreasing with an in­
crease in age (Hourani et a l,  1993a). However, no attempt was 
made to characterize the receptors at which adenosine acted at 
the various ages. In contrast in this study, we have shown the 
potency of the Ai-selective adenosine agonist, CPA, as an in­
hibitor of the nerve-mediated contractions, to be constant 
across the ages studied. Furthermore, the low concentrations 
of DPCPX (10 nM) required to antagonize this effect con­
firmed that CPA was acting at a prejunctional Ai receptor. In 
addition, CPA in the present study was more potent than 
adenosine had been in the study of Hourani et al. (1993a), 
consistent with an action at the prejunctional Ai receptor. The 
constant potency of CPA across the ages studied and the early 
appearance of this functional response suggests that this in­
hibitory prejunctional Ai receptor is as im portant in the neo­
nate as it is in the adult vas deferens.
For investigation of the postjunctional A% and Az receptors 
in the present study, KCl was used as the contractile agent as 
responses to KCl were evident from day 10 onwards, whereas
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Figure 2 Effect of CPA (0.1-10/iM ) in the absence (0) and 
presence (O) of DPCPX (10 nM) on the nerve-stimulated contractions 
of the vas deferens from animals aged (a) 15 days and (b) 25 days. 
Each point is the mean with s.e.mean of at least four determinations.
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Figure 4 Representative saturation plots and Scatchard transforma­
tion of f  H]-DPCPX binding to vas deferens from animals aged (a) 
20 days, (b) 25 days and (c) 30 days, showing (O) total, (□) non­
specific and (0) specific binding. In all cases the non-specific binding 
was defined by 1 ^M CPA. Scatchard transformation of the specific 
binding (0) from (a), (b) and (c) are shown in (d), (e) and (f) 
respectively.
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Figure 5 Variation in the density of adenosine Ai receptors 
expressed as amount bound relative to (a) protein content of 
homogenate (fmol mg protein) and (b) wet weight of tissue 
(fmol mg" ^  wet weight) against age. Each point is the mean of at 
least three determinations and the vertical bars show s.e.mean.
responses to both ATP and noradrenaline (NA), the two co­
transmitters in this tissue, vary with age (Hourani et a l, 
1993a), and we wished to avoid the complications associated 
with these factors when constructing developmental profiles 
for the adenosine receptor subtypes. Our results with NECA 
show that the ontogenetic profile of the inhibitory postjunc­
tional Az receptor is similar to that for the inhibitory pre­
junctional Ai receptor as the potency of NECA remained 
constant across all ages studied and was similar to that ob­
served in the adult. High concentrations of CPA (>0 .3  /zM) 
also inhibited the KCl-induced contractions presumably due to 
activation of the postjunctional Ag receptor, with NECA being 
more potent than CPA at all ages (see Figure lb). The onto­
geny of the postjunctional Az receptor in the rat vas deferens 
follows a similar pattern to that observed in the rat duodenum 
(Peachey et a l, unpublished observation), and urinary bladder 
(Nieholls et ah, 1990) where responses to NECA and adeno­
sine respectively, acting via Az receptors (Nieholls et a l,  1992), 
were observed from day 5 onwards.
The presence of an excitatory postjunctional A; receptor 
has heen established in the adult rat vas deferens (Hourani & 
Jones, 1994). The lack of enhancement o f the KCl-induced 
contractile response by low concentrations of CPA (10 n M -  
0.3 ^M) on the vas deferens from 10 and 15 day old rats in the 
present study indicates the absence of this A% receptor, whereas 
from day 20 onwards, enhancement of KCl-induced contrac­
tions mediated via this excitatory postjunctional A, receptor 
were detectable, achieving statistical significance by day 30. 
Responses to CPA increased with an increase in age and levels 
o f enhancement not significantly different from that observed 
in the adult were achieved by day 35, implying that this re­
ceptor subtype is more important in the later stages of devel­
opment. The late development of this stimulatory 
postjunctional A, receptor may explain why the overall in­
hibitory effect o f adenosine on nerve stimulation was observed 
to decrease with age in our previous study (Hourani et a l, 
1993a). Binding with [^H]-DPCPX to rat vas deferens of ani­
mals aged 10-15 days also failed to identify binding sites 
commensurate with an A; receptor. From day 20 onwards 
however, [^H]-DPCPX binding to an A, receptor was observed 
as shown by a X d value in the low nM range, equivalent to the 
Xd value previously established for adult rat vas deferens 
(0.93 +  0.17 nM) (Peachey et a l, 1994). The density of A, re­
ceptors expressed relative to protein content varied with age, 
being greatest at day 20 and declining at day 30 to levels 
equivalent to that previously established for adult rat vas de­
ferens (43.3 +  12.2 fmol m g“ * protein) (Peachey et a l, 1994).
However, the increase in protein content of the tissue homo­
genate from 20 days to 30 days resulted in the apparent de­
crease in receptor density over this period, as when expressed 
in terms of the wet weight of the tissue, a small increase in 
receptor density was observed between the ages (see Figure 
5b). The lack of variation in the ligand affinity with age in­
dicates that the observed differences in receptor density are not 
due to binding to another receptor system. Overall there is a 
similarity in the profile of the postjunctional A, receptor 
identified by functional studies and the A% receptor identified 
by radioligand binding studies, in that they both exhibit de­
layed development. This suggests that the [^H]-DPCPX bind­
ing assay identifies the postjunctional A, receptor only and not 
those Ai receptors present on the nerve terminals. The reasons 
for this apparent preferential binding to the postjunctional A; 
receptors are unknown, but it may simply be a consequence of 
the greater mass of smooth muscle than nerve tissue present in 
the vas deferens. The fact that the density of Ai binding sites 
expressed as fmol mg“ * protein was greater at day 20 than in 
the adult, whereas the functional response to CPA was still 
increasing at this age and achieved statistical significance only 
by day 30, may imply that there is a lag between appearance of 
the receptors and their functional coupling. A similar lag has 
been observed in the neonatal rat duodenum where the po­
tency of CPA appeared to lag behind the density of Ai re­
ceptors at 20 days (Peachey et ah, unpublished observation).
The relative rates o f development of the Ai receptor in 
smooth muscle preparations would appear to be tissue-de­
pendent. In the muscularis mucosae of the rat colon we have 
shown the A% receptor to be present from day 5 onwards 
(Hourani et al., 1993b), whereas in the rat duodenum the Ai 
receptors were evident only from day 20 onwards (Peachey et 
ah, unpublished observation). In the present study we have 
shown that the prejunctional A] receptor is present from day 
15 onwards, whereas the postjunctional Ai receptor identified 
by functional and radioligand binding studies is detectable 
from day 20. There is no evidence at present in the literature to 
indicate that there are subtypes of the Ai receptor and thus it is 
likely that some process occurs around day 20 which stimulates 
the development of these postjunctional receptors. It has been 
reported that the process of sexual m aturation in the male rat 
starts at around 4 weeks of age, with an increase in the number 
of Leydig cells per testes from the fourth to the tenth week of 
age, and a corresponding rise in plasma testosterone con­
centration (Pahnke et al., 1975). The appearance of the post­
junctional Ai receptors on the vas deferens a t post-natal day 
20, although earlier than the reported start o f sexual m atura­
tion in the rat, may have some involvement in this process.
In conclusion, we have shown that the prejunctional Ai and 
the postjunctional Az receptors on the rat vas deferens are 
present from day 15 and day 10 respectively, the earliest ages at 
which responses can be measured, and that the poteney of the 
adenosine analogues acting at these receptor subtypes is con­
stant with an increase in age. In contrast, the excitatory 
postjunctional A, receptors exhibit delayed development. The 
Ai binding sites identified with pH]-DPCPX were present only 
from day 20, and this suggests that this binding assay detects 
only the postjunctional A, receptors and not those present on 
the nerve terminals. This finding may have im portant im­
plications for the interpretation of radioligand binding studies 
in peripheral tissues.
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P120 THE ONTOGENY OF ADENOSINE RECEPTOR SUBTYPES IN THE RAT VAS DEFERENS
J.A. Peachey, V.R. Brownhill, S.M.O. Hourani & I. Kitchen. 
School of Biological Sciences, University of Surrey, Guildford, 
Surrey. GU2 5XH.
The rat vas deferens is a tissue which has been used extensively 
for adenosine receptor research. We have recently shown that 
the adult rat vas deferens contains inhibitory prejunctional Ai 
receptors, inhibitory postjunctional A2 receptors (Hourani et al.,
1993) and excitatory postjunctional Aj receptors (Hourani & 
Jones, 1994). RadioUgand binding assays using the Ai selective 
antagonist PH ]-1,3-dipropyl-8-cyclopentylxanthinc (PHj- 
DPCPX) have also identified [^HjDPCPX binding sites 
commensurate with Ai receptors in the rat vas deferens (Peachey 
cr a/.; 1994). As part of a continuing project to study the 
ontogeny of purinoceptors in smooth muscle, we have 
investigated the development with neonatal age of the adenosine 
receptors in the rat vas deferens using a combination of 
radioligand binding and functional assays.
Isolated vasa deferentia from male Wistar albino rats (University 
of Surrey strain) aged 10, 15, 20, 25, 30, 40 days and adult 
were used, the day of birth being designated as day 1. 
Functional assays were carried out as previously described 
(Houraiti cr a/., 1993; Hourani & Jones, 1994). Prejunctional 
A j receptors w^ measuring tiie inhibitory effect of
N*-cyclopentyladenosine (CPA) (O.Ol-lOjxM) on the nerve 
rnediated contractions (field stimulation. Grass 848 stimulator, 
twin pulses of 1ms duration, 75 ms delay, 70V). Excitatory 
postjunctional A 1 receptors were detected by measuring the 
enhancement of KCl (35n^)-induced contractions following 
preincubatipn (1 niin) with CPA (0.01-30jiM). The inhibitory 
effects p f  5'-N-ethylcarh^xanridpaden (NECA) (0.01- 
3 0 |i^  bn the Ka-mduced cpnnactions were used to show the 
presence o f postjunctional,À2 rece^torè^-. S binding
assays were performed as previously described (Peachey cr at.,
1994), using pHjDPCPX (0.05-lOnM). Insufficient tissue was
obtained from 10 day old animals for saturation assays to be 
performed, therefore homologous displacement assays Were 
performed using a Kp concentration of pHjDPCPX (InM) and 
unlabeUed DPCPX (O.l-lOOnM).
CPA inhibited nerve mediated contractions from day 15 
onwards, day 15 being the earliest age to responti to nerve 
stimulation, and potency values were constant acrpss the ages 
studied (pD2 6.5-7). NECA inhibited KCl induced contractions 
from day 10 onwards, potency values remaining constant across 
the ages studied (pEQ s 6.5-7). In contrast, CPA failed tP 
enhance KCl-induced contractions at days 10,15 and 20, with a 
small enhancement (< 10%) being observed at day 25 and 
increasing with age up to day 40 to a value similar to that seen in 
the adult (~35%). Binding studies failed to detect binding at 
days 10, 15 and 20, but by day 25 the density of binding sites 
peaked (Bmax 75.2±11.1 fmol/mg protein) declining at day 30 to 
a value commensurate with that found in the adult (~40 fnwl/mg 
protein).
These results show that the prejunctional Ai receptors and the 
posQunctional A2 receptors are M ly functional from days 15 and 
10 respectively, the earliest days which could be tested using 
functional assays. However, Âe excitatory postjunctipnal A j 
receptors developed later, the response being detectable only 
from day 25. The Ai binding sites identified using PH]DI^PX 
were also present from day 25, and this suggests that M s 
binding assay detects only the postjunctional \ \  receptors and 
not those present on the nerve terminals.
Hourani, S.M.O. & Jones, D.A.D. (1994). Gen Pharmacol:,
25, 417-420.
Hourani, S.M.O., Nieholls, J., Lee, S.B.S. et al. (1993). Br.
J. Pharmacol., 108,754-758.
Peachey, J.A., Hourani, S.M.O. & Kitchen, I. (1994). Br. V.
Pharmacol., 113,1249-1256.
Br. J. Pharmacol, 115, 143P.
CHARACTERIZATION OF P i - P U R I N G C E P T O R S  ON 
R A T  I S O L A T E D  D L O D E N U M  L O N G IT U D IN A L  
MUSCLE AND MUSCULARIS M U C O SA E .
J.Nicholls. V R.Brownhiil & S.M.O. Hourani.
School of Biological Sciences. Umversilv of Surrev, Guildford, 
Surrey. GU2 5XH. U.K.
Previous functional studies on the rat duodenum have shown that 
this tissue contains a mixture of A | and A2b receptors mediating 
relaxation (Nieholls et. al.. 1992). The significance of two Pj- 
punnoceptors both mediating an inhibitory response was unclear, 
and relaxations mediated v ia A] receptors have not been reported 
elsewhere. The aim of this work was to investigate whether the A; 
and A] receptors on the rat duodenum w ere localized at two distinct 
sites, as previously shown on the rat colon (Bailey & Hourahi. 
1990; 19%). therefore we investigated the effects of selective Pi* 
agonists and antagonists on the rat duodenum longitudinal muscle 
and musculans mucosae. In the longitudinal muscle Pi-agomsts 
relaxed the ussue with an order of potency of CPA > NECA > 
adenosine > CGS21680. Responses to CPA were antagonized b\ 
DPCPX with a Schild plot slope near to unity (0.96) and a pA% of 
9:8 sUggesUng that CPA acts on A| receptors. DPCPX (InM  - 
l//M )j^so antagonized responses to NECA however a Schild plot 
slope of Ô.67 was obtained suggesting that NECA acts on both A i 
and A2 receptors. Since CGS21680 was much less potent than 
adenosine the A2 receptors are of the A2b subtype. In the 
muscularis mucosae Pi-agonists contracted the tissue with an order 
of potency of NECA > R-PIA = CPA > 2-CADO > adenosine. 
D F tP X  (ljiM ) antagonized responses to NECA and CPA 
suggesting that they are acting on A 2b receptors.
Nieholls. J et. al., (1992). Br. J. Pharm. 105,639-642.
Bailey. SJ & Hourani. S.MO ( 1990). Br. J. Pharm. 100,753-756. 
Bailey. SJ & Hourani. S.MO ( 1992). Br. J. Pharm. 105,885-892.
Drug Dev. Res., 37, 187.
D IF F E R E N T IA L  D IS T R IB U T IO N  O F  A D E N O S I N E  
RECEPTORS IN THE RAT VAS DEFERENS.
V.R. Brownhill. S.M.O. Hourani ami I. Kitchen
School ol Biological Sciences. Universiiv of Surrev, Guildford,
Surrey. GU2 5XH. U.K.
Adenosine, formed by the breakdown of ATP. has been show n 
to have a neurom odulatory role causing inhibition of 
neurotransmitter release by activating prejunctional Aj receptors in 
the rat vas deferens, and recently the presence of postjunctional A i 
(excitatory) and A] receptors (inhibitory ) has also been shown 
(Hourani et al. 1993; Hourani & Jones, 1994). in this tissue it is 
known that the adrenergic component of the nerve-mediated 
response predominates in the epididymal region (ER) and the 
punnergic component predominates in the pros ta tic region (PR) 
(Sneddon & Machaly, 1992). We therefore investigated the 
distnbution of adenosine receptors in the PR and the ER of the 
bisected rat vas deferens, to see whether these receptors are also 
differentially localised. Functional studies were carried out using 
N^-cyclopentyladenosine (CPA), 5’-N-ethylcarboxamidoadenosine 
(NECA). 2-[p-(carboxyethyi)-phenylethylaminôl-5'-N-ethyIcarb- 
oxam idoadenosine (CGS 21680) and 1 ;3-dipropyl-8-cyclo- 
pentyixanthine (DPCPX). In the ER, CPA and NECA both 
inhibited nerve-mediated contractions by activating prejuncUonaJ 
A| receptors, whereas in the PR, CPA activated prejunctional Ai 
receptors while NECA activated postjunctional A2b receptors. 
CPA enhanced KCl-induced contractions acting via postjuncuonal 
Ai receptors in both regions of the Ussue. In conclusion, the pre- 
and postjunctional A; receptors were present on both portions o f 
the bisected tissue. However, postjunctional A2b receptors appear 
to be present only in the PR. show ing that adenosine receptors are 
differentially distnbuted along the length of the rat vas deferens.
Hourani. S.M.O. & Jones, D.A.D. ( 1994) Gen. Pharm:: 25; 417. 
Hourani et al., ( 1993) Br. J. Pharmacol.. 108, 754.
Sneddon. P. & Machaly, M. ( 1992) J. Auioh. Pharm. I 2. 421. . ,
Drug Dev. Res., 37,188.
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